rudi - cv - 2e - university of illinois college of medicine at chicago
TRANSCRIPT
1 out of 115
06/13
CURRICULUM VITAE
Name: ISRAEL (RUDI) RUBINSTEIN, M.D.
Citizenship: U.S.A.
Business address: Research & Development Service (151)
Jesse Brown VA Medical Center
820 South Damen Avenue
Chicago, Illinois 60612
U.S.A.
Phone: (312) 569-6166
FAX: (312) 569-8114
E-mail: [email protected]
Section of Pulmonary, Critical Care, Sleep and
and Allergy Medicine Department of Medicine (M/C 719)
College of Medicine University of Illinois at Chicago 840 South Wood Street Clinical Sciences Building 920, Room 913-N Chicago, Illinois 60612-4325
U.S.A. E-mail: [email protected]
Place of birth: Tel-Aviv, Israel
Marital status: Married; two children
Education:
1969-1977 M.D., Hebrew University-Hadassah School of Medicine
Jerusalem, Israel
Postdoctoral training:
Internship and Residencies:
Marc 1976- Rotating Internship
Feb. 1977 The Chaim Sheba Medical Center
Tel-Hashomer, Israel
Israel Rubinstein, M.D.
2 of 115
Oct. 1981- Resident in Medicine, The Chaim Sheba
Dec. 1984 Medical Center
Tel-Hashomer, Israel
Jan. 1985- Clinical Associate, Pulmonary Division
June 1985 The Chaim Sheba Medical Center
Tel-Hashomer, Israel
Fellowships:
July 1985- Fellow, Respirology, University
June 1987 of Toronto
Toronto, Ontario
Canada
July 1987- Fellow, Cardiovascular Research
June 1989 Institute, University of California
San Francisco, California
Academic and Hospital Appointments:
October 2012- Associate Chief of Staff for Research and Development
Present Jesse Brown VA Medical Center
Chicago, Illinois
April 2008-Present Member, Cancer Center
University of Illinois at Chicago
Chicago, Illinois
Aug. 2006-Present Faculty at Large, Center for Integrated Networks of
Nanoscale Sensors and Signal Transmission Systems for
Biomedical Applications
College of Engineering
University of Illinois at Chicago
Chicago, Illinois
Sept. 1999-Present Professor of Medicine,
University of Illinois at Chicago
College of Medicine
Chicago, Illinois
Sept. 1999-Present Faculty, Interdisciplinary Training Program in Neuroscience,
University of Illinois at Chicago
Chicago, Illinois
Israel Rubinstein, M.D.
3 of 115
July 1998-Present Medical Staff
Tuberculosis Clinic
West Town Neighborhood Health Center
City of Chicago, Department of Health
Chicago, Illinois
Sep. 1997-Present Member, UIC Cancer Center
University of Illinois at Chicago
College of Medicine, Chicago, Illinois
Nov. 1993-Present Faculty Affiliate, Department of Physiology and Biophysics,
University of Illinois at Chicago,
Chicago, Illinois
Nov. 1993-Present Medical Director, Respiratory Therapy
Jesse Brown VA Medical Center
Chicago, Illinois
Nov. 1993-Present Staff Physician
Jesse Brown VA Medical Center
Chicago, Illinois
Oct. 1993-Present Attending Physician
University Hospital
University of Illinois at Chicago
Chicago, Illinois
Oct. 1993-Present Member, Graduate College
University of Illinois at Chicago
Chicago, Illinois
June 2008- Acting Associate Chief of Staff for Research and
Sep. 2012 Development
Jesse Brown VA Medical Center
Chicago, Illinois
Sept. 1999- Professor of Biopharmaceutical Sciences (adjunct
Jan. 2010 appointment)
University of Illinois at Chicago
College of Pharmacy
Chicago, Illinois
Nov. 1999- Medical Staff
Dec. 2006 Kindred Care-Lake Shore Hospital
Israel Rubinstein, M.D.
4 of 115
Chicago, Illinois
June 1999- Associated Professor of Pharmaceutics (adjunct appointment)
Sept.1999 University of Illinois at Chicago
College of Pharmacy
Chicago, Illinois
Sept. 1993- Associate Professor of Medicine
Aug. 1999 University of Illinois at Chicago
College of Medicine
Chicago, Illinois
July 1993- Associate Professor of Medicine
Aug. 1993 and Physiology, University of Nebraska Medical Center
College of Medicine
Omaha, Nebraska
Nov. 1990- Attending Physician
Aug. 1993 Department of Veterans Affairs Medical Center
Omaha, Nebraska
Sep. 1990- Attending Physician
Aug. 1993 University Hospital
University of Nebraska Medical Center
Omaha, Nebraska
March 1990- Member
Aug. 1993 Graduate Faculty
Graduate College
University of Nebraska
Lincoln, Nebraska
Nov. 1989- Assistant Professor of Physiology and
June 1993 Biophysics (courtesy)
University of Nebraska Medical Center
College of Medicine
Omaha, Nebraska
July 1989- Director
Aug. 1993 Sleep Medicine Service
University of Nebraska Medical Center
Omaha, Nebraska
July 1989- Assistant Professor of Internal Medicine
June 1993 University of Nebraska Medical Center
College of Medicine
Israel Rubinstein, M.D.
5 of 115
Omaha, Nebraska
1983-1985 Instructor in Internal Medicine
Sackler School of Medicine
Tel-Aviv University
Tel-Aviv, Israel
Grant/Contract support:
Present
Title: Mechanisms and translation of lipid resuscitation
Source: Department of Veterans Affairs Merit Review (1I01BX001514-01A1)
Period of Support: 10/01/2012-09/30/2016
Amount: $650,000 direct costs (P.I.)
Past
Title: Long-acting VIP formulations for the treatment of chronic inflammatory diseases
Source: National Institutes of Health Small Business Innovation Research Grant (PharmaIN,
Ltd., Seattle, Washington); 1 R43 AI082723-01
Period of Support: 08/01/09-04/30/12
Amount: $ 200,000 total costs (P.I. at University of Illinois at Chicago)
Title: Active targeting of paclitaxel to breast cancer in vivo
Source: Department of Veterans Affairs Merit Review
Period of Support: 10/01/05-09/30/11
Amount: $530,000 direct costs (P.I.)
Title: Feasibility Study of UIC’S Sterically Stabilized Phospholipid
Micelle Containing BB138560
Source: Novartis Pharma AG
Period of Support: 06/15/08-03/31/10
Amount: $285,000 direct costs (Co-I.)
Title: Novel nanomedicines for breast cancer
Source: National Institutes of Health 1 RO1 CA121797
Period of Support: 09/04/07-08/03/09
Amount: $760,000 direct costs (Co-I.)
Title: Micellar VIP nanoparticles: a novel, long-acting, biocompatible, disease-modifying
targeted therapy for rheumatoid arthritis
Source: National Institutes of Health 1 RO1 AG024026
Israel Rubinstein, M.D.
6 of 115
Period of Support: 08/15/04-05/29/09
Amount: $720,000 direct costs (P.I.)
Title: Targeting drugs to breast cancer
Source: Flight Attendant Medical Research Institute
Period of Support: 07/01/07-06/30/10
Amount: $300,000 direct costs (Co-.I.)
Grant rescinded by Sponsor due to contarct restrictions not accepted
by University of Illinois at Chicago
Title: Metals in exhaled breath condensate as COPD biomarkers
In response to RFA: Novel biomarkers of chronic obstructive pulmonary disease (COPD)
Source: National Institutes of Health 1 RO1 HL72343-01
Period of Support: 10/1/02-07/31/07
Amount: $429,400 direct costs of the Chicago site (Co-I in the multi-national consortium)
Title: A potential novel nanomedicine for Alzheimer’s Disease IDPH 8N
Source: Illinois Department of Public Health, Alzheimer’s Disease Research Fund
Period of Support: 06/1/06-05/31/07
Amount: $30,000 direct costs (Co-I.)
Title: Tc-99m labeled and VIP receptor targeted liposomes for effective
imaging of breast cancer
Source: U.S. Army Medical and Material Command
Period of Support: 09/1/02-09/30/06
Amount: $299,931 direct costs (Co-I.)
Title: Pilot study to compare the effects of clarithromycin XL in
reducing pulmonary inflammatory mediators in the exhaled breath
condensate of young patients with cystic fibrosis
Source: Abbott Laboratories
Period of Support: 6/1/01-11/30/04
Amount: $122,438 direct costs (P.I.)
Title: Suppression of breast cancer growth in female Sprague-Dawley rats
by tetramethyl NDGA in micellar formulation
Source: Johns Hopkins University
Period of Support: 12/1/00-11/30/02
Amount: $34,444 direct costs (Co-I.)
Title: Immunosurveillance of active TB by breath condensate
Source: Society of Infectious Diseases Pharmacists
Period of Support: 10/1/00-9/30/02
Amount: $24,900 direct costs
Research Preceptor and Co-Investigator
Awardee: Dr. Kevin W. Garey
Title: A novel breast cancer targeted drug delivery system
Israel Rubinstein, M.D.
7 of 115
Source: Illinois Department of Public Health - Penny Severns
Breast and Cervical Cancer Research Funds
Period of Support: 09/1/01-8/31/02
Amount: $56,100 direct costs (Co-I.)
Title: Pharmacodynamic and immunomodulatory profiles of telithromycin
in Streptococcus pneumoniae thigh infection model
Source: Aventis Pharmaceuticals
Period of Support: 4/1/01-3/31/02
Amount: $6,500 direct costs (P.I. of the sub-study)
Title: Targeted delivery of paclitaxel to breast cancer
Source: University of Illinois at Chicago Campus Research Board
Period: 1/1/01-12/31/01
Amount: $14,978 direct costs (Co-I.)
Title: A pilot study on the anti-inflammatory effects of Synercid in vivo
Source: Aventis Pharmaceuticals
Period: 4/1/99-10/31/01
Amount: $32,000 direct costs (P.I.)
Title: Pilot study to compare the effects of clarithromycin versus
levofloxacin in reducing pulmonary inflammatory mediators in exhaled
gas and condensate of patients with community-acquired pneumonia
Source: Abbott Laboratories
Period: 4/1/99-3/31/01
Amount: $89,000 direct costs (P.I.)
Title: Breast cancer targeted liposomes
Source: American Cancer Society, Illinois Division, Inc.
and the Blowitz-Ridgeway Foundation
Period of Support: 9/1/98-8/31/00
Amount: $50,000 direct costs (Co-P.I.)
Title: A multicenter, open-label, randomized study to compare the safety
and efficacy of levofloxacin vs. ceftriaxone sodium and erythromycin
followed by clarithromycin and amoxicillin/clavulanate in the
treatment of serious community acquired pneumonia in adults
Source: Ortho-McNeil Pharmaceutical
Period of Support: 7/1/98-6/30/00
Amount: $30,000 direct costs (P.I.)
Israel Rubinstein, M.D.
8 of 115
Title: Mechanisms of mucociliary transport
Source: Department of Veterans Affairs Merit Review
Period of Support: 12/1/96-11/30/99
Amount: $300,000 direct costs (Collaborator)
Title: TBC11251 and LVH in spontaneously hypertensive hamsters
Source: Texas Biotechnology Corporation
Period: 2/1/99-10/31/99
Amount: $6,000 direct costs (P.I.)
Title: A randomized double-blind, double dummy, multicenter,
parallel group study to assess the efficacy and safety of
oral SB-265805 320 mg once daily versus oral clarithromycin 500 mg
twice daily for 7 days in the treatment of acute exacerbation of chronic
bronchitis
Source: SmithKline Beecham Pharmaceuticals
Period: 12/1/98-8/31/1999
Amount: $30,000 direct costs (P.I.)
Title: A randomized double-blind, double dummy, multicenter, parallel
group study to assess the efficacy and safety of oral SB-265805
320 mg once daily versus oral trovafloxacin 200 mg once daily
for 7 or 14 days in the treatment of bacterial community acquired
pneumonia (CAP) in adults
Source: SmithKline Beecham Pharmaceuticals
Period: 12/1/98-8/31/1999
Amount: $30,000 direct costs (P.I.)
Title: Effects of air pollution on obstructive sleep apnea
Source: American Lung Association
Period of Support: 7/1/96-6/30/99
Amount: $50,000 direct costs (Co-I.)
Title: VIP-liposomes for breast cancer imaging
Source: University of Illinois at Chicago Women and Gender Seed Grant
Period of Support: 5/1/98-6/30/99
Amount: $12,750 direct costs (Co-I.)
Title: Innovative therapeutic strategy to improve hypertension control
Source: University of Illinois at Chicago Campus Research Board
Period: 7/1/98-6/30/99
Amount: $9,000 direct costs (P.I.)
Title: Smokeless tobacco: mechanisms of buccal mucosa injury
Source: National Institutes of Health, Research Career Development Award
(1KO4 DE00386)
Israel Rubinstein, M.D.
9 of 115
Period of Support: 4/01/94-3/31/99
Amount: $332,703 direct costs (P.I.)
Title: Community based head start asthma intervention project
Source: The Otho S.A. Sprague Memorial Institute
Period: 12/1/95-11/30/98
Amount: $299,532 direct costs (Co-I.)
Title: Interaction of vasoactive intestinal peptide with phospholipid molecules
Awardee: Bavish Bodalia (Sponsors: Drs. H. Alkan- Önyüksel and I. Rubinstein)
Source: Pharmaceutical Research and Manufacturers of America Foundation
Period of Support: 6/1/98-5/31/99
Amount: $5,000 direct costs (Undergraduate Research Fellowship in Pharmaceutics)
Title: A double-blind, placebo-controlled trial to evaluate the efficacy of
clarithromycin in subjects with corticosteroid-dependent asthma
Source: Abbott Laboratories
Period of Support: 3/1/98-2/28/99
Amount: $25,000 direct costs (Co-P.I.)
Title: University Scholar Award
Source: University of Illinois
Period: 10/1/94-9/30/98
Amount: $18,000
Title: Immediate changes in vasomotor tone during short-term exposure to
lipopolysaccharide in vivo
Source: American Heart Association of Metropolitan Chicago
Period: 7/1/96-6/30/97
Amount: $50,000 (Co-I.)
Title: Sterically stabilized liposome formulations of vasoactive intestinal peptide
to enhance its biological activities
Source: University of Illinois at Chicago Invention Development Fund
Period of Support: 7/1/96-6/30/97
Amount: $9,986 direct costs (Co-P.I.)
Title: Smokeless tobacco: mechanisms of buccal mucosa injury
Source: National Institutes of Health (1RO1 DE10347)
Period of Support: 4/01/93 - 3/31/97
Amount: $337,667 direct costs (P.I.)
Title: Smokeless tobacco: mechanisms of buccal mucosa injury
Source: National Institutes of Health (1RO1 DE10347-S)
Period of Support: 4/1/94-3/31/97
Israel Rubinstein, M.D.
10 of 115
Amount: $89,288 direct costs
Research Supplement for Underrepresented Minorities
Awardee: Dr. Christopher O. Olopade
Title: Early vasomotor response to Pseudomonas aeruginosa
lipopolysaccharide in situ
Source: The Laerdal Foundation for Acute Medicine
Period: 12/1/95-11/30/96
Amount: $5,000 direct costs (P.I.)
Title: Regulation of peripheral microvascular tone during
short-term exposure to lipopolysaccharide in vivo
Source: The Laerdal Foundation for Acute Medicine
Period: 12/1/94-11/30/95
Amount: $7,700 direct costs (P.I.)
Title: Phase III study of Zileuton in moderate asthma
Source: Abbott Laboratories
Period of Support: 6/20/94-12/31/95
Amount: $ 31,920 direct costs (P.I.)
Title: Effects of 0.40 ppm ozone on arteriolar diameter in
hamsters with hereditary cardiomyopathy
Source: State of California Air Resources Board
Period of Support: 11/1/94-10/31/95
(Transfer of funds halted by the Governor of California)
Amount: $37,323 direct costs (P.I.)
Title: Ozone and obstructive sleep apnea
Source: University of Illinois at Chicago Campus Research Board
Period: 7/1/94-6/30/95
Amount: $11,000 direct costs (Co.-I.)
Title: Artificial surfactant and arteriolar diameter in cardiomyopathy
Source: University of Illinois at Chicago Campus Research Board
Period: 1/1/94-12/31/94
Amount: $6,000 direct costs (P.I.)
Title: Kinins, kininases and arteriolar reactivity in hypertension
Source: American Heart Association-Nebraska Affiliate
Period of Support: 7/1/92-12/31/94
Amount: $40,000 direct costs (P.I.)
Title: Endothelin research
Source: Parke-Davis Pharmaceutical Research
Period of Support: Unrestricted
Israel Rubinstein, M.D.
11 of 115
Amount: $10,000 direct costs (Co-P.I.)
Title: Role of chloride anion in modulating quinaprilat-induced decrease
in blood pressure in aging spontaneously hypertensive hamsters
Source: National Institute of Health (5KO7 AG00474-03)
Period of Support: 10/1/92-8/30/93
Amount: $5,000 direct costs (Co-P.I.)
Title: Kininases and arteriolar reactivity in hypertension
Awardee: Dr. Günther E. Müns (Sponsor: Dr. I. Rubinstein)
Source: American Heart Association-Nebraska Affiliate Fellowship
Period of Support: 7/1/93-6/30/94
Amount: $20,000 salary support
Title: The role of exosurf and the L-arginine/nitric oxide biosynthetic
pathway in regulating arteriolar diameter in the cheek pouch of hamsters
with hereditary cardiomyopathy
Source: University of Nebraska Medical Center Seed Grant 94-02
Period of Support: 7/1/93-6/30/94 (declined)
Amount: $7,500 direct costs (P.I.)
Title: Modulation of airway microvascular injury caused by grain
sorghum dust extract by substance P antagonist
Source: Nebraska Grain Sorghum Development, Utilization
and Marketing Board
Period of Support: 7/1/92-6/30/93
Amount: $3,275 direct costs (Co-P.I.)
Title: Smokeless tobacco and epithelial cell proliferation in the buccal mucosa
Source: Milheim Foundation
Period of Support: 7/1/92-6/30/93
Amount: $14,000 direct costs (P.I.)
Title: Neutral endopeptidase modulates neurotensin-induced changes
in coronary artery reactivity in dogs
Source: University of Nebraska Medical Center Seed Grant 92-41
Period of Support: 7/1/91-6/30/92
Amount: $7,500 direct costs (P.I.)
Title: Interleukin-1 modulation of baroreflex control of heart rate in dogs
Source: American Heart Association-Nebraska Affiliate
Period of Support: 7/1/91-6/30/92
Amount: $20,000 direct costs (P.I.)
Title: Smokeless tobacco-mechanisms of buccal mucosa injury
Source: American Cancer Society Institutional Research Grant (IRG-165D)
Period of Support: 10/1/91-9/30/92
Israel Rubinstein, M.D.
12 of 115
Amount: $9,375 direct costs (P.I.)
Title: Tachykinins and bronchial epithelial cell release of leukocyte
chemoattractant activity
Source: University of Nebraska Medical Center Seed Grant 91-80
Period of Support: 7/1/90-6/30/91
Amount: $7,500 direct costs (P.I.)
Title: Asthma research
Source: The American-Israel Medical Foundation
Period of Support: Unrestricted
Amount: $7,000 salary support
Title: Mechanisms of bronchial hyperreactivity
Source: Canadian Lung Association
Period of Support: 7/1/86-6/30/88
Amount: $50,000 Canadian salary support (Research Fellowship)
Title: Mechanisms of bronchial hyperreactivity
Source: Non-Resident Fellowship of the Israel Medical Association
-Canadian Chapter
Period of Support: 1985
Amount: $2,000 Canadian salary support (Fellowship)
Pending
Title: Intralipid: a novel frontline countermeasure for brodifacoum poisoning
Source: National Institutes of Health (U01; PAR-11-155)
Period of Support: 07/01/13-06/30/17
Amount: $1,890,000 direct costs (Co-PI)
Other appointments or positions:
2010 - Co-Founder and Principal
Present ResQ Pharma, LLC
Northbrook, Illinois
2001- Member
Present Board of Directors
Advanced Life Sciences (NASDAQ symbol: ADLS)
Woodridge, Illinois
Member, Audit Committee
Member, Compensation Committee
2004- Member
Israel Rubinstein, M.D.
13 of 115
2010 Board of Governors, Endowment Fund
Society of Experimental Biology and Medicine
2004- Member
2010 Membership Committee
Society of Experimental Biology and Medicine
1998- Co-founder and Principal
2006 MedLipids, Inc.
Highland Park, Illinois
2002- Minority shareholder
2004 Vipogen, LLC
Wilmette, Illinois
1996- President and Chief Executive Officer
2000 Hyperpeptide, Inc.
Highland Park, Illinois
2003- Councilor
2004 Society of Experimental Biology and Medicine
1989- Board of Trustees
1994 American-Israel Medical Foundation
Cleveland, Ohio
Medical certification:
1976 ECFMG Certificate
1977 Israel License
1981 VQE Certificate
1985- Education License, College of
1987 Physicians and Surgeons of Ontario, Canada
1989 FLEX, FIN
1990 Nebraska License (active)
1990 DEA Certificate
1990 Diplomat, American Board of Internal Medicine,
1992 Diplomat, American Board of Internal Medicine,
Pulmonary Disease Subspecialty
Israel Rubinstein, M.D.
14 of 115
1993 Illinois License (active)
1993 Illinois Controlled Substance Certificate
Consulting positions:
Editor
Journal of Nanotechnology, Science and Applications - Editor-in-Chief
International Journal of Nanomedicine - Associate Editor
Frontiers in Drug Delivery Biotechnology – Associate Editor (past)
Journal of Biomedical Nanotechnology - Associate Editor (past)
Editorial Board
Angiology
Chest (1998 - 2005)
Clinical and Molecular Allergy
Clinical Medicine: Arthritis and Musculoskeletal Disorders
Current Respiratory Medicine Reviews
Hypertension
Journal of Heart Disease
Journal of Nanomedicine and Biotherapeutic Discovery
Microcirculation
Nanomedicine: Nanotechnology, Biology and Medicine
Nanotechnology, Science and Applications
PLOS ONE
Recent Patents on CNS Drug Discovery
Respiration
Respiratory Research (Reporter)
The Open Hypertension Journal
The Open Sports Medicine Journal
Turkish Thoracic Journal
Journal review
Acta Haematologica
African Journal of Microbiology Research
American Journal of Pathology
American Journal of Physiology
American Journal of Respiratory Cell and Molecular Biology
American Journal of Respiratory and Critical Care Medicine
(formerly American Review of Respiratory Diseases)
American Journal of Respiratory Medicine
Israel Rubinstein, M.D.
15 of 115
Anesthesia & Analgesia
Angiology
Antimicrobial Agents and Chemotherapy
Biochemica Biophysica Acta
Biochemical Pharmacology
BioMed Research International
BioMed Central Pulmonary Medicine
Cancer, Epidemiology, Biomarkers & Prevention
Cancer Letters
Carcinogenesis
Chemistry and Physics of Lipids
Chest
Circulation
Clinica Chimica Acta
Clinical and Applied Immunology Reviews
Clinical and Experimental Immunology
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
Clinical Science
Current Molecular Pharmacology
Current Respiratory Medicine Reviews
Disease Markers
Drugs of Today
European Respiratory Journal
Experimental Biology and Medicine
Expert Opinion on Drug Delivery
Expert Review of Respiratory Medicine
Free Radical Biology & Medicine
Hypertension
Human Gene Therapy
Inflammation Research
International Journal of Nanomedicine
International Journal of Obesity and Related Metabolic Disorders
International Journal of Pharmaceutics
Journal of Allergy and Clinical Immunology
Journal of Applied Physiology
Journal of Biomedical Nanotechnology
Journal of Clinical Investigation
Journal of Controlled Release
Journal of Dental Research
Journal of Diabetes and Its Complications
Journal of Immunological Methods
Journal of Immunology
Journal of Infection
Journal of Laboratory and Clinical Medicine
Journal of Nanobiotechnology
Journal of Pain Research
Journal of Pharmacy and Pharmacology
Israel Rubinstein, M.D.
16 of 115
Journal of the National Medical Association
Journal of Translational Medicine
Kidney
Kidney International
Life Sciences
Lung
Mediators of Inflammation
Medical Science Monitor
Medicinal Research Reviews
Microcirculation
Microvascular Research
Molecular Cancer Therapeutics
Molecular and Cellular Biochemistry
Molecular Pharmaceutics
Nanomedicine
New England Journal of Medicine
Pediatric Drugs
Peptides
Pharmaceutical Research
Physiological Genomics
PLoS ONE
Regulatory Peptides
Respiratory Medicine
Scandinavian Journal of Infectious Diseases
Seminars in Arthritis and Rheumatism
Sleep
Southern Medical Journal
The Open Sports Medicine Journal
The Open Transplantation
Therapeutics and Clinical Risk Management
Therapeutic Delivery
Thorax
Translational Research
Treatments in Respiratory Medicine
Grant review
Member, Special Emphasis Panel, ZGM1 TWD-Y C2, COBRE II Panel 11, Review of
PAR-12-224, Limited Competition: Renewal of Centers of Biomedical Research
Excellence (COBRE) [P20], National Institute of General Medical Sciences, National
Institutes of Health
Member, Bioengineering BSc 1 Committee, American Heart Association
Member, R4 Basic Cell & Molecular Biology 1 Committee, American Heart
Association
Ad hoc, Universiteit Gent, Ghent, Belgium
Israel Rubinstein, M.D.
17 of 115
Ad hoc, Indo-US Science & Technology Forum, New Delhi, India
Ad hoc, Research Management Group, Linthicum Heights, Maryland
Ad hoc, Health Effects Institute, Boston, Massachusetts
Ad hoc, American Lung Association of Metropolitan Chicago Grant Review Committee
Member, Special Emphasis Panel, ZDE1 RW 11, Review of RFA-DE-09-001 and RFA-
09-002 Harnessing Inflammation for Reconstruction of Oral and Craniofacial Tissues,
National Institute of Dental and Craniofacial Research, National Institutes of Health
Past member, American Heart Association, National Center (Affiliate) and
Metropolitan Chicago
Ad hoc, Department of Veterans Affairs Merit Review
Ad hoc, Israel Academy of Sciences and Humanities
Ad hoc, Center for Indoor Air Research
Past member, Campus Review Board Clinical Sciences Subcommittee, University of
Illinois at Chicago
Ad hoc, Research Program/ Center Seed Grant Proposal Review Committee, University
of Illinois at Chicago
Ad hoc, Cure Autism Now Foundation
Ad hoc, North Carolina Biotechnology Center, Science and Technology Development
Program
Ad hoc, Manitoba Medical Service Foundation
Member, Special Emphasis Panel, ZHL1 CSR-A S1, Review of RFA HL-04-036,
Causes and Mechanisms of COPD Exacerbations, National Heart, Lung, and Blood
Institute, National Institutes of Health
Member, Jesse Brown VA Medical Center, Westside Institute for Science & Education
Young Investigator Grant Award Subcommittee
Consultant
1994-Present National Institutes of Health, Bethesda, Maryland
Advisory Board
2008-Present CME Advisor, Amedco, Inc., St. Paul, Minnesoata
2001-Present Member, Scientific Executive Committee, International Academy of
Cardiology, Inc.
2001-Present Member, Scientific Executive Committee, World Congress on Heart
Disease, International Academy of Cardiology, Inc.
2001- Present Faculty Member, Aventis Pharmaceuticals - National Visiting Professor
Program, Bridgewater, New Jersey
2007 Award Committee, 13th
World Congress on Heart Annual Scientific
Sessions 2007, International Academy of Cardiology, Inc., Vancouver,
B.C., Canada, July 28-31, 2007
Israel Rubinstein, M.D.
18 of 115
2000-2006 Faculty Member, Airways: The Chiron National Speakers’ Council,
New York, New York
2000-2006 Member, Anti-Infective Forum, Abbott Laboratories, Abbott Park,
Illinois
2005-2006 Member, R&D Respiratory Advisory Board, Kos Pharmaceuticals, Inc.
Weston, Florida
2000- 2003 Faculty Member, Vital Signs: Improving Care for the Medicare Patient
with Community-Acquired Pneumonia, Evolution Health Initiatives,
Iselin, New Jersey
2003 Award Committee, 3rd
Congress on Heart Disease – New Trends in
Research, Diagnosis and Treatment, International Academy of
Cardiology, Inc., Washington, D.C., July 12-15, 2003.
1997-2000 Member, Scientific Advisory Board, International Congress on Heart
Disease - New Trends in Research, Diagnosis and Treatment,
International Academy of Cardiology, Inc.
1996-2000 Scientific Advisory Board, World Congress on Heart Failure –
Mechanisms and Management, International Society of Heart Failure,
Inc.
Additional professional activities:
2013 Organizing Committee, Pharmaceutica-2013, 3rd
International
Conference and Exhibition of Pharmaceutics & Novel Drug Delivery
Systems, April 8-10, 2013; Chicago, Illinois, USA
2009 American Association of Pharmaceutical Scientis (AAPS) 2009 Annual
Meeting, The Physical Pharmacy and Biopharmaceutics (PPB) Section
Abstract Screener
2008 Diplomat, The Problem Based Learning Institute, LLC, Chesterfiled,
Missouri, USA; Certificate Number 0077
2001- Member, Joint European Society/American Thoracic Society Task Force
Present on Exhaled Breath Condensate
1999-Present Member, Professional Assisted Cessation Therapy Organization
1998-Present Organizational representative of Jesse Brown VA Medical Center to the
Chicago Asthma Consortium
Israel Rubinstein, M.D.
19 of 115
1996-Present Question Author, American Board of Internal Medicine,
Philadelphia, Pennsylvania
1995-Present Abstract Grader, International Academy of Cardiology Annual Scientific
Sessions
2006 Judge, Graduate Student and Post-Doctoral Poster Competitions,
Neuropharmacology Division, American Society for Experimental
Pharmacology and Therapeutics, Experimental Biology 2006, San
Francisco, California
1998 Member, American Thoracic Society Workshop on the Standardization
of Endogenous Nitric Oxide Measurement in Exhaled Breath and Nasal
Nitric Oxide, Toronto, Ontario, Canada
1994- Member, Joint Peer Review Committee, American
1995 Heart Association of Metropolitan Chicago
1992- Member, Research Committee, American Heart Association
1993 Nebraska Affiliate, Omaha, Nebraska
1993 Member, Seed Grants Review Committee,
University of Nebraska Medical Center, Omaha, Nebraska
Military service:
May 1977- Medical Officer (Captain), compulsory military service, Israel Defense
Sept. 1981 Forces, Medical Corps, including two years as Chief, Multidisciplinary
Outpatient Clinic, Southern Command Headquarters, and one year as
Scientist, R&D Branch, Medical Corps Headquarters; honorably
discharged with yearly active reserve duty thereafter.
Academic awards and honors:
2001-Present Fellow, American Heart Association and Council for High Blood
Pressure Research
2001-Present Fellow, American Heart Association and Council on Basic
Cardiovascular Sciences
1995-Present Fellow, Council on Circulation, American Heart Association
Israel Rubinstein, M.D.
20 of 115
1994-Present Fellow, American College of Physicians
1994-Present Fellow, Cardiovascular Section, American Physiological Society
1993-Present Fellow, Council for High Blood Pressure Research,
American Heart Association
1993-Present Fellow, American College of Chest Physicians
1994-1999 Research Career Development Award
National Institutes of Health
1994-1997 Richard G. and Carole J. Cline University Scholar, University of Illinois
1993 University of Nebraska Medical Center, College of Medicine
Young Investigator Award
1986-1988 Canadian Lung Association Fellowship
1987 Honorable Mention, Department of Medicine
Research Competition, Toronto General Hospital,
Toronto, Ontario, Canada
1970-1972 Hebrew University-Hadassah School of Medicine Scholarship
Society memberships:
American Association of Pharmaceutical Scientists
American College of Chest Physicians
American College of Physicians
American Heart Association
American Physiological Society
American Society for Microbiology
American Society for Pharmacology and Experimental Therapeutics
American Thoracic Society
Controlled Release Society
International Society for Heart Research, American Section
Israel Medical Association
Microcirculatory Society, Inc.
Society for Experimental Biology and Medicine
Society for Neuroscience
UCSF Alumni Association
Committee assignments:
2008-Present Member, Integrated Ethics Council, Jesse Brown VA Medical Center,
Chicago, Illinois
Israel Rubinstein, M.D.
21 of 115
1996-Present Member, Thesis Defense Examination Committee, Graduate College,
University of Illinois at Chicago, Chicago, Illinois
1994-Present Member, Department of Medicine Institutional Review Board,
University of Illinois at Chicago, Chicago, Illinois
2007-2008 Chair, Research and Development Committee, Jesse Brown VA
Medical Center, Chicago, Illinois
2006-2007 Vice Chair, Human Subject Research Subcommittee, Jesse Brown VA
Medical Center, Chicago, Illinois
2007 Awards Committee, 13th
World Congress on Heart Disease,
Vancouver, British Columbia, Canada
2005-2006 Member, Human Subject Research Subcommittee, Jesse Brown VA
Medical Center, Chicago, Illinois
1994-2005 Member, Research and Development Committee, Jesse Brown VA
Medical Center, Chicago, Illinois
2002- 2003 Member, Scientific Advisory Committee, General Clinical Research
Center, University of Illinois at Chicago, Chicago, Illinois
2000 Panelist, Campus Research Board, University of Illinois at Chicago,
Chicago, Illinois, “How to Get Funded by the CRB.”
1999- 2001 Member, University Scholar Review Panel, University of Illinois at
Chicago, Chicago, Illinois
1997- 1999 Member, Research Program/ Center Seed Grant Proposal Review
Committee, University of Illinois at Chicago
1995-1999 Member, Program Committee of UIC University Scholars, University
of Illinois at Chicago, Chicago, Illinois
1997-1999 Member, Campus Research Board Clinical Sciences Subcommittee,
University of Illinois at Chicago, Chicago, Illinois
1994-1995 Program Committee, Chicago Thoracic Society Monthly Lecture
Series, Chicago, Illinois
1994-1995 Seminar Co-Chairman; Section of Respiratory and Critical Care
Medicine, Department of Medicine, University of Illinois at Chicago,
Chicago, Illinois
Israel Rubinstein, M.D.
22 of 115
1994-1995 Member, Chief of Rheumatology Search Committee, University of
Illinois at Chicago, College of Medicine, Chicago, Illinois
1989-1993 Seminar Chairman; Pulmonary and Critical Care Medicine Section,
University of Nebraska Medical Center, Omaha, Nebraska
Community service:
2008 Guest; WHIT radio, South Haven, Michigan; Health Matters – COPD
2000 Guest; CAN TV, Chicago, Illinois; National Sarcoidosis Networking
Society of America, Inc., HOTLINE live call-in program
1992-1993 Organizer; Sleep Apnea Support Group, University of Nebraska
Medical Center, Omaha, Nebraska
BIBLIOGRAPHY
Articles published in scholarly journals
Rubinstein I, Baum GL, Kalter Y, Pauzner Y, Lieberman Y, Bubis JJ. Resectional surgery in
the treatment of primary carcinoma of the lung with mediastinal lymph node metastases.
Thorax 34: 33-35, 1979.
Rubinstein I, Baum GL, Kalter Y, Pauzner Y, Lieberman Y, Bubis JJ. The influence of cell
type and lymph node metastases on survival of patients with carcinoma of the lung undergoing
thoracotomy. American Review of Respiratory Disease 119: 253-262, 1979.
Rubinstein I, Hiss Y, Baum GL. Neurological presenting symptoms in sarcoidosis. Harefuah
105: 210-211, 1983.
Rubinstein I, Hiss Y, Baum GL. Intramedullary spinal cord sarcoidosis. Surgical Neurology
21: 272-274, 1984.
Zwas ST, Rubinstein I. The value of dual radionuclide studies in solitary parotid gland
sarcoidosis. Clinical Nuclear Medicine 9: 359, 1984.
Rubinstein I, Baum GL. Selective IgA deficiency associated with recurrent sinopulmonary
infections in a patient with sarcoidosis. European Journal of Respiratory Diseases 65: 550-552,
1984.
Rubinstein I, Baum GL, Lieberman Y, Bubis JJ. Asymptomatic pulmonary nodule in
sarcoidosis - A case report with long-term follow-up. European Journal of Respiratory
Diseases 66: 74-76, 1985.
Israel Rubinstein, M.D.
23 of 115
Rubinstein I, Baum GL, Bubis JJ, Kalter Y, Lieberman Y. Prognosis of patients with
adenocarcinoma of the lung and mediastinal lymph node metastases undergoing pulmonary
resection. Respiration 47: 70-72, 1985.
Rubinstein I, Langevitz P, Shibi G. Isolated malignant lymphoma of the jejunum and long-
term diphenylhydantoin therapy. Oncology 42: 104-106, 1985.
Rubinstein I, Baum GL, Hiss Y. Misdiagnosis of sarcoidosis in three patients with active
pulmonary tuberculosis. Harefuah 108: 175-176, 1985.
Rubinstein I, Baum GL, Hiss Y, Solomon A. Hemoptysis in sarcoidosis. European Journal of
Respiratory Diseases 66: 302-305, 1985.
Rubinstein I, Baum GL, Hiss Y. Cardiac tamponade as the presenting symptom of sarcoidosis.
American Heart Journal 109: 1387-1388, 1985.
Rubinstein I, Baum GL, Yellin A, Herczeg E. Sarcoidosis-A cause of bilateral hilar
lymphadenopathy after excision of malignant melanoma of the arm. Southern Medical Journal
78: 1139-1140, 1985.
Rubinstein I, Baum GL, Hiss Y, Margaliot S, Yellin A. Sarcoidosis and Hashimoto's
thyroiditis - A chance occurrence? Respiration 48: 136-139, 1985.
Rubinstein I, Langevitz P, Hirsch R, Berckowicz M, Lieberman Y, Shibi G. Autoimmune
hemolytic anemia as the presenting manifestation of malignant thymoma. Acta Haematologica
74: 40-42, 1985.
Rubinstein I, Solomon A, Baum GL, Hiss Y. Pulmonary sarcoidosis presenting with unusual
roentgenographic manifestations. European Journal of Respiratory Disease 67: 335-340, 1985.
Rubinstein I, Baum GL, Hiss Y. Sarcoidosis of the penis-Report of a case. Journal of Urology
135: 1016-1017, 1986.
Rubinstein I, Baum GL, Hiss Y, Goldhammer Y. Does prolonged use of diphenylhydantoin
predispose to pulmonary sarcoidosis? European Neurology 25: 281-284, 1986.
Rubinstein I, Fisman EZ, Rosenblum Y, Pines A, Shiner RD, Ben-Ari E, Baum GL, Kellerman
JJ. Left ventricular exercise echocardiographic abnormalities in patients with sarcoidosis
without clinical cardiac dysfunction. Israel Journal of the Medical Sciences 22: 865-872, 1986.
Rubinstein I, Vanek AW, McClean PA, Boucher R, Zamel N, Slutsky AS. An isovolume
method for analysis of density dependence of maximal expiratory flows. Journal of Applied
Physiology 62: 2115-2120, 1987.
Rubinstein I, Hoffstein V. Unexpected death associated with unusual thoracic sarcoidosis.
Canadian Medical Association Journal 136: 1064-1065, 1987.
Israel Rubinstein, M.D.
24 of 115
Rubinstein I, McClean PA, Boucher R, Zamel N, Fredberg JJ, Hoffstein V. Effect of
mouthpiece, nose clips, and head position on airway area by acoustic reflections. Journal of
Applied Physiology 63: 1469-1474, 1987.
Rubinstein I, Levison H, Slutsky AS, Hak H, Wells J, Zamel N, Rebuck AS. Immediate and
delayed bronchoconstriction after exercise in patients with asthma. New England Journal of
Medicine 317: 482-485, 1987.
Rubinstein I, Langevitz P, Pras M. Aurothioglucose overdosage in five patients with
rheumatoid arthritis. Clinical Rheumatology 6: 583-587, 1987.
Schewach-Millet M, Ziv R, Trau H, Zwas ST, Ronnen M, Rubinstein I. Sarcoidosis versus
foreign-body granulomas. International Journal of Dermatology 26: 582-585, 1987.
D'Urzo AD, Rubinstein I, Lawson VG, Vassal KP, Rebuck AS, Slutsky AS, Hoffstein V.
Comparison of glottic areas measured by acoustic reflections vs. computerized tomography.
Journal of Applied Physiology 64: 367-370, 1988.
Rubinstein I, Mullen JBM, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary
lipoproteinosis-revisited. Archives of Internal Medicine, 148: 813-816, 1988.
Rubinstein I, Slutsky AS, Zamel N, Hoffstein V. Paradoxical glottic narrowing in patients with
severe obstructive sleep apnea. Journal of Clinical Investigation 81: 1051-1055, 1988.
Rubinstein I, Slutsky AS, Rebuck AS, McClean PA, Boucher R, Szeinberg A, Zamel N.
Assessment of maximal expiratory pressure in healthy adults. Journal of Applied Physiology
64: 2215-2219, 1988.
Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary emboli in hospitalized patients. An
autopsy study. Archives of Internal Medicine 148: 1425-1426, 1988.
Hoffstein V, Chaban R, Cole P, Rubinstein I. Snoring and upper airway properties. Chest
94:87-89, 1988.
Rubinstein I, Gray TA, Moldovsky H, Hoffstein V. Neurosarcoidosis associated with
hypersomnolence treated with corticosteroids and brain irradiation. Chest 94: 205-206, 1988.
Hoffstein V, Rubinstein I, Mateika S, Slutsky AS. Determinants of blood pressure in snorers.
Lancet 2: 992-994, 1988.
Rubinstein I, Zamel N, Rebuck AS, Hoffstein V, D’Urzo AD, Slutsky AS. Dichotomous
airway response to exercise in asthmatic patients. American Review of Respiratory Disease
138: 1164-1168, 1988.
Rubinstein I, Colapinto N, Rotstein LE, Brown IG, Hoffstein V. Improvement in pharyngeal
function after weight loss in patients with obstructive sleep apnea. American Review of
Respiratory Disease 138: 1192-1195, 1988.
Israel Rubinstein, M.D.
25 of 115
Standnyk AN, Rubinstein I, Grossman RF, Baum GL, Hiss Y, Solomon A, Rosenthal T.
Clinical features of sarcoidosis in elderly patients. Sarcoidosis 5: 121-123, 1988.
Rubinstein I, Hoffstein V, Bradley TD. Lung volume-related changes in the pharyngeal area of
obese females with and without obstructive sleep apnea. European Respiratory Journal 2: 344-
351, 1989.
Rubinstein I, Knecht A, deBeer FC, Baum GL, Pras M. Serum amyloid-A protein
concentrations in sarcoidosis. Israel Journal of Medical Sciences 25: 461-462, 1989.
Rubinstein I, Zamel N, Slutsky AS, Rebuck AS, Hoffstein V. Expiratory glottic widening in
asthmatic subjects during exercise-induced bronchoconstriction. American Review of
Respiratory Disease 140: 606-609, 1989.
Rubinstein I, England SJ, Zamel N, Hoffstein V. Glottic dimensions in healthy men and
women. Respiration Physiology 77: 291-299, 1989.
Dusser DJ, Jacoby DB, Djokic TD, Rubinstein I, Borson DB, Nadel JA. Virus induces airway
hyperreactivity to tachykinins: role of neutral endopeptidase. Journal of Applied Physiology
67: 1504-1511, 1989.
Reiss TF, Rubinstein I, Emery DL, Gold WM, Boushey HA, Jr. Local mediator release after
antigen challenge of a bronchial segment in allergic dogs. American Journal of Physiology
257: L366-L372, 1989.
Rubinstein I, Bradley TD, Zamel N, Hoffstein V. Glottic and cervical tracheal narrowing in
patients with obstructive sleep apnea. Journal of Applied Physiology 67: 2427-2431, 1989.
Rubinstein I, Reiss TF, Gardner DG, Liu J, Bigby BG, Boushey HA, Jr. Effect of exercise,
hyperpnea, and bronchoconstriction on plasma atrial natriuretic peptide in humans. Journal of
Applied Physiology 67: 2565-2570, 1989.
D'Urzo AD, Jhirad R, Jenne H, Avendano MA, Rubinstein I, D'Costa M, Goldstein RS. Effect
of caffeine on ventilatory responses to hypercapnia, hypoxia, and exercise in humans. Journal
of Applied Physiology 68: 322-328, 1990.
Rubinstein I, Bigby BG, Reiss TF, Boushey HA. Acute exposure to nitrogen dioxide does not
potentiate airway responsiveness to sulfur dioxide in asthmatic subjects. American Review of
Respiratory Disease 141: 381-385, 1990.
Rubinstein I, DuBarry L, Zamel N, Hoffstein V. Airflow limitation in morbidly obese, non-
smoking men. Annals of Internal Medicine 112: 828-832, 1990.
Rubinstein I, Iwamoto I, Ueki IF, Borson DB, Nadel JA. Recombinant neutral endopeptidase
attenuates substance P-induced plasma extravasation in the guinea pig skin. International
Archives of Allergy and Applied Immunology 91: 232-238, 1990.
Israel Rubinstein, M.D.
26 of 115
Rubinstein I, Nadel JA, Graf PD, Caughey GH. Mast cell chymase potentiates histamine-
induced wheal formation in the skin of ragweed-allergic dogs. Journal of Clinical
Investigation, 86: 555-559, 1990.
Franconi GM, Rubinstein I, Levine EH, Nadel JA. Mechanical removal of airway epithelium
degranulates mast cells. American Journal of Physiology 259: L372-L377, 1990.
Matsuda T, Eccleston CA, Rubinstein I, Rennard SI, Joyner WL. Antioxidants attenuate
endotoxin-induced microvascular leakage of macromolecules in vivo. Journal of Applied
Physiology 70: 1483-1489, 1991.
Rubinstein I, Reiss TF, Bigby BG, Stites DP, Boushey HA Jr. Effects of 0.60 PPM nitrogen
dioxide on circulating and bronchoalveolar lavage lymphocyte phenotypes in healthy subjects.
Environmental Research 55: 18-30, 1991.
Matsuda T, Rubinstein I, Robbins RA, Koyama S, Joyner WL, Rennard SI. Role of neutrophils
in endotoxin-mediated microvascular injury in hamsters. Journal of Applied Physiology 71:
307-313, 1991.
Rubinstein I, Yong T, Rennard SI, Mayhan WG. Cigarette smoke extract attenuates
endothelium-dependent arteriolar dilatation in vivo. American Journal of Physiology 261:
H1913-H1918, 1991.
Matsuda T, Joyner WL, Eccleston-Joyner CA, Rubinstein I, Rennard SI. Morphological study
of bovine lung grafted into the hamster cheek pouch. Experimental Lung Research 18: 145-
154, 1992.
Rubinstein I, Houmsse M, Davis RG, Vishwanatha JK. Tissue angiotensin I-converting
enzyme activity in spontaneously hypertensive hamsters. Biochemical and Biophysical
Research Communications 183: 1117-1123, 1992.
Yong T, Gao X-p, Koizumi S, Conlon JM, Rennard SI, Mayhan WG, Rubinstein I. Role of
peptidases in bradykinin-induced increase in vascular permeability in vivo. Circulation
Research 70: 952-959, 1992.
Mayhan WG, Rubinstein I. Acetylcholine induces vasoconstriction in the microcirculation of
cardiomyopathic hamsters: reversal by L-arginine. Biochemical and Biophysical Research
Communications 184: 1372-1377, 1992.
Von Essen SG, Rennard SI, O'Neill D, Ertl RF, Robbins RA, Koyama S, Rubinstein I.
Bronchial epithelial cells release neutrophil chemotactic activity in response to tachykinins.
American Journal of Physiology 263: L226-L231, 1992.
Robbins RA, Hamel FG, Floreani AA, Gossman GL, Nelson KJ, Belenky S, Rubinstein I.
Bovine bronchial epithelial cells metabolize L-arginine to L-citrulline: possible role of nitric
oxide synthase. Life Sciences 52: 709-716, 1993.
Israel Rubinstein, M.D.
27 of 115
Jain B, Rubinstein I, Robbins RA, Leise KL, Sisson JH. Modulation of airway epithelial cell
ciliary beat frequency by nitric oxide. Biochemical and Biophysical Research Communications
191: 83-88, 1993.
Thompson AB, Huerta G, Robbins RA, Sisson JH, Spurzem JR, Von Essen S, Rickard KA,
Romberger DJ, Rubinstein I, Ghafouri M, Daughton DM, Rennard SI. The bronchitis index: a
semiquantitative visual scale for the assessment of airways inflammation. Chest 103: 1482-
1488, 1993.
Belenky SA, Robbins RA, Rubinstein I. Nitric oxide synthase inhibitors attenuate human
monocyte chemotaxis in vitro. Journal of Leukocyte Biology 53: 498-503, 1993.
Gao X-p, Mayhan WG, Conlon JM, Rennard SI, Rubinstein I. Mechanisms of T-kinin-induced
increases in macromolecule extravasation in vivo. Journal of Applied Physiology 74: 2896-
2903, 1993.
Mayhan WG, Rubinstein I. Cigarette smoke extract potentiates bradykinin-induced increases
in microvascular permeability. Journal of Applied Physiology 75: 27-32, 1993.
Gao X-p, Robbins RA, Snider RM, Lowe J III, Rennard SI, Anding P, Rubinstein I. NK1
receptors mediate tachykinin-induced increase in microvascular clearance in hamster cheek
pouch. American Journal of Physiology 265: H593-H598, 1993.
Belenky S, Robbins RA, Gossman G, Nelson K, Rennard SI, Rubinstein I. Inhibitors of nitric
oxide synthase attenuate human neutrophil chemotaxis in vitro. Journal of Laboratory and
Clinical Medicine 122: 388-394, 1993.
Müns G, Vishwanatha JK, Rubinstein I. Regulation of angiotensin I-converting enzyme in
cultured bovine bronchial epithelial cells. Journal of Cellular Biochemistry 53: 352-359, 1993.
De Blasio F, Daughton DM, Thompson AB, Robbins RA, Spurzem JR, Sisson JH, Von Essen
SG, Romberger DJ, Rubinstein I, Floreani AA, Boomsma J, Pezza A, Rennard SI. General vs.
local anesthesia: effect on bronchoalveolar lavage findings. Chest 104: 1032-1037, 1993.
Gao X-p, Anding P, Robbins RA, Rennard SI, Rubinstein I. Peptidases modulate bradykinin-
induced arteriolar dilatation in the hamster cheek pouch. American Journal of Physiology 266:
H93-H98, 1994.
DeRose V, Robbins RA, Snider RM, Spurzem JR, Thiele GM, Rennard SI, Rubinstein I.
Substance P increases neutrophil adhesion to bronchial epithelial cells. Journal of Immunology
152: 1339-1346, 1994.
Gao X-p, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in
liposomes: effects on systemic arterial blood pressure. Life Sciences 54: PL247-PL252, 1994.
Metcalf J, Rennard SI, Reed EC, Haire WD, Sisson JH, Walter T, Robbins RA and the
University of Nebraska Medical Center Bone Marrow Transplant Group. Corticosteroids as
Israel Rubinstein, M.D.
28 of 115
adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow
transplantation. American Journal of Medicine 96: 327-334, 1994.
Müns G, Vishwanatha JK, Rubinstein I. Effects of smokeless tobacco on chemically
transformed hamster oral keratinocytes: role of angiotensin I-converting enzyme.
Carcinogenesis 15: 1325-1327, 1994.
Mayhan WG, Rubinstein I. Effects of endothelin receptor antagonists on bradykinin-induced
increases in macromolecular efflux. Inflammation 18: 633-644, 1994.
Rubinstein I, Müns G, Zucker IH. Changes in vascular permeability in the skin of conscious
dogs with pacing-induced congestive heart failure. Basic Research in Cardiology 89: 487-498,
1994.
Gao X-p, Suzuki H, Olopade CO, Rubinstein I. Short-term exposure to lipopolysaccharide is
associated with microvascular contractile dysfunction in vivo. Life Sciences 56: 1243-1249,
1995.
Rubinstein I. Nasal inflammation is present in patients with obstructive sleep apnea.
Laryngoscope 105: 175-177, 1995.
Gao X-p, Rubinstein I. Neutral endopeptidase modulates substance P-induced vasodilation in
vivo. Journal of Applied Physiology 72: 562-568, 1995.
Vishwanatha JK, Müns G, Beckmann JD, Davis RG, Rubinstein I. Differential expression of
annexins I and II in bovine bronchial epithelial cells. American Journal of Respiratory Cell and
Molecular Biology 12: 280-286, 1995.
Müns G, Singer P, Wolf F, Rubinstein I. Impaired nasal mucociliary clearance in long-distance
runners. International Journal of Sports Medicine 16: 209-213, 1995.
Rubinstein I, Mayhan WG. L-arginine dilates cheek pouch arterioles in hamsters with
hereditary cardiomyopathy. Journal of Laboratory and Clinical Medicine 125: 313-318, 1995.
Rubinstein I, Gao X-p, Engel JA, Vishwanatha JK. Tissue angiotensin I-converting enzyme
activity in ageing hamsters with and without cardiomyopathy. Mechanisms of Ageing and
Development 78: 163-170, 1995.
Robbins RA, Nelson KJ, Gossman GL, Rubinstein I. Neurotensin stimulates neutrophil
adherence to bronchial epithelial cells in vitro. Life Sciences 56: 1353-1359, 1995.
Mayhan WG, Rubinstein I. Reactivity of the hamster cheek pouch microcirculation in response
to endothelin and endothelin receptor antagonists. International Journal of Microcirculation 15:
48-52, 1995.
Israel Rubinstein, M.D.
29 of 115
Jain B, Rubinstein I, Robbins RA, Sisson JH. TNFα and IL-1ß upregulate nitric oxide-
dependent ciliary motility in bovine airway epithelium. American Journal of Physiology 268:
L911-L917, 1995.
Gao X-p, Jaffe HA, Olopade CO, Rubinstein I. Stable VIP analogue Ro 24-9981 potentiates
substance P-induced plasma exudation in hamster cheek pouch. Journal of Applied Physiology
79: 968-974, 1995.
Suzuki H, Noda Y, Paul S, Gao X-p, Rubinstein I. Encapsulation of vasoactive intestinal
peptide into liposomes: effects on vasodilation in vivo. Life Sciences 57: 1451-1457, 1995.
Müns G, Rubinstein I, Singer P. Phagocytosis and oxidative burst of granulocytes in the upper
respiratory tract in chronic and acute inflammation. Journal of Otolaryngology 24: 105-110,
1995.
Gao X-p, Rubinstein I. Ro 24-9981 potentiates bradykinin-induced increases in clearance of
macromolecules. American Journal of Physiology 269: H1648-H1655, 1995.
Müns G, Rubinstein I, Bergmann K-C. Phagocytosis and oxidative burst of blood phagocytes
in chronic obstructive airway disease. Scandinavian Journal of Infectious Diseases 27: 369-
373, 1995.
Müns G, Rubinstein I, Singer P. Neutrophil chemotactic activity is increased in nasal
secretions of long-distance runners. International Journal of Sports Medicine 17: 56-59, 1996.
Rubinstein I, Daughton DM, Rennard SI. Physician reporting of and referral for patient
complaints about sleep disorders. Southern Medical Journal 89: 483-486, 1996.
Robbins RA, Floreani AA, Von Essen S, Sisson JH, Hill GE, Rubinstein I, Townley RG.
Measurement of exhaled nitric oxide by three different techniques. American Journal of
Respiratory and Critical Care Medicine 153: 1631-1635, 1996.
Gao X-p, Conlon JM, Vishwanatha JK, Robbins RA, Rubinstein I. Loop diuretics attenuate
bradykinin-induced increase in clearance of macromolecules in the oral mucosa. Journal of
Applied Physiology 80: 818-823, 1996.
Suzuki H, Noda Y, Gao X-p, Séjourné F, Alkan-Önyuksel H, Paul S, Rubinstein I.
Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ. American
Journal of Physiology 271: H282-H287, 1996.
Suzuki H, Gao X-p, Olopade CO, Jaffe HA, Pakhlevaniants S, Rubinstein I. Aqueous
smokeless tobacco extract impairs endothelium-dependent vasodilation in the oral mucosa.
Journal of Applied Physiology 81: 225-231, 1996.
Suzuki H, Gao X-p, Olopade CO, Rubinstein I. Neutral endopeptidase modulates VIP-induced
vasodilation in hamster cheek pouch vessels in situ. American Journal of Physiology 271:
R393-R397, 1996.
Israel Rubinstein, M.D.
30 of 115
Sekosan M, Zakkar M, Wenig B, Olopade CO, Rubinstein I. Inflammation in the uvula
mucosa of patients with obstructive sleep apnea. Laryngoscope 106: 1018-1020, 1996.
Gao X-p, Vishwanatha JK, Conlon JM, Olopade CO, Rubinstein I. Mechanisms of smokeless
tobacco-induced buccal mucosa inflammation: role of bradykinin. Journal of Immunology 157:
4624-4633, 1996.
Gao X-p, Rubinstein I. Interleukin-1α potentiates bradykinin-induced macromolecular efflux
from the hamster oral mucosa. American Journal of Physiology 272: R294-R301, 1997.
Gao X-p, Von Essen SG, Rubinstein I. Neurogenic plasma exudation mediates grain dust-
induced tissue injury in vivo. American Journal of Physiology 272: R475-R481, 1997.
Séjourné F, Rubinstein I, Suzuki H, Alkan-Önyüksel H. Development of a novel bioactive
formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharmaceutical
Research 14: 362-365, 1997.
Olopade CO, Zakkar M, Swedler WI, Rubinstein I. Exhaled pentane levels in acute asthma.
Chest 111: 862-865, 1997.
Olopade CO, Alikakos Z, Abubaker J, Rubinstein I. Characteristics of predominantly nonwhite
patients with frequent hospitalizations for acute asthma in Chicago. Journal of Asthma 34:
243-248, 1997.
Zakkar M, Sekosan M, Wenig B, Olopade CO, Rubinstein I. Immunoreactive neutral
endopeptidase is decreased in uvula epithelium of patients with obstructive sleep apnea.
Annals of Otology, Rhinology & Laryngology 106: 474-477, 1997.
Olopade CO, Christon JA, Zakkar M, Hua C-w, Swedler WI, Scheff PA, Rubinstein I. Exhaled
pentane and nitric oxide levels in patients with obstructive sleep apnea. Chest 111: 1500-1504,
1997.
Patel M, Rubinstein I, Ikezaki H, Alkan-Onyuksel H. Simplified preparation of vasoactive
intestinal peptide in sterically stabilized liposomes. Proceedings of the International
Symposium on Controlled Release of Bioactive Materials 24: 913-914, 1997.
Gao X-p, Suzuki H, Olopade CO, Pakhlevaniants S, Rubinstein I. Purified ACE attenuates
smokeless tobacco-induced macromolecular efflux from the oral mucosa. Journal of Applied
Physiology 83: 74-81, 1997.
Séjourné F, Suzuki H, Alkan-Önyüksel H, Gao X-p, Ikezaki H, Rubinstein I. Mechanisms of
vasodilation elicited by VIP in sterically stabilized liposomes in vivo. American Journal of
Physiology 273: R287-R292, 1997.
Thomas CL, Artwohl JE, Suzuki H, Gao X-p, White E, Saroli A, Bunte RM, Rubinstein I.
Initial characterization of hamsters with spontaneous hypertension. Hypertension 30[part 1]:
301-304, 1997.
Israel Rubinstein, M.D.
31 of 115
Gao X-p, Rubinstein I. Methotrexate potentiates bradykinin-induced macromolecular efflux
from the hamster oral mucosa. American Journal of Physiology 273: R1254-R1262, 1997.
Gao X-p, Suzuki H, Olopade CO, Pakhlevaniants S, Rubinstein I. Angiotensin-converting
enzyme and neutral endopeptidase modulate smokeless tobacco-induced increase in
macromolecular efflux from the oral mucosa in vivo. Journal of Laboratory and Clinical
Medicine 130: 395-400, 1997.
Gao X-p, Akhter SR, Rubinstein I. Ovalbumin increases macromolecular efflux from the in
situ nasal mucosa of allergic hamsters. Journal of Applied Physiology 84: 169-176, 1998.
Rubinstein I, Gao X-p, Pakhlevaniants S, Oda D. Smokeless tobacco-exposed oral
keratinocytes increase macromolecular efflux from the oral mucosa. American Journal of
Physiology 274: R104-R111, 1998.
Suzuki H, Caughey GH, Gao X-p, Rubinstein I. Mast cell chymase-like protease(s) modulates
Escherichia coli lipopolysaccharide-induced vasomotor dysfunction in skeletal in vivo. Journal
of Pharmacology and Experimental Therapeutics 284: 1156-1164, 1998.
Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S.
Stabilization of vasoactive intestinal peptide by lipids. Journal of Pharmacology and
Experimental Therapeutics 285: 753-758, 1998.
Vishwanatha JK, Davis RG, Blumberg S, Gao X-p, Rubinstein I. Tissue neutral endopeptidase
24.11 activity in hamsters with spontaneous hypertension. American Journal of Hypertension
11: 585-590, 1998.
Ikezaki H, Paul S, Alkan-Önyüksel H, Patel M, Gao X-p, Rubinstein I. Vasodilation elicited by
liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. American Journal
of Physiology 275: R56-R62, 1998.
Hatipoglu U, Gao X-p, Verral S, Séjourné F, Pitrak D, Alkan-Önyüksel H, Rubinstein I.
Sterically stabilized phospholipids attenuate human neutrophils chemotaxis in vitro. Life
Sciences 63: 693-699, 1998.
Ikezaki H, Alkan-Önyüksel H, Rubinstein I. Liposomal VIP attenuates phenylephrine- and
angiotensin II-induced vasoconstriction in vivo. American Journal of Physiology 275: R588-
R595, 1998.
Gulati A, Artwohl JE, Kumar A, Gao X-p, Rubinstein I. Endothelin-1-like immunoreactivity in
a new rodent model of spontaneous hypertension . American Journal of Hypertension 11: 866-
869, 1998.
Vishwanatha JK, Davis RG, Rubinstein I, Floreani A. Annexin I degradation in
bronchoalveolar lavage fluids from healthy smokers: a possible mechanism of inflammation.
Clinical Cancer Research 10: 2559-2564, 1998.
Israel Rubinstein, M.D.
32 of 115
Önyüksel H, Ikezaki H, Patel M, Rubinstein I. A novel formulation of VIP in sterically
stabilized micelles amplifies vasodilation in vivo. Pharmaceutical Research 16:155-160, 1999.
Akhter SR, Gao X-p, Ikezaki H, Rubinstein I. Dexamethasone attenuates grain sorghum dust-
induced increase in macromolecular efflux in vivo. Journal of Applied Physiology 86:1603-
1609, 1999.
Ikezaki H, Patel M, Önyüksel H, Akhter SR, Rubinstein I. Exogenous calmodulin potentiates
vasodilation elicited by phospholipid-associated VIP in vivo. American Journal of Physiology
276: R1359-R1365, 1999.
Dagar S, Sekosan M, Akhter S, Blend M, Rubinstein I, Onyuksel H. Identification and
targeting of VIP receptors in rats with chemically induced breast cancer. Proceedings of the
International Symposium on Controlled Release of Bioactive Materials 26: 22-23, 1999.
Patel M, Onyuksel H, Ikezaki H, Dagar S, Akhter SR, Rubinstein I. Optimized formulation of
vasoactive intestinal peptide on sterically stabilized liposomes. Proceedings of the
International Symposium on Controlled Release of Bioactive Materials 26: 831-832, 1999.
Gao X-p, Akhter SR, Ikezaki H, Hong D, Rubinstein I. Dexamethasone attenuates acute
macromolecular efflux increase evoked by smokeless tobacco extract. Journal of Applied
Physiology 87: 619-625, 1999.
Rubinstein I, Patel M, Ikezaki H, Dagar S, Önyüksel H. Conformation and vasoreactivity of
VIP in phospholipid micelles: effects of calmodulin. Peptides 20: 1497-1501, 1999.
Rubinstein I. Smokeless tobacco potentiates VIP-induced DNA synthesis and inactivates NEP
24.11 in oral keratinocytes. American Journal of Physiology Cell Physiology 278: C391-C396,
2000.
Ikezaki H, Akhter SR, Hong D, Suzuki H, Gao X-p, Rubinstein I. Tyrosine kinase inhibitors
modulate agonist-induced vasodilation in the hamster cheek pouch. Journal of Applied
Physiology 88: 857-862, 2000.
Önyüksel H, Bodalia B, Sehti V, Dagar S, Rubinstein I. Surface-active properties of vasoactive
intestinal peptide. Peptides 21: 419-423, 2000.
Suzuki H, Ikezaki H, Hong D, Rubinstein I. PGH2-TXA2 receptor blockade restores
vasoreactivity in a new rodent model of genetic hypertension. Journal of Applied Physiology
88: 1983-1988, 2000.
Önyüksel H, Dagar S, Gandhi S, Rubinstein I. Formulation of peptide drugs with the use of
phospholipid micelles. Proceedings of the 6th International Symposium on Pharmaceutical
Sciences ISOPS-6, June 27-29, 2000, Ankara, Turkey, PL-25: 91-94.
Rubinstein I. Subtilisin increases macromolecular efflux from the oral mucosa. Clinical and
Diagnostic Laboratory Immunology 7: 794-802, 2000.
Israel Rubinstein, M.D.
33 of 115
Garey K, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term
clarithromycin decreases prednisone requirements in elderly patients with prednisone-
dependent asthma. Chest 118: 1826-1827, 2000.
Rubinstein I, Potempa J, Travis J, Gao-X-p. Mechanisms mediating Porphyromonas gingivalis
gingipain RgpA-induced oral mucosa inflammation in vivo. Infection and Immunity 69: 1199-
1201, 2001.
Dagar S, Sekosan M, Rubinstein I, Önyüksel H. Detection of VIP receptors in MNU-induced
breast cancer in rats: implications for breast cancer targeting. Breast Cancer Research and
Treatment 65: 49-54, 2001.
Rubinstein I, Dagar S, Sethi V, Krishnadas A, Önyüksel H. Liposomal VIP potentiates DNA
synthesis in cultured oral keratinocytes. Peptides 22: 671-675, 2001.
Suzuki H, Ikezaki H, Chandiwala R, Hong D, Rubinstein I. Effects of Pseudomonas
aeruginosa endotoxin on vasodilation in the intact spinotrapezius muscle. Journal of Applied
Physiology 91: 353-356, 2001.
Kirchhoff C, Rubinstein I, Ludwig J, Önyüksel H. DSPE-PEG 5000 increases physical stability
of human interleukin-2 in vitro. Proceedings of the International Symposium on Controlled
Release of Bioactive Materials 28: 524-525, 2001.
Hjlem RP, Ashok B, Onyuksel H, Rubinstein I, Hepelmann R. Characterization of
phospholipid micelles by light scattering investigations: implications for effective drug
delivery. Proceedings of the International Symposium on Controlled Release of Bioactive
Materials 28: 556-557, 2001.
Gandhi S, Onyuksel H, Tsueshita T, Rubinstein I. Increased bioactivity of secretin in sterically
stabilized micelles: implications for therapy. Proceedings of the International Symposium on
Controlled Release of Bioactive Materials 28: 572-573, 2001.
Rubinstein I, Chandiwala R, Dagar S, Hong D, Gao X-p. Adenosine A1 receptors mediate
plasma exudation from the oral mucosa. Journal of Applied Physiology 91: 552-560, 2001.
Dagar S, Sekosan M, Lee B-S, Rubinstein I, Önyüksel H. VIP receptors as molecular targets of
breast cancer: implications for targeted imaging and drug delivery. Journal of Controlled
Release 74: 129-134, 2001.
Gandhi S, Rubinstein I, Tsueshita T, Önyüksel H. Secretin self-assembles and interacts
spontaneously with phospholipids in vitro. Peptides 23: 201-204, 2002.
Tsueshita T, Gandhi S, Rubinstein I. Effects of quinupristin/dalfopristin on vasomotor tone in
the intact peripheral microcirculation. Journal of Antimicrobial Chemotherapy 49: 1027-1030,
2002.
Israel Rubinstein, M.D.
34 of 115
Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: a
novel carrier for water-insoluble drugs. Proceedings of the International Symposium on
Controlled Release of Bioactive Materials 29: 391-392, 2002.
Koo O, Rubinstein I, Önyüksel H. Solubilization of camptothecin using DSPE-PEG 2000
micelles. Proceedings of the International Symposium on Controlled Release of Bioactive
Materials 29: 698-699, 2002.
Gandhi S, Tsueshita T, Önyüksel H, Chandiwala R, Rubinstein I. Self-association of secretin
with phospholipids amplifies vasoreactivity in vivo. Peptides 23: 1433-1439, 2002.
Rubinstein I, Pedersen GW. Bacillus species are present in chewing tobacco sold in the United
States and evoke plasma exudation from the oral mucosa. Clinical and Diagnostic Laboratory
Immunology 9:1057-1060, 2002.
Tsueshita T, Gandhi S, Önyüksel H, Rubinstein I. Phospholipids modulate the biophysical
properties and vasoactivity of PACAP(1-38). Journal of Applied Physiology 93: 1377-1383,
2002.
Onyuksel H, Dagar S, Krishnadas A, Blend MJ, Rubinstein I. VIP-liposomes for active, cell-
specific targeted delivery to breast cancer in vivo. Transactions of the 2nd
International
Symposium on Tumor Targeted Delivery Systems, The National Cancer Institute and
Controlled Release Society, Rockville, Maryland, September 22-25, 2002, pp. 63-65.
Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: in
vitro evaluation as a novel carrier for water-insoluble drugs. Pharmaceutical Research 20: 297-
302, 2003.
Önyüksel H, Ashok B, Dagar S, Sethi V, Rubinstein I. Interactions of VIP with rigid
phospholipid bilayers: implications for vasoreactivity. Peptides 24: 281-286, 2003.
Corradi M, Rubinstein I, Apostoli P, Andreoli R, Goldoni M, Manini P, Vettori MV, Mutti A.
Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary
disease. American Journal of Respiratory and Critical Care Medicine 167: 1380-1386, 2003.
Yeomans DC, Önyüksel, Dagar S, Ikezaki H, Lu Y, Rubinstein I. Conformation-dependent
effects of VIP on nociception in rats. Peptides 24: 617-622, 2003.
Ashok B, Rubinstein I, Önyüksel H. Solubilization by phospholipid mixed micelles composed
of different PEGylated lipids and phosphtidylcholine. Proceedings of the International
Symposium on Controlled Release of Bioactive Materials 30: 200-201, 2003.
Sethi V, Önyüksel H, Rubinstein I. Stabilization of -helical vasoactive intestinal peptide in
sterically stabilized micelles for potential treatment of rheumatoid arthritis. Proceedings of the
International Symposium on Controlled Release of Bioactive Materials 30: 691-692, 2003.
Israel Rubinstein, M.D.
35 of 115
Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Önyüksel H. VIP-grafted sterically stabilized
liposomes for targeted imaging of breast cancer: in vivo studies. Journal of Controlled Release
91: 123-133, 2003.
Dagar S, Önyüksel H, Akhter S, Krishnadas A, Rubinstein I. Human galanin expresses
amphipathic properties that modulate its vasoreactivity in vivo. Peptides 24: 1373-1380, 2003.
Ramirez A, Fry MB, Rubinstein I. Newly-diagnosed mycobacterial disease in inner-city
Chicago: the pulmonary fellow perspective. Respiration 70: 611-614, 2003.
Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I. Markers of
inflammation in exhaled breath condensate of young healthy smokers. Chest 125: 22-26, 2004.
Rubinstein I, Kumar B, Schriever C. Chronic montelukast therapy in moderate to severe
COPD – a preliminary observation. Respiratory Medicine 98: 134-138, 2004.
Tsueshita T, Önyüksel H, Sethi V, Gandhi S, Rubinstein I. Helospectin I and II evoke
vasodilation in the intact peripheral microcirculation. Peptides 25: 65-69, 2004.
Ashok B, Arleth L, Hjelm RP, Rubinstein I, Önyüksel H. In vitro characterization of pegylated
phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC
incorporation. Journal of Pharmaceutical Sciences 93: 2476-2487, 2004.
Ashok B, Rubinstein I, Tsueshita T, Önyüksel H. Effects of peptide molecular mass and PEG
chain length on the vasoreactivity of VIP and PACAP1-38 in pegylated phospholipid micelles.
Peptides 25: 1253-1258, 2004.
Rubinstein I, Ashok B, Tsueshita T, Önyüksel H. All D-VIP mitigates vasodilation elicited by
L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo. Peptides 26: 509-
515, 2005.
Koo OM, Rubinstein I, Önyüksel H. Camptothecin in sterically stabilized phospholipids
micelles: a novel nanomedicine. Nanomedicine: Nanotechnology, Biology, and Medicine 1:
77-84, 2005.
Nicolau DP, Tessier PR, Rubinstein I, Nightingale CH. In vivo immunomodulatory profile of
telithromycin in a murine infection model. Pharmazie 61: 343-347, 2006.
Rubinstein I, Ikezaki H, Önyüksel H. Intratracheal and subcutaneous liposomal VIP normalizes
systemic arterial pressure in spontaneously hypertensive hamsters. International Journal of
Pharmaceutics 316: 144-147, 2006.
Rubinstein I, Von Essen S. Modulation of hog barn dust extract-induced increase in
macromolecular efflux from the hamster cheek pouch. Journal of Applied Physiology 101: 128-
134, 2006.
Israel Rubinstein, M.D.
36 of 115
Mutlu GM, Rubinstein I. Clinical manifestations of sarcoidosis among inner-city African-
Americans dwellers. Journal of the National Medical Association 98: 1140-1143, 2006.
Önyüksel H, Séjourné F, Suzuki H, Rubinstein I. Human VIP-α: a long-acting, biocompatible
and biodegradable peptide nanomedicine for essential hypertension. Peptides 27: 2271-2275,
2006.
Koo OM, Rubinstein I, Önyüksel H. Camptothecin in sterically stabilized phospholipid nano-
micelles: a novel solvent pH change solubilization method. Journal of Nanoscience and
Nanotechnology 6: 2996-3000, 2006.
Pai AS, Rubinstein I, Önyüksel H. Pegylated phospholipid micelles interact with ß-amyloid(1-
42) and mitigate its ß-sheet formation, aggregation, and neurotoxicity in vitro. Peptides 27:
2858-2865, 2006.
Rubinstein I. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ETA
endothelin receptor antagonist, in spontaneously hypertensive hamsters. Cardiovascular Drugs
and Therapy 20: 387-390, 2006.
Rubinstein I, Önyüksel H. Biocompatible and biodegradable sterically stabilized phospholipid
nanomicelles improve cryopreservation of oral keratinocytes. International Journal of
Pharmaceuticals 338: 333-335, 2007
Jain R, Schriever, CA, Danziger L, Cho SH, Rubinstein I. The IS6110 repetitive DNA element
of Mycobacterium tuberculosis is not detected in exhaled breath condensate of patients with
active pulmonary tuberculosis. Respiration 74: 329-333, 2007.
Rubinstein I. Bradykinin- and substance P-induced edema formation in the hamster cheek
pouch is tyrosine kinase dependent. Journal of Applied Physiology 103:184-189, 2007.
Desai E, Önyüksel H, Jeon E, Rubinstein I. Neuropeptide Y self-associates with long-
circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles
resulting in amplified bioactivity. Proceedings of the International Symposium on Controlled
Release of Bioactive Materials 34: 224-225, 2007.
Wang H, Önyüksel H, Gulati A, Rubinstein I. Self-association of endothelin-1 with sterically
stabilized phospholipid nanomicelles amplifies its hemodynamic effects in rats. Journal of
Biomedical Nanotechnology 3: 270-276, 2007.
Önyüksel H, Sethi V, Weinberg G, Dudeja PK, Rubinstein I. Bupivacaine, but not lidocaine,
disrupts cardiolipin-containing small biomimetic unilamellar liposomes. Chemico-Biological
Interactions 169: 154-159, 2007.
Rubinstein I, Soos I, Önyüksel H. Intracellular delivery of VIP-grafted sterically stabilized
phospholipid mixed nanomicelles in human breast cancer cells. Chemico-Biological
Interactions 171: 190-194, 2008.
Israel Rubinstein, M.D.
37 of 115
Sethi V, Rubinstein I, Dudeja PK, Weinberg G, Önyüksel H. Biphasic behavior of bupivacaine
and cardiolipin-containing biomimetic membrane interaction. Journal of Drug Delivery
Science and Technology 18: 69-72, 2008.
Lim SB, Rubinstein I, Önyüksel H. Freeze drying of peptide drugs self-associated with long-
circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.
International Journal of Pharmaceutics 356; 345-350, 2008.
Önyüksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid
nanomicellar 17-allylamino-demethoxygeldanamycin: a novel nanomedicine. International
Journal of Pharmaceutics 365: 157-161, 2009.
Önyüksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases Cytotoxicity of multidrug
resistance breast cancer cells. Cancer Letters 274: 327-330, 2009.
Cesur J, Rubinstein I, Pai A, Önyüksel H. Self-associated indisulam in phospholipid-based
nanomicelles: a potential nanomedicine for cancer. Nanomedicine: Nanotechnology, Biology,
and Medicine 5:178-183, 2009.
Gao X-p, Rubinstein I. E. coli lipopolysaccharide attenuates adenosine A1 receptor-mediated
increase in plasma exudation from the hamster cheek pouch. Inflammation Research 60: 195-
201, 2011. Epub 2010 Oct 6.
Lim SM , Rubinstein I, Sadikot RT, James E. Artwohl JE, Önyüksel
H. A novel peptide
nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharmaceutical
Research 28: 662-672, 2011.
Koo OMY, Rubinstein I, Önyüksel H. Actively targeted low-dose camptothecin as a safe, long-
acting disease-modifying nanomedicine for rheumatoid arthritis. Pharmaceutical Research 28:
776-787, 2011. Epub 2010 Dec 4.
Kuzmis A, Lim SB, Desai E, Jeon E, Lee B-S, Rubinstein I, Önyüksel H. Micellar
nanomedicine of human neuropeptide Y. Nanomedicine: Nanotechnology, Biology, and
Medicine 7:464-471, 2011.
Weinberg G, Rubinstein I. Pig in a poke: species specificity in modeling lipid resuscitation.
Anesth Analg 114:907-909, 2012.
Famuyiwa F, Rubinstein I. Chronic sinopulmonary inflammatory diseases in adults with
undetectable serum IgE in inner-city Chicago – A preliminary observation. Lung 190;291-294,
2012.
Krishnamoorthy V, Hiller DB, Ripper R, Lin B, Vogel SM, Feinstein DL, Oswald S,
Rothschild L, Hensel P, Rubinstein I, Minshall R, Weinberg GL. Epinephrine induces rapid
deterioration in pulmonary oxygen exchange in intact, anesthetized rats: A flow and pulmonary
capillary pressure-dependent phenomenon. Anesthesiology 117:745-754, 2012.
Israel Rubinstein, M.D.
38 of 115
Brandenburg KS, Rubinstein I, Sadikot RT, Önyüksel H. Polymyxin B self-associated with
phospholipid nanomicelles. Pharmaceutical Development and Technology 17:654-660, 2012.
Dagar A, Kuzmis A, Rubinstein I, Sekosan M, Onyuksel H. VIP-targeted cytotoxic
nanomedicine for breast cancer. Drug Delivery and Translational Research 2: 454-462, 2012.
Polak PE, Dull RO, Kalinin S, Sharp AJ, Ripper R, Weinberg G, Rubinstein I, Feinstein DL.
Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis. Journal of
Neuroinflammation 2012 Dec 19;9:272.
Sethi V, Rubinstein I, Kuzmis A, Kastrissiois H, Artwohl J, Önyüksel H. Novel,
biocompatible, disease modifying nanomedicine of VIP for rheumatoid arthritis. Molecular
Pharmaceutics 10: 728-738, 2013.
Reichstetter S, Castillo GM, Rubinstein I, Nishimoto-Ashfield A, Lai MS, Jones CC, Aryamitra
B, Lyubimov A, Bloedow DC, Bogdanov A, Jr., Bolotin EM. Protected Graft Copolymer
Excipient Leads to a Higher Acute Maximum Tolerated Dose and Extends Residence Time of
Vasoactive Intestinal Peptide Significantly Better than Sterically Stabilized Micelles.
Pharmaceutical Research 30: 670-682, 2013.
Fettiplace M, Lin B, Ripper R, Lis K, Lang J, Zider B, Wang J, Rubinstein I, Weinberg G.
Rapid cardiotonic effects of lipid emulsion infusion. Critical Care Medicine (In Press)
Kalinin S, Willard SL, Shiveley CA, Kaplan JR, Register T, Jorgensen MJ, Polak PE,
Rubinstein I, Finstein DL. Development of amyloid burden in African green monkeys.
Neurobiology of Aging (In press)
Books
Rubinstein I. Preventive Medicine, Jerusalem, Akademon Publishing House, The Hebrew
University, 1974, pp. 1-221.
Bawa B, Audette GF, Rubinstein I (Editors): Handbook of Clinical Nanomedicine – From
Bench to Bedside, Pan Stanford Series in Nanomedicine (Raj Bawa, Series Editor), Volume 1,
Pan Stanford Publishing, Singapore, 2013 (In press)
Chapters in books
Boushey HA, Rubinstein I. Pruebas de provocacion bronquial. In: Enfermedades
Respiratorias. Utilidad del laboratorio. Segunda Edicion (in Spanish). Ancic P, and Clark TJH,
eds. Camugraf Ediciones Cientificas, Santiago, Chile, 1990, pp. 77-91.
Israel Rubinstein, M.D.
39 of 115
Rennard SI, Beckmann J, Daughton D, Ertl RF, Koyama S, Romberger D, Rubinstein I, et al:
The role of airway epithelium in cellular migration. In: The Airway Epithelium. Physiology,
Pathophysiology and Pharmacology. Farmer SG and Hay DWP, eds. (Lung Biology in Health
and Disease Series). New York: Dekker, 1991, Vol. 55, pp. 117-133.
Romberger D, Floreani AA, Robbins RA, Thompson AB, Sisson JH, Spurzem JR, Von Essen
S, Rennard SI, Rubinstein I. Respiratory tract defense mechanisms. In: Textbook of Pulmonary
Diseases (5th ed). Baum GL and Wolinsky E, eds. Boston: Little, Brown and Company, 1993,
pp. 23-46.
Rubinstein I. Autoimmunity in patients with essential hypertension. In: Pathogenic
Autoimmune Reactions. Paul S, ed. Totowa: The Humana Press Inc., 1998, pp. 79-83.
Hatipoğlu U, Rubinstein I. Analysis of exhaled breath condensate: potential implications for
diagnosis and therapy of lung diseases. In: New Perspectives in the Monitoring of Lung
Inflammation. Analysis of exhaled breath condensate. Montuschi P, ed. London: Taylor &
Francis Books Ltd, 2004, pp. 123-138.
Hatipoğlu U, Rubinstein I. Bacterial Pneumonia. In: Conn’s Current Therapy 2008. Rankle RE
and Bope ET, eds. Philadelphia: Elsevier, 2008, pp.253-260.
Sadikot RT, Rubinstein I. Nanomedicine for acute lung injury/acute respiratory distress
syndrome: a shifting paradigm? In: Bawa B, Audette GF, Rubinstein I (Editors): Handbook of
Clinical Nanomedicine – From Bench to Bedside, Pan Stanford Series in Nanomedicine (Raj
Bawa, Series Editor), Volume 1, Pan Stanford Publishing, Singapore, 2013 (In press)
Abstracts and preliminary communications
Baum GL, Rubinstein I, Kalter Y, et al. Lung cancer survival and mediastinal glands:
Reassessment. American Review of Respiratory Disease 115(Part 2): A87, 1977.
Baum GL, Rubinstein I, Kalter Y, et al. Relationship of mediastinal node metastases and cell
type to five-year survival in patients operated on for lung cancer. Thorax 32: 651-652, 1977.
Rubinstein I, Baum GL, Bubis JJ, et al. The prognosis of patients with adenocarcinoma of the
lung and mediastinal lymph node metastases undergoing pulmonary resection. 12th World
Congress of the Israel Medical Association, Jerusalem, Israel, May 1982.
Rubinstein I, Baum GL, Hiss Y, et al. Sarcoidosis in Israel. 10th International Conference on
Sarcoidosis and other Granulomatous Disorders, Baltimore, Maryland, September 1984.
Rubinstein I, Fisman EZ, Pines A, et al. Exercise echocardiographic abnormalities in patients
with sarcoidosis without clinical cardiac dysfunction. American Review of Respiratory Disease
131(Part 2): A73, 1985.
Israel Rubinstein, M.D.
40 of 115
Rubinstein I, Baum GL, Hiss Y, et al. Sarcoidosis in Israel-A 31 year experience in a general
hospital. American Review of Respiratory Disease 131(Part 2): A113, 1985.
Rubinstein I, Zwas ST, Solomon A, et al. Intrathoracic accumulation of gallium-67 in
evaluating chronic pulmonary sarcoidosis. 13th World Congress of the Israel Medical
Association, Jerusalem, Israel, May 1985.
Rubinstein I, Zwas ST, Solomon A, et al. The need to redefine disease activity in assessing
chronic pulmonary sarcoidosis. Chest 88: 30S, 1985.
Rubinstein I, Knecht A, deBeer FC, et al. Serum amyloid-A protein (SAA) levels in
sarcoidosis-A marker of disease activity? Chest, 88: 30S, 1985.
Rubinstein I, McClean PA, Rebuck AS, et al. Methodology influences normal maximal
expiratory pressure (MEP) values in adults. Federation Proceedings 45: A1020, 1986.
Zamel N, Rubinstein I, Vanek AW, et al. A rebreathing technique (RT) for analyzing air and
helium-O2 (HeO2) maximal expiratory flow volume curves (MEFVC). Federation Proceedings
45: A311, 1986.
Rubinstein I, Zwas ST, Rosenthal T, et al. Gallium-67 scintigraphy (GLS), serum amyloid-A
protein (SAA) and serum angiotensin-converting enzyme (SACE) in chronic inactive
pulmonary sarcoidosis (CIPS). American Review of Respiratory Disease 132(Part 2): A23,
1986.
Fisman EZ, Rubinstein I, Shiner RJ, et al. Exercise echocardiographic assessment of left
ventricular function in patients with systemic sarcoidosis. 6th European Congress on Diseases
of the Chest, Tel-Aviv, Israel, June 1986.
Rubinstein I, D'Urzo AD, McClean PA, et al. Pharyngeal airway changes in patients with
exercise-induced bronchoconstriction. Clinical and Investigative Medicine 9: A156, 1986.
Rubinstein I, D'Urzo AD, McClean PA, et al. Assessment of central airway geometry by
acoustic reflection technique during exercise-induced bronchoconstriction (EIB). Clinical and
Investigative Medicine 9: A152, 1986.
Zwas ST, Rubinstein I, Baum GL. Triple radionuclide lung studies in the prognostic evaluation
of chronic sarcoidosis. Medax-86, 5th Israel Medical Week, Jerusalem, Israel, September
1986.
Fisman EZ, Rubinstein I, Pines A, et al. The usefulness of exercise echocardiology in the
detection of left ventricular function abnormalities in sarcoid patients without ischemic heart
disease. Annual Meeting of the Israel Heart Society, Herzliya, Israel, January 1987.
Rubinstein I, McClean PA, Boucher R, et al. Effect of mouthpiece, nose clips, and head
position on airway area by acoustic reflection technique. Federation Proceedings 46: A511,
1987.
Israel Rubinstein, M.D.
41 of 115
D'Urzo AD, Rubinstein I, Lawson VG, et al. Airway area by acoustic reflection technique
(ART) and computerized tomography (CT). Federation Proceedings 46: A511, 1987.
Rubinstein I, Brown IG, Colapinto N, Rotstein LE, Hoffstein V. Changes in pharyngeal
properties with weight reduction in obese subjects with and without obstructive sleep apnea
(OSA). American Review of Respiratory Disease 135: (Part 2)A46, 1987.
Rubinstein I, Levison H, Slutsky AS, Wells J, Zamel N, Rebuck AS. Putative late asthmatic
response to exercise. American Review of Respiratory Disease 135: (Part 2)A90, 1987.
Rubinstein I, D'Urzo AD, McClean PA, et al. Assessment of central airway geometry by
acoustic reflection technique during exercise-induced bronchoconstriction. American Review
of Respiratory Disease 135(Part 2): A95, 1987.
Zwas ST, Rubinstein I, Baum GL. Prognostic evaluation of chronic sarcoidosis using triple
radionuclide lung studies. American Review of Respiratory Disease 135(Part 2): A458, 1987.
Rubinstein I, McClean PA, Boucher R, et al. Glottic cross-sectional area and longitudinal
movement during breathing in normal subjects. American Review of Respiratory Disease,
135(Part 2): A480, 1987.
McClean PA, D'Urzo AD, Rubinstein I, et al. Comparison of exercise ventilation determined
by Tissot spirometer with a computerized turbine flow transducer (CTFT). American Review
of Respiratory Disease 135(Part 2): A484, 1987.
Zamel N, Rubinstein I, Hoffstein V. Methacholine-induced narrowing of the trachea measured
by acoustic reflection technique. Bulletin Europeen de Physiopathologie Respiratoire
23(Supplement 12): 311S, 1987.
Bradley TD, Rubinstein I, Hoffstein V. Pharyngeal area in obese females with and without
obstructive sleep apnea. Bulletin Europeen de Physiopathologie Respiratoire 23(Supplement
12): 421S, 1987.
Chaban R, Rubinstein I, Cole P, Hoffstein V. Snoring and upper airway properties. First
International Congress on Chronic Rhonchopathy-Snoring Disease, Paris, France, July 1987.
Rubinstein I, Reiss TF, Gardner DG, Liu J, Bigby BG, Boushey HA. Plasma immunoreactive
atrial natriuretic peptide (IR-ANP) concentrations during exercise and eucapnic hyperpnea.
FASEB Journal 2: A1147, 1988.
Reiss TF, Rubinstein I, Liu J, Gold WM, Boushey HA. A method for isolated bronchial
challenge: The response to antigen in ragweed allergic dogs. FASEB Journal 2: A1174, 1988.
Hoffstein V, Rubinstein I, Bradley TD, Zamel N. Upper airway area in snorers, non-snorers,
and patients with obstructive sleep apnea. American Review of Respiratory Disease 137(Part
2): A53, 1988.
Israel Rubinstein, M.D.
42 of 115
Rubinstein I, Slutsky AS, Zamel N, Hoffstein V. Paradoxical glottic narrowing in patients with
severe obstructive sleep apnea. American Review of Respiratory Disease 137(Part 2): A57,
1988.
Hoffstein V, Rubinstein I, Mateika S, Chaban R, Cole P. Airway properties and nocturnal
oxygen saturation in patients with habitual snoring. American Review of Respiratory Disease
137(Part 2): A128, 1988.
Hoffstein V, Rubinstein I, DuBarry L, Zamel N. Pulmonary function in obesity. American
Review of Respiratory Disease 137(Part 2): A190, 1988.
Rubinstein I, Zamel N, Slutsky AS, Rebuck AS, Hoffstein V. Glottic area in asthmatics before
and after exercise-induced bronchoconstriction. American Review of Respiratory Disease
137(Part 2): A413, 1988.
Rubinstein I, Bigby BG, Reiss TF, Boushey HA. Short-term inhalation of 0.3 ppm NO2 does
not potentiate airway responsiveness to inhaled SO2 in asymptomatic asthmatic volunteers.
American Review of Respiratory Disease 139(Part 2): A124, 1989.
Rubinstein I, Reiss TF, Bigby BG, Stites DP, Boushey HA. Effect of repeated exposure to 0.6
ppm nitrogen dioxide on lymphocyte phenotypes in the blood and bronchoalveolar lavage fluid
of healthy subjects. Clinical Research 38: 139A, 1990.
Huerta G, Robbins RA, Thompson AB, Stahl M, Ghafouri M, Sisson J, Spurzem J, Von Essen
S, Rickard K, Rubinstein I, Metcalf J, Yates R, Romberger D, Daughton D, Rennard SI. Uso
de un indice visual para categorizar grados de inflamacion bronquial mediante la bronchoscopia
fibro-optica. American Review of Respiratory Disease 141(Part 2): A230, 1990.
Franconi GM, Rubinstein I, Levine EH, Nadel JA. Removal of airway epithelium by rubbing
causes mast cell degranulation. American Review of Respiratory Disease 141(Part 2): A291,
1990.
Rubinstein I, Graf PD, Wilson AN, Gold WM. Histamine (HIS) release and prostaglandin D2
(PGD2) generation during prolonged airway exposure to antigen in atopic dogs. American
Review of Respiratory Disease 141(Part 2): A395, 1990.
Rubinstein I, DuBarry L, Zamel N, Hoffstein V. Dysanapsis of lung growth in adults with
simple obesity. American Review of Respiratory Disease 141: (Part 2)A715, 1990.
Rubinstein I, Nadel JA, Graf PD, Caughey GH. Mast cell chymase augments histamine-
induced wheal formation in allergic dog skin. FASEB Journal 4: A1939, 1990.
Rubinstein I, Rennard SI, Mayhan WG. Cigarette smoke extract attenuates endothelium-
dependent arteriolar dilatation in vivo. Clinical Research 38: 829A, 1990.
Israel Rubinstein, M.D.
43 of 115
Koizumi S, Yong T, Rennard S, Mayhan W, Rubinstein I. Neutral endopeptidase and
angiotensin-converting enzyme inhibitors potentiate bradykinin-induced increases in
microvascular permeability in vivo. FASEB Journal 5: A1577, 1991.
Metcalf J, Armitage J, Arneson M, Bierman P, Darrington D, Huerta G, Reed E, Rennard S,
Rickard K, Romberger D, Rubinstein I, Shumway M, Sisson J, Spurzem J, Thompson A,
Vaughan W, Vose J,
Walter T, Yates R, Robbins R. The effect of glucocorticoids on survival and development of
subsequent opportunistic infections in bone marrow transplant patients with diffuse alveolar
hemorrhage. American Review of Respiratory Disease 143(Part 2): A474, 1991.
Matsuda T, Rubinstein I, Robbins RA, Koyama S, Eccleston-Joyner C, Joyner W, Rennard SI.
The role of neutrophils in endotoxin-induced increase in microvascular hyperpermeability for
macromolecules in vivo. American Review of Respiratory Disease 143(Part 2): A680, 1991.
Von Essen SG, O'Neill DP, Ertl R, Rennard SI, Rubinstein I. Tachykinins stimulate cultured
bovine bronchial epithelial cells to release neutrophil chemotactic activity. American Review
of Respiratory Disease 143(Part 2): A619, 1991.
Rubinstein I, Rennard SI, Mayhan WG. Cigarette smoke extract alters arteriolar reactivity in
vivo. American Review of Respiratory Disease 143(Part 2): A490, 1991.
Huerta G, Goldsmith JC, Beckmann J, Curseen A, Metcalf J, Rennard SI, Rickard K, Robbins
RA, Romberger DJ, Sisson J, Spurzem J, Thompson AB, Von Essen SG, Yates R, Rubinstein I.
Airway inflammation in AIDS patients without evidence of pulmonary infection. American
Review of Respiratory Disease 143(Part 2): A714, 1991.
Rubinstein I, Daughton DM, Boomsma J, Rennard SI. Sleep disorders in a rural state: the
physician's perspective. Clinical Research 39: 771A, 1991.
Belenky S, Robbins RA, Gossman G, Nelson K, Rennard SI, Rubinstein I. Inhibitors of nitric
oxide synthase (NOS) attenuate neutrophil chemotaxis (CTX) in vitro. American Review of
Respiratory Disease 145(Part 2): A694, 1992.
Gao X-p, Anding P, Rennard SI, Rubinstein I. Neutral endopeptidase and angiotensin-
converting enzyme inhibitors potentiate bradykinin-induced increase in arteriolar diameter in
vivo. American Review of Respiratory Disease 145(Part 2): A37, 1992.
Gao X-p, Anding P, Robbins RA, Rennard SI, Snider RM, Rubinstein I. CP-96,345, a non-
peptide neurokinin-1 (NK1) receptor antagonist attenuates substance P-induced increase in
vascular permeability in vivo. American Review of Respiratory Disease 145(Part 2): A46,
1992.
DeRose V, Robbins RA, Spurzem JR, Snider RM, Thiele G, Rennard SI, Pozzi E, Rubinstein I.
Substance P increases neutrophil adhesion to bronchial epithelial cells. American Review of
Respiratory Disease 145(Part 2): A681, 1992.
Israel Rubinstein, M.D.
44 of 115
Koyama S, Rennard SI, Rubinstein I, Robbins RA. Bradykinin stimulates bronchial epithelial
cells to release neutrophil and monocyte chemotactic activity in vitro. American Review of
Respiratory Disease 145(Part 2): A696, 1992.
Claassen L, Rubinstein I, Robbins R, Rennard S, Romberger D. Modulation of cultured bovine
bronchial epithelial cell fibronectin release by substance P: role of neutral endopeptidase.
American Review of Respiratory Disease 145(Part 2): A46, 1992.
Gao X-p, Mayhan WG, Rennard SI, Rubinstein I. Mechanisms of T-kinin-induced increase in
vascular permeability in vivo. FASEB Journal 6: A985, 1992.
Houmsse M, Vishwanatha JK, Davis RG, Rubinstein I. Tissue angiotensin I-converting
enzyme activity in spontaneously hypertensive hamsters. FASEB Journal 6: A946, 1992.
Daughton DM, Thompson, AB, Floreani AA, Romberger DJ, Robbins RA, Sisson JH,
Rubinstein I, Millatmal T, Rennard SI. Switching to reduced nicotine yield cigarettes may not
improve airway inflammation. Chest 102: 61S, 1992.
Belenky SN, Robbins RA, Rubinstein I. Nitric oxide and monocyte chemotaxis. Circulation
86: (Part 2) I-473, 1992.
Robbins RA, Hamel FG, Floreani AA, Gossman GL, Nelson KJ, Belenky S, Rubinstein I.
Bovine bronchial epithelial cells metabolize L-arginine to L-citrulline: possible role of nitric
oxide synthase. FASEB Journal 7: A355, 1993.
Rubinstein I, Gao X-p, Conlon JM, Vishwanatha JK. Mechanisms of smokeless tobacco-
induced increase in microvascular permeability in vivo. FASEB Journal 7: A507, 1993.
Sharpe GM, Rubinstein I, Mayhan WG. Cigarette smoke extract potentiates bradykinin-
induced increases in microvascular permeability in the hamster cheek pouch. FASEB Journal
7: A558, 1993.
Floreani AA, Gao X-p, Anding P, Rubinstein I. Neutral endopeptidase modulates substance P-
and capsaicin-induced increase in arteriolar diameter in vivo. FASEB Journal 7: A621, 1993.
Gao X-p, Vishwanatha JK, Conlon JM, Rubinstein I. Loop diuretics attenuate bradykinin-
induced increase in microvascular permeability in vivo. FASEB Journal 7: A750, 1993.
Engel JA, Vishwanatha JK, Piao J, Davis RJ, Rubinstein I. Tissue angiotensin I-converting
enzyme activity in aged hamsters with hereditary cardiomyopathy. FASEB Journal 7: A819,
1993.
Robbins RA, Nelson KJ, Gossman GL, Spurzem JR, Sisson JH, Romberger DJ, Rennard SI,
Rubinstein I. Modulation of neutrophil adhesion to bronchial epithelial cells by nitric oxide.
American Review of Respiratory Disease 147(Part 2): A435, 1993.
Jain B, Rubinstein I, Robbins RA, Leise KL, Sisson JH. Nitric oxide modulates ciliary activity
in airway epithelium. American Review of Respiratory Disease 147(Part 2): A937, 1993.
Israel Rubinstein, M.D.
45 of 115
Robbins RA, Nelson KJ, Gossman GL, Spurzem JR, Rennard SI, Rubinstein I. Neurotensin
stimulates neutrophil adherence to bronchial epithelial cells. American Review of Respiratory
Disease 147(Part 2): A712, 1993.
Von Essen S, O'Neill D, Robbins RA, Kohlmeier P, Rubinstein I. CGRP augments production
of neutrophil chemotactic activity by bronchial epithelial cells after challenge with substance P.
American Review of Respiratory Disease 147(Part 2): A712, 1993.
Gao X-p, Von Essen SG, Rennard SI, O'Neill D, Rubinstein I. Grain dust extract increases
vascular permeability in the upper airway: role of NK1 receptors. American Review of
Respiratory Disease 147(Part 2): A662, 1993.
Gao X-p, Floreani AA, Robbins RA, Rubinstein I. Interleukin-1 potentiates bradykinin-
induced increase in vascular permeability in the hamster cheek pouch. American Review of
Respiratory Disease 147(Part 2): A1014, 1993.
Robbins RA, Gossman GL, Nelson KJ, Floreani AA, Von Essen SG, Sisson JH, Romberger
DJ, Rennard SI, Rubinstein I. Nitric oxide modulates the release of neutrophil chemotactic
activity from human bronchial epithelial cells. American Review of Respiratory Disease
147(Part 2): A45, 1993.
Floreani AA, Diamond J, Von Essen SG, Conrad D, Müns G, Betts M, Rennard SI, Rubinstein
I. Upper airway inflammation is present in patients with obstructive sleep apnea. American
Review of Respiratory Disease 147(Part 2): A948, 1993.
Belenky SN, Gossman GL, Nelson KJ, Rubinstein I, Von Essen SG, Sisson JH, Rennard SI,
Robbins RA. Nitric oxide enhances neutrophil and monocyte chemotactic activity. American
Review of Respiratory Disease 147(Part 2): A303, 1993.
Rubinstein I, Hackley J, Curry P, Zucker IH. Changes in vascular permeability in the skin of
conscious dogs with pacing-Induced congestive heart failure. Journal of Molecular and
Cellular Cardiology 25(Supplement III): S.45, 1993.
Rubinstein I, Mayhan WG. L-arginine dilates cheek pouch arterioles in hamsters with
hereditary cardiomyopathy. Circulation 88(Part 2): I-332, 1993.
Gao X-p, Rubinstein I. Vasoactive intestinal peptide potentiates bradykinin-induced plasma
extravasation in vivo: role of nitric oxide. Circulation 88(Part 2): I-377, 1993.
Sharpe GM, Rubinstein I, Mayhan WG. Effect of endothelin receptor antagonists on
bradykinin-induced increases in macromolecular extravasation. FASEB Journal 8: A325, 1994.
Rubinstein I, Müns G, Vishwanatha JK. Effects of smokeless tobacco on chemically
transformed hamster oral keratinocytes: role of angiotensin I-converting enzyme. FASEB
Journal 8: A405, 1994.
Israel Rubinstein, M.D.
46 of 115
Gao X-p, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in
liposomes: effects on systemic arterial blood pressure. FASEB Journal 8: A803, 1994.
Vishwanatha JK, Floreani A, Rubinstein I, Rennard SI, Davis RG. Annexin I is secreted in
human bronchoalveolar lavage fluids (BALF) and is specifically cleaved in BALF from
smokers. Proceedings of the American Association for Cancer Research 35; 236, 1994.
Jain B, Robbins RA, Rubinstein I, Sisson JH. TNF and IL-1ß modulate airway epithelial
ciliary activity by a nitric oxide-dependent mechanism. Clinical Research 42: 115A, 1994.
Floreani AA, Davis RG, Müns G, Rubinstein I, Thompson AB, Buchalter SE, Rennard SI, Von
Essen SG, Vishwanatha JK. Proteolytic cleavage of annexin I in bronchoalveolar lavage fluid
(BALF) from healthy smokers and nonsmokers. American Journal of Respiratory and Critical
Care Medicine 149(Part 2): A330, 1994.
Müns G, Beckmann JD, Floreani AA, Davis RG, Rubinstein I, Vishwanatha JK. Differential
expression on annexins I and II in bovine bronchial epithelial cells. American Journal of
Respiratory and Critical Care Medicine 149(Part 2): A330, 1994.
Gao X-p, Jaffe HA, Rubinstein I. Vasoactive intestinal peptide modulates substance P-induced
plasma extravasation: role of nitric oxide. American Journal of Respiratory and Critical Care
Medicine 149(Part 2): A619, 1994.
Rubinstein I, Gao X-P. Regulation of arteriolar diameter in the peripheral microcirculation
during acute exposure to lipopolysaccharide. Clinical Research 42: 350A, 1994.
Gao X-p, Rubinstein I. Mechanisms of adenosine-induced plasma exudation. Clinical Research
42: 391A, 1994.
Swedler WI, Rubinstein I. Exhaled pentane levels during oral and nasal breathing in healthy
males and pre-menopausal females. Journal of Investigative Medicine 43: (Supplement 1):
A155, 1995.
Iatropulos NA, Scheff PA, Rubinstein I. Determinants of exhaled nitric oxide levels in healthy
volunteers. Journal of Investigative Medicine 43: (Supplement 1): A155, 1995.
Sekosan M, Wenig B, Stepanski EJ, Rubinstein I. Inflammation is present in the soft palate of
patients with obstructive sleep apnea. Journal of Investigative Medicine 43: (Supplement 1):
A179, 1995.
Gao X-p, Suzuki H, Jaffe HA, Olopade CO, Rubinstein I. Adenosine-induced plasma
exudation in the buccal mucosa. FASEB Journal 9: A19, 1995.
Christon JA, Zakkar M, Stepanski EJ, Swedler WI, Basner RC, Olopade CO, Rubinstein I.
Exhaled pentane levels in patients with obstructive sleep apnea. FASEB Journal 9: A375,
1995.
Israel Rubinstein, M.D.
47 of 115
Rubinstein I, Gao X-p, Olopade CO, Suzuki H, Pakhlevaniants S, Jaffe HA. Potentiation of
smokeless tobacco-induced plasma exudation in vivo by neutral endopeptidase and angiotensin
I-converting enzyme inhibitors. FASEB Journal 9: A545, 1995.
Suzuki H, Gao X-p, Pakhlevaniants S, Olopade CO, Jaffe HA, Rubinstein I. Effects of
lipopolysaccharide on agonist-induced plasma exudation in vivo. FASEB Journal 9: A875,
1995.
Olopade CO, Gao X-p, Suzuki H, Jaffe HA, Pakhlevaniants S, Rubinstein I. Nitric oxide
modulates smokeless tobacco-induced plasma exudation in the buccal mucosa. FASEB Journal
9: A876, 1995.
Christon JA, Zakkar M, Scheff PA, Hua C, Stepanski EJ, Basner RC, Olopade CO, Rubinstein
I. Exhaled nitric oxide levels in patients with obstructive sleep apnea. American Journal of
Respiratory and Critical Care Medicine 151(Part 2): A103, 1995.
Zakkar M, Rubinstein I, Christon JA, Basner RC, Stepanski EJ. Sleep habits among male
farmers in midwestern U.S.A. American Journal of Respiratory and Critical Care Medicine
151(Part 2): A105, 1995.
Gao X-p, Suzuki H, Jaffe HA, Olopade CO, Rubinstein I. Mechanisms of tannic acid-induced
plasma exudation in vivo. American Journal of Respiratory and Critical Care Medicine
151(Part 2): A143, 1995.
Gao X-p, Suzuki H, Olopade CO, Rubinstein I, Jaffe HA. Regulation of arteriolar diameter
during short-term exposure to lipopolysaccharide in vivo. American Journal of Respiratory and
Critical Care Medicine 151(Part 2): A323, 1995.
Olopade CO, Alikakos Z. Abubaker J, Akhras N, Bloomingberg K, Rubinstein I. Determinants
of frequent hospitalizations for acute asthma in inner city Chicago. American Journal of
Respiratory and Critical Care Medicine 151(Part 2): A593, 1995.
Swedler WI, Guttman RT, Christon JA, Zakkar M, Olopade CO, Rubinstein I. Exhaled
pentane levels during oral and nasal breathing in healthy males and pre-menopausal females.
American Journal of Respiratory and Critical Care Medicine 151(Part 2): A649, 1995.
Iatropulos NA, Scheff PA, Christon JA, Olopade CO, Rubinstein I. Determinants of exhaled
nitric oxide levels in health volunteers. American Journal of Respiratory and Critical Care
Medicine 151(Part 2): A699, 1995.
Gao X-p, Suzuki H, Jaffe HA, Olopade CO, Swedler WI, Rubinstein I. Methotrexate
potentiates bradykinin-induced plasma exudation in vivo. American Journal of Respiratory and
Critical Care Medicine 151(Part 2): A705, 1995.
Suzuki H, Gao X-p, Olopade CO, Jaffe HA, Pakhlevaniants S, Rubinstein I. Smokeless tobacco
impairs endothelium-dependent vasodilation in vivo. Journal of Heart Failure 2: 326, 1995.
Israel Rubinstein, M.D.
48 of 115
Suzuki H, Paul S, Noda Y, Rubinstein I. Encapsulation of vasoactive intestinal peptide into
liposomes potentiates its vasorelaxant effects in vivo. Journal of Molecular and Cellular
Cardiology 27: A104, 1995.
Suzuki H, Paul S, Gao X-p, Noda Y, Rubinstein I. Impaired vasoactive intestinal peptide-
induced vasodilation in hypertension in vivo: restoration by liposomes. Journal of Investigative
Medicine 43(Supplement): 420A, 1995.
Suzuki H, Paul S, Gao X-p, Rubinstein I. Role of neutral endopeptidase in modulating
vasoactive intestinal peptide-induced vasodilation in situ. Journal of Investigative Medicine
43(Supplement): 423A, 1995.
Pitaro N, Rubinstein I, Swedler WI, Park CL, Yeates DB. Elevated exhaled pentane levels
following ragweed challenge in a canine model of immunologically-induced hyperresponsive
airway. Journal of Investigative Medicine 43(Supplement): 470A, 1995.
Olopade CO, Young E, Dela-Cruz F, Khan M, Swedler WI, Rubinstein I. Exhaled pentane
levels in acute asthma. Journal of Investigative Medicine 43(Supplement): 487A, 1995.
Sekosan M, Wenig B, Stepanski EJ, Rubinstein I. Inflammation is present in the soft palate of
patients with obstructive sleep apnea. Otolaryngology-Head and Neck Surgery 113: P91, 1995.
Müns G, Rubinstein I. Function of granulocytes in the upper respiratory tract in chronic and
acute inflammation. Chest 108: 172S, 1995.
Müns G, Rubinstein I. Function of blood phagocytes in chronic obstructive airway disease.
Chest 108: 172S, 1995.
Zakkar M, Sekosan M, Wenig B, Olopade CO, Rubinstein I. Decrease in immunoreactive
neutral endopeptidase in uvula epithelium of patients with obstructive sleep apnea. Journal of
Investigative Medicine 44: 118A, 1996.
Suzuki H, Gao X-p, Rubinstein I. Immediate biphasic vasomotor response to E. coli
lipopolysaccharide in the spinotrapezius muscle in situ. Journal of Investigative Medicine 44:
185A, 1996.
Rubinstein I, Jaffe HA, Pakhlevaniants S. Smokeless tobacco modulates vasoactive intestinal
peptide-induced oral keratinocyte proliferation in vitro. FASEB Journal 10: A348, 1996.
Pikovskaya G, Wenig B, Sekosan M, Olopade CO, Rubinstein I. Determinants of nasal airway
area and volume by acoustic rhinometry. FASEB Journal 10: A407, 1996.
Gao X-p, Olopade CO, Rubinstein I. Exogenous angiotensin I-converting enzyme attenuates
smokeless tobacco-induced plasma exudation in the oral mucosa. FASEB Journal 10: A539,
1996.
Israel Rubinstein, M.D.
49 of 115
Suzuki H, Rubinstein I, Gao X-p. Pseudomonas aeroginosa lipopolysaccharide elicits
immediate vasodilation in situ. FASEB Journal 10: A597, 1996.
Artwohl JE, Suzuki H, X-p Gao, Rubinstein I. Initial characterization of hamsters with
spontaneous hypertension. FASEB Journal 10: A629, 1996.
Vishwanatha JK, Davis RG, Blumberg S, Rubinstein I. Tissue neutral endopeptidase activity in
hamsters with spontaneous hypertension. FASEB Journal 10: A628, 1996.
Gao Xp, Von Essen SG, Rubinstein I. Mechanisms of grain sorghum dust-induced
macromolecular efflux from the nasal mucosa in situ. American Journal of Respiratory and
Critical Care Medicine 153(Part 2): A40, 1996.
Olopade CO, Zakkar M, Swedler WI, Sloan EP, Dela-Cruz F, Rubinstein I. Exhaled pentane
levels in acute asthma. American Journal of Respiratory and Critical Care Medicine 153(Part
2): A213, 1996.
Yeates DB, Pitaro N, Rubinstein I, Park CL. Increased exhaled pentane levels in ragweed
sensitized dogs. American Journal of Respiratory and Critical Care Medicine 153(Part 2):
A217, 1996.
Zakkar M, Sekosan M, Wenig B, Olopade CO, Rubinstein I. Decrease in immunoreactive
neutral endopeptidase in uvula epithelium of patients with obstructive sleep apnea. American
Journal of Respiratory and Critical Care Medicine 153(Part 2): A692, 1996.
Suzuki H, Gao Xp, Alkan-Onyuksel H, Sejourne F, Rubinstein I. Neutral endopeptidase
modulates vasoactive intestinal peptide-induced vasodilation in the oral mucosa. American
Journal of Respiratory and Critical Care Medicine 153(Part 2): A692, 1996.
Gao Xp, Rubinstein I. Nitric oxide modulates ovalbumin-induced macromolecular efflux from
the nasal mucosa. American Journal of Respiratory and Critical Care Medicine 153(Part 2):
A797, 1996.
Suzuki H, Rubinstein I, Gao Xp. Immediate biphasic vasomotor response to E. coli
lipopolysaccharide in the spinotrapezius muscle in situ. American Journal of Respiratory and
Critical Care Medicine 153(Part 2): A836, 1996.
Suzuki H, Séjourné F, Alkan-Önyüksel H, Gao X-p, Rubinstein I. Effects of vasoactive
intestinal peptide encapsulated into liposomes on hypertension. Journal of Heart Failure 3:
164, 1996.
Séjourné F, Alkan-Önyüksel H, Suzuki H, Rubinstein I. Development of bioactive formulation
of vasoactive intestinal peptide in sterically stabilized liposomes. Journal of Investigative
Medicine 44: 378A, 1996.
Israel Rubinstein, M.D.
50 of 115
Hatipoglu U, Séjourné F, Alkan-Önyüksel H, Gao X-p, Pitrak DL, Rubinstein I. Vasoactive
intestinal peptide in sterically stabilized liposomes attenuates human neutrophil chemotaxis in
vitro. Journal of Investigative Medicine 44: 381A, 1996.
Rubinstein I, Gao X-p, Oda D. Smokeless tobacco-stimulated cultured human oral
keratinocytes elicit plasma exudation in the oral mucosa in situ. Journal of Vascular Research
33(Supplement 1): 85, 1996.
Séjourné F, Rubinstein I, Suzuki H, Alkan-Önyüksel H. Development of a bioactive
formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharmaceutical
Research 13(Supplement): S-95, 1996.
Du Buske LM, Grossman J, Carpentier PJ, Dubé LM, and the Zileuton Study Group. The
effect of reducing Zileuton 600 mg QID in patients with moderate asthma. The American
College of Allergy, Asthma & Immunology 1996 Annual Meeting, Boston, November 8-13,
1996, p. 35.
Suzuki H, Gao X-p, Rubinstein I. Prostaglandin H2/thromboxane A2 receptor antagonism
restores endothelium-dependent vasodilation in hamsters with spontaneous hypertension.
FASEB Journal 11: A39, 1997.
Guerrieri A, Persky V, Scheff P, Swedler WI, Ramakrishnan V, Rubinstein I. Exhaled pentane
levels in children with stable asthma residing in inner city Chicago. FASEB Journal 11: A128,
1997.
Rubinstein I, Gao X-p. Subtilisin increases macromolecular efflux from the in situ oral
mucosa. FASEB Journal 11: A385, 1997.
Gao X-p, Suzuki H, Rubinstein I. Protein tyrosine kinases modulate bradykinin- and substance
P-induced increases in macromolecular efflux from the oral mucosa in vivo. FASEB Journal
11: A520, 1997.
Guerrieri A, Persky V, Scheff P, Ramakrishnan V, Rubinstein I. Exhaled nitric oxide levels in
children with stable asthma in inner city Chicago. American Journal of Respiratory and
Critical Care Medicine 155: A268, 1997.
Hatipoglu U, Séjourné F, Alkan-Önyüksel H, Gao X-p, Pitrak DL, Rubinstein I. Vasoactive
intestinal peptide in sterically stabilized liposomes attenuates human neutrophil chemotaxis in
vitro. American Journal of Respiratory and Critical Care Medicine 155(Part 2): A465, 1997.
Pakhlevaniants S, Séjourné F, Alkan-Önyüksel H, Rubinstein I. Vasoactive intestinal peptide
in sterically stabilized liposomes potentiates oral keratinocyte proliferation in vitro. American
Journal of Respiratory and Critical Care Medicine 155(Part 2): A617, 1997.
Caughey GH, Suzuki H, Gao X, Rubinstein I. A role for mast cell chymase in LPS-induced
vasomotor dysfunction in hamster skeletal muscle. American Journal of Respiratory and
Critical Care Medicine 155(Part 2): A651, 1997.
Israel Rubinstein, M.D.
51 of 115
Séjourné F, Suzuki H, Gao X-p, Rubinstein I. Mechanisms of vasodilation elicited in vivo by
vasoactive intestinal peptide in sterically stabilized liposomes. American Journal of
Respiratory and Critical Care Medicine 155(Part 2): A789, 1997.
Ikezaki H, Patel M, Alkan-Önyüksel H, Gao X-p, Rubinstein I. Calmodulin potentiates
vasodilation elicited by vasoactive intestinal peptide in sterically stabilized liposomes.
American Journal of Respiratory and Critical Care Medicine 155(Part 2): A789, 1997.
Rubinstein I. Neurogenic vasodilation in hypertension. Journal of Heart Failure 4: 81, 1997.
Ikezaki H, Alkan-Önyüksel H, Patel M, Rubinstein I. Vasoactive intestinal peptide in
liposomes decreases sensitivity to vasoconstrictors. Journal of Molecular and Cellular
Cardiology 29: A218, 1997.
Olopade CO, Yu J, Abubaker J, Myles T, Rubinstein I, Paul S. VIP hydrolysis is increased in
the pregnant patient with asthma. Chest 112(Supplement): 113S, 1997.
Patel M, Rubinstein I, Ikezaki H, Alkan-Onyuksel H. A novel bioactive formulation of
vasoactive intestinal peptide in micelles. Pharmaceutical Research 14(Supplement): S-153,
1997.
Patel M, Ikezaki H, Rubinstein I, Alkan-Onyuksel H. Effects of time and temperature on
passive loading of vasoactive intestinal peptide (VIP) in sterically stabilized liposomes (SSL).
Pharmaceutical Research 14(Supplement): S-157, 1997.
Séjourné F, Suzuki H, Alkan-Önyüksel H, Gao X-p, Patel M, Rubinstein I. VIP in sterically
stabilized liposomes: a novel approach to improve hypertension control. Circulation
96(Supplement): I-251, 1997.
Ikezaki H, Alkan-Onyuksel H, Patel M, Rubinstein I. Calmodulin interacts with plasma
membrane lipids to amplify vasoactive intestinal peptide-induced vasodilation in vivo.
American Journal of Respiratory and Critical Care Medicine 157(Part 2): A381, 1998.
Ikezaki H, Paul S, Alkan-Onyuksel H, Patel M, Gao X-p, Rubinstein I. Vasodilation elicited by
vasoactive intestinal peptide in sterically stabilized liposomes is unimpeded by anti-VIP
antibody in vivo. American Journal of Respiratory and Critical Care Medicine 157(Part 2):
A381, 1998.
Akhter SR, Contreras A, Persky VW, Scheff P, Swedler WI, Rubinstein I. Domicliary exhaled
pentane and nitric oxide levels in children with stable asthma in inner city Chicago. American
Journal of Respiratory and Critical Care Medicine 157(Part 2): A542, 1998.
Persky VW, Scheff P, Curtis L, Contreras A, Rubinstein I, Coover L, Slezak J, Hernandez E.
Allergen levels in Chicago inner city homes. American Journal of Respiratory and Critical Care
Medicine 157(Part 2): A648, 1998.
Israel Rubinstein, M.D.
52 of 115
Akhter SR, Gao X-p, Pakhlevaniants S, Von Essen SG, Rubinstein I. Reactive oxygen species
mediate swine dust-induced increase in macromolecular efflux from the in situ hamster cheek
pouch. American Journal of Respiratory and Critical Care Medicine 157(Part 2): A732, 1998.
Gao X-p, Ahkter SR, Ikezaki H, Rubinstein I. Role of cyclooxygenase-2 in swine dust-induced
increase in macromolecular efflux from the in situ hamster cheek pouch. American Journal of
Respiratory and Critical Care Medicine 157(Part 2): A732, 1998.
Akhter SR, Gao X-p, Ikezaki H, Rubinstein I. Dexamethasone modulates grain sorghum dust-
induced increase in macromolecular efflux in vivo. FASEB Journal 12: A22, 1998.
Rubinstein I, Artwohl JE, Kumar A, Gao X-p, Gulati A. Endothelin-1-like immunoreactivity in
hamsters with spontaneous hypertension. FASEB Journal 12: A91, 1998.
Gao X-p, Akhter SR, Ikezaki H, Rubinstein I. Dexamethasone attenuates smokeless tobacco-
induced increase in macromolecular efflux from the in situ oral mucosa. FASEB Journal 12:
A760, 1998.
Rubinstein I. Novel experimental therapeutic approaches to improve control of hypertension.
Journal of Heart Failure 5: 22, 1998.
Rubinstein I, Patel M, Onyuksel H. Calmodulin amplifies vasoactive intestinal peptide
conformational transition in sterically stabilized micelles. PharmSci 1(Supplement): S-229,
1998.
Onyuksel H, Li P, Dudeja PK, Rubinstein I. Interaction of poly(ethylene glycol)2,000-
conjugated distearoyl-phosphoethanolamine with model membranes. PharmSci
1(Supplement): S-257, 1998.
Li P, Dudeja PK, Rubinstein I, Onyuksel H. Critical micellar concentration of poly(ethylene
glycol)2,000-conjugated distearoyl-phosphoethanolamine micelles systems. PharmSci
1(Supplement): S-260-S-261, 1998.
Dagar S, Rubinstein I, Stastny J, Blend M, Onyuksel H. Preparation of sterically stabilized
VIP-liposomes encapsulating 99mTc-HMPAO for breast cancer imaging. PharmSci
1(Supplement): S-294, 1998.
Wang H, Li P, Palaparthy H, Onyuksel H, Rubinstein I, Gulati A. Formulation of endothelin-1
in sterically stabilized phospholipid micelles potentiates its hemodynamic effects in rats.
FASEB Journal 13:A156, 1999.
Ikezaki H, Onyuksel H, Akhter SR, Patel M, Rubinstein I. Subcutaneous and intratracheal
liposomal vasoactive intestinal peptide normalizes systemic arterial pressure in spontaneously
hypertensive hamsters. FASEB Journal 13:A774, 1999.
Israel Rubinstein, M.D.
53 of 115
Yeomans DC, Lu Y, Ikezaki H, Onyuksel H, Rubinstein I. Intrathecal micellar vasoactive
intestinal peptide shortens foot withdrawal latency to noxious radiant skin heating in rats.
FASEB Journal 13:A803, 1999.
Bodalia B, Onyuksel H, Rubinstein I. Surface-active properties of vasoactive intestinal peptide
in vitro. American Journal of Respiratory and Critical Care Medicine 159(Part 2): A283, 1999.
Ikezaki H, Onyuksel H, Akhter SR, Patel M, Rubinstein I. Biophysical state of liposomes
modulates vasoactive intestinal peptide vasodilation in vivo. American Journal of Respiratory
and Critical Care Medicine 159(Part 2): A283, 1999.
Rubinstein I. The Halls Harbour spontaneously hypertensive hamster (4H): a new rodent
model of essential hypertension. Journal of Heart Disease 1:21, 1999.
Godfried MH, Jung R, Messick C, Rubinstein I, Garey KW, Rodvold KA, Danziger LH.
Placebo controlled trial evaluating the efficacy of calrithromycin in subjects with
corticosteroid-dependent asthma. Journal of Antimicrobial Chemotherapy 44(Supplement
A):100, 1999.
Garey KW, Gao XP, Travis J, Rubinstein I. Porphyromonas gingivalis-derived Arg-gingipain-
B elicits plasma exudation from the in situ oral mucosa. 39th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999.
Rubinstein I, Saroli A, White E, Artwohl J. Antihypertensive effects of oral TBC11251Na, a
novel selective ETA endothelin receptor antagonist, in spontaneously hypertensive hamsters.
ET-6 Sixth International Conference on Endothelins, Montreal, Quebec, Canada, October 10-
13, 1999.
Rubinstein I, Önyüksel H, Dagar S, Yeomans DC. Conformation-dependence of VIP
nociception in the spinal cord of anesthetized rats. Clinical Autonomic Research 9: 232-233,
1999.
Dagar S, Chai H, Pezzuto JM, Rubinstein I, Önyüksel H. A novel, lipid-based aqueous
formulation of betulinic acid, a malignant melanoma-specific cytotoxic agent. PharmSci
1(Supplement): S-1689, 1999.
Sethi V, Rubinstein I, Weinberg GL, Önyüksel H. Bupivacaine interacts with cardiolipin and
alters surface pressure of model membranes. PharmSci 1(Supplement): S-2209, 1999.
Önyüksel H, Patel M, Akhter S, Rubinstein I. Phospholipid micelles as conformation modifiers
and bioactivity enhancers for peptides and proteins. Materials Research Society Fall Meeting,
Boston, MA, November 29-December 3, 1999.
Gotfried M, Jung R, Messick C, Rubinstein I, Garey K, Redvold K, Danziger L. Placebo
controlled trial evaluating the efficacy of clarithromycin (CLA) in patients with corticosteroid-
dependent asthma. The Fifth International Conference on the Macrolides, Azalides,
Sterptogramins, Ketolides and Oxazolidinones, Seville, Spain, January 26-28, 2000; abstract
book program number 11.05.
Israel Rubinstein, M.D.
54 of 115
Garey KW, Neuhauser MM, Jung R, Danziger LH, Rubinstein I. Repeated positive cultures in
patients heralds increased antimicrobial resistance. 9th International Congress on Infectious
Diseases, Buenos Aires, Argentina, April 10-13, 2000.
Krishnadas A, Rubinstein I, Onyuksel H. Novel formulation of water insoluble drugs as
sterically stabilized phospholipid micelles and crystals: paclitaxel as a model drug. Millennial
World Congress of Pharmaceutical Sciences, San Francisco, California, April 16-20, 2000;
abstract book program page 122.
Garey KW, Neuhauser MM, Radice AL, Robbins RA, Danziger LH, Rubinstein I. Protein,
nitrate/nitrite and cytokine concentrations in exhaled breath condensate of young smokers.
American Journal of Respiratory and Critical Care Medicine 161: A175, 2000.
Garey KW, Khan I, Varma S, Varma SR, Dhanini H, Danziger LH, Rubinstein I. Clinical
manifestations of sarcoidosis in predominantly African-American patients from inner city
Chicago. American Journal of Respiratory and Critical Care Medicine 161: A264, 2000.
Garey KW, Khan IJ, Varma S, Gotfried MH, Rubinstein I, Danziger LH. Decreased prednisone
requirements with extended use of clarithromycin in elderly patients with corticosteroid-
dependent asthma. American Journal of Respiratory and Critical Care Medicine 161: A613,
2000.
Janka EM, Persky VW, Scheff PA, Freels SA, Park CL, Rubinstein I. Expired nitric oxide over
time in asthmatic children. American Journal of Respiratory and Critical Care Medicine 161:
A794, 2000.
Garey KW, Neuhauser MM, Jung R, Schreckenberger PC, Rubinstein I, Danziger LH.
Outpatient pathogen frequency and antimicrobial susceptibilities in an inner-city Chicago
hospital. 100th General Meeting of the American Society for Microbiology, Los Angeles,
California, May 21-25, 2000; abstract book program page 201.
Neuhauser MM, Garey KW, Jung R, Schreckenberger PC, Rubinstein I, Danziger LH.
Antibiogram susceptibility patterns based upon limiting one positive culture per patient. 100th
General Meeting of the American Society for Microbiology, Los Angeles, California, May 21-
25, 2000; abstract book program page 202.
Garey KW, Neuhauser MM, Jung R, Schreckenberger PC, Danziger LH, Rubinstein I.
Pathogen frequency (PF) and antimicrobial susceptibility (AS) patterns differ within inpatient
wards (IW) of a large inner-city Chicago hospital. Infectious Diseases Society of America 2000
Annual Meeting, New Orleans, Louisiana, September 7-10, 2000; abstract book program page
229.
Önyüksel H, Dagar S, Krishnadas A, Rubinstein I. Vasoactive Intestinal peptide receptors as
molecular targets of breast cancer: implications for targeted imaging and drug delivery.
International Symposium on Tumor Targeted Delivery Systems, National Institutes of Health,
Bethesda, Maryland, September 25-27, 2000; abstract book program.
Israel Rubinstein, M.D.
55 of 115
Dagar S, Lee B, Sekosan M, Rubinstein I, Önyüksel H. A novel carrier for active breast cancer
targeting: vasoactive intestinal peptide conjugated DSPE-PEG-grafted liposomes. PharmSci
2(Supplement): S-664, 2000.
Dagar S, Bhakta Y, Önyüksel H, Rubinstein I. A novel lipid-based formulation of human
galanin: biophysical characterization of galanin-phospholipid interactions. PharmSci
2(Supplement): S-794, 2000.
Krishnadas A, Rubinstein I, Chai HB, Pezzuto JM, Onyuksel H. A novel aqueous formulation
of paclitaxel as sterically stabilized phospholipid micelles and crystals: in vivo characterization
and cytotoxicity. PharmSci 2(Supplement): S-1941, 2000.
Sethi V, Rubinstein I, Heller J, Huang RCC, Chai H, Pezzuto JM, Onyuksel H. A novel lipid-
based formulation of tetra methyl nordihydroguaiaretic acid (M4N) showing enhanced in vitro
anti-cancer activity. PharmSci 2(Supplement): S-1971, 2000.
Garey KW, Neuhauser MM, Mody A, Kumar B, Danziger LH, Rubinstein I. Circadian
variation in inflammatory mediators, pH, and collection volume in exhaled breath condensate
of healthy volunteers. American Journal of Respiratory and Critical Care Medicine 163: A64,
2001.
Jones G, Tsueshita T, Gandhi S, Onyuksel H, Rubinstein I. Sterically stabilized micelles
amplify PACAP’s vasoreactivity in vivo. American Journal of Respiratory and Critical Care
Medicine 163: A397, 2001.
Garey KW, Kumar B, Mody A, Rubinstein I. Chronic montelukast therapy for severe COPD.
American Journal of Respiratory and Critical Care Medicine 163: A910, 2001.
Nelson DK, Garey KW, Campbell S, Hadeli K, Habib M, Hoyt JC, Sato E, Koyama S,
Rubinstein I, Robbins RA. Exhaled breath condensate contains increased neutrophil
chemotactic activity in smokers. American Journal of Respiratory and Critical Care Medicine
163: A987, 2001.
Garey KW, Chandiwala R, Gao XP, Hulett FM, Pedersen GW, Rubinstein I. Bacillus species
are present in commercially-available chewing tobacco (CA-CT) and elicit plasma exudation in
the oral mucosa. International Journal of Antimicrobial Agents 17: Supplement 1: S75, 2001.
Rubinstein I, Dagar S, Onyuksel H. Formulation of galanin in sterically stabilized micelles
amplifies its bioactivity in vivo. World Congress of Pharmacy and Pharmaceutical Sciences
2001. 61st International Congress of FIP, Singapore, September 1-6, 2001, abstract book
program page 72, PPP-O-003.
Onyuksel H, Ashok B, Rubinstein I. Effect of PEG chain length on size, CMC and
solubilization potential of sterically stabilized phospholipid micelles. World Congress of
Pharmacy and Pharmaceutical Sciences 2001. 61st International Congress of FIP, Singapore,
September 1-6, 2001; abstract book program page 82, PPP-P-160.
Israel Rubinstein, M.D.
56 of 115
Ashok B, Rubinstein I, Onyuksel H. Particulate behavior of self-assembled DSPE-PEG 2000
and EPC aggregates at different molar ratios. PharmSci 3(Supplement): W4322, 2001.
Sethi V, Rubinstein I, Huang RCC, Onyuksel H. Sterically stabilized liposomes (SSL) increase
stability and solubility of tetra methyl nordihydroguaiaretic acid (M4N), a chemotherapeutic
drug. PharmSci 3(Supplement): W4326, 2001.
Gandhi S, Tsueshita T, Onyuksel H, Rubinstein I. Secretin vasoactivity in vivo is mediated by
VIP receptors. 1st Annual Meeting, International Meeting for Autism Research, San Diego,
November 9-10, 2001 abstract book program page B-15.
Tsueshita T, Gandhi S, Rubinstein I. Effects of quinupristin/dalfopristin on vasomotor tone in
the intact peripheral microcirculation. The Sixth International Conference of the Macrolides,
Azalides, Streptogramins, Ketolides & Oxazolidiones, Bologna, Italy, January 23-25, 2002
abstract book program 6.04.
Kumar B, Schriever CA, Rubinstein I. Long-term montelukast therapy in patients with severe
COPD. American Journal of Respiratory and Critical Care Medicine 165: A228, 2002.
Ramirez A, Rubinstein I. Clinical encounters of pulmonary fellows with active mycobacterial
infections in inner-city Chicago. American Journal of Respiratory and Critical Care Medicine
165: A657, 2002.
Rubinstein I. Novel aspects of hypertension control by vasoactive intestinal peptide. Journal of
Heart Failure 7: 15, 2002.
Sethi V, Rubinstein I, Onyuksel H. Vasoactive intestinal peptide (VIP) loaded sterically
stabilized micelles (SSM) for improved therapy of collagen induced arthritis (CIA) in mice.
PharmSci 4(Supplement): T2036, 2002.
Ashok B, Rubinstein I, Dagar S, Onyuksel H. Interactions of Vasoactive intestinal peptide
(VIP) with gel phase liposomes: implications for peptide vasoreactivity. PharmSci
4(Supplement): T2083, 2002.
Krishnadas A, Dagar S, Rubinstein I, Onyuksel H. A novel active targeting carrier for
paclitaxel: Vasoactive intestinal peptide (VIP)-conjugated liposomes. PharmSci
4(Supplement): W4089, 2002.
Kirchhof C, Rubinstein I, , Önyüksel H. Interaction of pegylated phospholipids with a chimeric
cytokine: a fluorescence and circular dichroism study. Parenteral Drug Association (PDA)
Annual Meeting Courses and Exhibition, New Orleans, Louisiana, December 9-14, 2002.
Vettori MV, Corradi M, Apostoli P, Rubinstein I, Folesani G, Palmi S, Prtyx M, Mutti A.
Exhaled breath condensate as a tool to assess target tissue dose and effect of pneumotoxic
metals. 27th
International Congress on Occupational Health (ICOH 2003), Iguassu Falls,
Brazil, February 23-28, 2003; abstract book program.
Israel Rubinstein, M.D.
57 of 115
Koo O, Rubinstein I, Onyuksel H. Solubilization of camptothecin using DSPE-PEG2000
micelles. CUBIC 2003 Advancing Bioengineering, Chicago, Illinois, March 7, 2003.
Rubinstein I, Tsueshita T, Gandhi S, Onyuksel H. Helospectin I and II evoke VIP and
PACAP1-38 receptor-independent vasodilation in vivo. Experimental Biology 2003, San
Diego, California, April 11-15, 2003; abstract book program #399.9.
Sethi V, Onyuksel H, Rubinstein I. A novel therapy for rheumatoid arthritis (RA) using α-helix
VIP. Experimental Biology 2003, San Diego, California, April 11-15, 2003 abstract book
program #660.3.
Nicolau DP, Tessier PR, Rubinstin I, Nightingale CH. In vivo immunomodulatory profile of
Telithromycin in a murine infection model. 13th
European Congress of Clinical Microbiology
and Infectious Diseases, Galsgow, U.K., May 10-13, 2003; abstract book program #P1620.
Mutti A, Corradi M, Apostoli P, Andreoli R, Goldoni M, Manini P, Vettori MV, Rubinstein I.
Exhaled breath condensate as a tool to assess target tissue dose and effects of pneumotoxic
metals. American Journal of Respiratory and Critical Care Medicine 167: A334, 2003.
Garey KW, Schriever C, Mutlu GM, Kumar BJ, Dizikes G, Danziger LH, Rubinstein I.
Exhaled breath condensate analysis for mycobacterium tuberculosis rRNA correlates with
sputum smear negative specimens. American Journal of Respiratory and Critical Care
Medicine 165: A821, 2003.
Onyuksel H, Rubinstein I. Targeted drug delivery & improved drug solubility.
www.vpted.uillinois.edu/~pdf_files/-iemerging520past%20pdfs/Spring%202003/Medlipids.pdf
Krishnadas A, Rubinstein I, Peddakota LR, Onyuksel H. Sterically stabilized mixed micelles
loaded with paclitaxel (P-SSMM) for improved chemotherapy of breast cancer. PharmSci 5(4),
Abstract M1213, 2003.
Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. Characterization of sterically
stabilized phospholipid mixed micelles: effect of PC amount and PEG chain length. PharmSci
5(4), Abstract M1180, 2003.
Kirchhoff CF, Rubinstein I, Nema S, Onyuksel H. Heterogeneity assessment of pegylated
phospholipid – protein physical complexes. PharmSci 5(4), Abstract T2075, 2003.
Koo OM, Rubinstein I, Onyuksel H. Camptothecin solubilization in pegylated phospholipid
micelles utilizing novel pH change method. PharmSci 5(4), Abstract M1212, 2003.
Sethi V, Onyuksel H, Kastrissios H, Rubinstein I. Enhanced circulation half-life and reduced
clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized micelles (SSM) in
mice with collagen-induced arthritis (CIA). PharmSci 5(4), Abstract M1045, 2003.
Rubinstein I, Sethi V, Kastrissios H, Onyuksel H. Safety of vasoactive intestinal peptide (VIP)-
loaded sterically stabilized phospholipid micelles (SSM) for treatment of respiratory disorders.
American Journal of Respiratory and Critical Care Medicine 169: A354, 2004.
Israel Rubinstein, M.D.
58 of 115
Massimo C, Bernard A, Rubinstein I, Acampa O, Apostoli P, Mutti A. Pneumoproteinemia in
patients with chronic obstructive pulmonary disease, asthma, and healthy smoking and non
smoking subjects. American Journal of Respiratory and Critical Care Medicine 169: A553,
2004.
Jain R, Schriever C, Danziger L, Franzblau S, Cho S, Glowacki R, Welbel S, Rubinstein I.
Failure to detect the IS6110 repetitive DNA element of Mycobacterium tuberculosis in exhaled
breath condensate of patienst with active pulmonary tuberculosis. Clinical Microbiology and
Infection 10(Supplement 3); 417-418, 2004.
Robbins RA, Hoyt JC, Ballering J, Nelson D, Numanami H, Rubinstein I. Noninvasive
assessment of the lower respiratory tract inflammation in smokers. Flight Attendant Medical
Research Institute Annual Meeting, Miami, Florida, May 13-14, 2004; abstract book program.
Ashok B, Rubinstein I, Önyüksel H. Peptide delivery using PEGylated phospholipids: effects
of peptide and PEG size. 7th
World Biomaterials Congress, Sydney, Australia, May 17-21,
2004; abstract book program.
Koo O, Rubinstein I, Onyuksel H. Delivery of Camptothecin in nanosized pegylated
phospholipid micelles. PGSRM 2004; 37th
Annual Pharmaceutics Graduate Student Research
Meeting, Iowa City, Iowa, June 10-12, 2004; abstract book #PD8.
Schriever CA, Shafer M, Schauer J, Worley C, Rubinstein I. Analysis of trace metal
contamination in supplies used for exhaled breath condensate collection (EBC) using
inductively coupled plasma-mass spectrometry (ICPMS). European Respiratory Journal 24
(Supplement 48): 679s, 2004.
Peddakota LR, Rubinstein I, Dudeja PK, Önyüksel H. Effects of PEGylated lipids on the
properties of egg phosphatidylcholine model membranes. 7th
New Jersey Symposium of
Biomaterials Science, New Brunswick, NJ; October 24-26, 2004; abstract book page 101.
Krishnadas A, Rubinstein I, Sekosan M, Onyuksel H. Targeted delivery of paclitaxel to breast
cancer by vasoactive intestinal peptide conjugated sterically stabilized phospholipid mixed
micelles. AAPS Journal 6: Abstract M1191, 2004.
Ashok B, Dudeja P, Rubinstein I, Onyuksel H. Effect of incorporation of egg-
phosphatidylcholine on the core properties of pegylated phospholipid micelles. AAPS Journal
6: Abstract M1197, 2004.
Koo O, Rubinstein I, Onyuksel H. Delivery of camptothecin in nanosized pegylated
phospholipid micelles to treat murine collagen-induced arthritis. AAPS Journal 6: Abstract
M1267, 2004.
Onyuksel H, Koo O, Krishnadas A, Sethi V, Rubinstein I. Nanothechnology in drug delivery.
Invited Lecture at a session entitled: “Drug Delivery by Nanotechnology”, Wednesday, May 11,
Israel Rubinstein, M.D.
59 of 115
2005. 2005 NSTI Bio Nano Conference and Trade Show, Anaheim, California, May 8-12,
2005.
Ashok B, Önyuksel H, Tsueshita T, Rubinstein I. All D-vasoactive intestinal peptide (VIP)
mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar pituitary adenylate
cyclase activating peptide (PACAP)1-38, but not PACAP1-38, in vivo. Proceedings of the
American Thoracic Society 2; A70, 2005.
Rubinstein I, Krishnadas A, Peddakota LR, Önyüksel H. Nanoparticulate paclitaxel loaded into
sterically stabilized mixed phospholipid micelles to improve chemotherapy of breast cancer.
Breast Cancer Research 7(Supplement 1):S20, 2005.
Koo O, Rubinstein I, Önyüksel H. Delivery of Camptothecin in nanosized PEGylated
phospholipid micelles to treat murine collagen-induced arthritis. PGSRM 2005; 38th
Annual
Pharmaceutics Graduate Student Research Meeting, Lawrence, Kansas, June 16-18, 2005;
abstract book #PS-28.
Onyuksel H, Koo O, Krishnadas A, Rubinstein I. VIP-receptor targeted phospholipid
nanocarriers for in vivo anti-cancer drug delivery. Third International Nanomedicine and Drug
Delivery Symposium, Baltimore, Maryland, September 26-27, 2005; abstract book pp. 55-56.
Koo O, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles:
a novel nanomedicine for rheumatoid arthritis. AAPS Journal 7(S2): Abstract W5089, 2005.
Pai A, Rubinstein I, Onyuksel H. Stabilization of beta amyloid (Aß1-42) using PEGylated
phospholipid micelles. AAPS Journal 7(S2): Abstract W5156, 2005.
Jeon E, Rubinstein I, Onyuksel H. VIP receptor expression in MNU-induced rat breast cancer.
AAPS Journal 7(S2): Abstract R6039, 2005.
Onyuksel H, Koo OM, Sethi V, Rubinstein I. Sterically stabilized phospholipid micellar
human vasoactive intestinal peptide: A novel disease-modifying drug for rheumatoid arthritis.
2005 American College of Rheumatology Annual Scientific Meeting, San Diego, California,
November 12-17, 2005; Presentation number 638.
Rubinstein I, Soos IH, Onyuksel H. Intravital optical tracking of actively targeted phospholipid
mixed micelle drug delivery nanocarriers in breast cancer using quantum dots. FASEB Journal
20, Abstract number 179.8, 2006.
Rubinstein I, Onyuksel H. Nanoparticulate sterically stabilized phospholipid micelles improve
cryopreservation of oral keratinocytes. Proceedings of the American Thoracic Society 3; A425,
2006.
Pai A, Rubinstein I, Önyüksel H. PEGylated phospholipids modulate ß-amyloid peptide
fibrillogenesis and confer neuroprotection in vitro. CINP 2006 Chicago Congress – Collegium
Internationale Neuro-Psychopharmacologium. Chicago, Illinois, July 9-13, 2006; Abstract
book.
Israel Rubinstein, M.D.
60 of 115
Jeon E, Rubinstein I, Önyüksel H. Interaction of peptide drugs with sterically stabilized
phospholipid micelles at a molecular level. Transactions of the 33rd
Annual Meeting &
Exposition of the Controlled Release Society. Vienna, Austria, July 22-26, 2006; Abstract book
#445.
Pai AS, Rubinstein I, Önyüksel H. Nanosized sterically stabilized phospholipid micelles
attenuate ß-amyloid aggregation and neurotoxicity in vitro. Transactions of the 33rd
Annual
Meeting & Exposition of the Controlled Release Society. Vienna, Austria, July 22-26, 2006;
Abstract book #656.
Rubinstein I, Soos I, Önyüksel H. Real time tracking of actively targeted phospholipid mixed
micelles to human breast cancer cells using quantum dots. Transactions of the 33rd
Annual
Meeting & Exposition of the Controlled Release Society. Vienna, Austria, July 22-26, 2006;
Abstract book #663.
Onyuksel H, Sethi V, Koo O, Rubinstein. Targeted novel nanomedicines for rheumatoid
arthritis. 13th
International Pharmaceutical Technology Symposium, Antalya, Turkey,
September 10-13, 2006; Proceedings page 14.
Onyuksel H, Soos I, Rubinstein I. Targeted lipid nanomicelles are internalized into cancer cells
through vasoactive intestinal peptide (VIP) receptors. AAPS Journal 8(S2): Abstract W4234,
2006.
Pai A, Rubinstein I, Onyuksel H. Phospholipid nanomicelles inhibit monomeric to oligomeric
and pre-fibrillar to fibrillar transitions of Alzheimer’s beta amyloid peptide in vitro. AAPS
Journal 8(S2): Abstract W5069, 2006.
Jeon EJ, Rubinstein I, Onyuksel H. Modeling of amphipathic therapeutic peptide –
phospholipid nanomicelles interactions in silico. AAPS Journal 8(S2): Abstract W5101, 2006.
Desai E, Rubinstein I, Önyüksel H. Neuropeptide Y self-associated with sterically stabilized
phospholipid nanomicelles to form a nanomedicine. 2007 Professional and Student Research
Forum at UIC 18: 10; 2007.
Lim SB, Rubinstein I, Önyüksel H. Study of sterically stabilized phospholipid simple and
mixed micelles as nanocarriers for peptide drugs. Transactions of the Society for Biomaterials
Annual Meeting 32: 541, 2007.
Mohanty PS, Rubinstein I, Önyüksel H. Solubilization of 17-allylamino-17-
demethoxygeldanamycin in biocompatible and biodegradable sterically stabilized phospholipid
mixed micelles – a novel nanomedicine for treatment of breast cancer. Transactions of the
Society for Biomaterials Annual Meeting 32: 555, 2007.
Pai AS, Rubinstein I, Önyüksel H. PEGylated phospholipid nanomicelles disaggregate pre-
formed amyloid fibrils in vitro: implications for Alzheimer’s disease therapeutics. Pre-Satellite
Israel Rubinstein, M.D.
61 of 115
Meeting, 3rd Pharmaceutical Sciences World Congress, Amsterdam, The Netherlands, April
20-21, 2007; abstract book pages 19-20. http://pharmacie.univ-lille2.fr/presatellitePSWC/
Rubinstein I, Lim SB, Jeon E, Önyüksel H. Human GLP-1a and GIPa: novel, long-acting
nanomedicines for type II diabetes mellitus. FASEB Journal 21: A434, 2007.
Lim SB, Onyuksel H, Rubinstein I. Inhaled human VIP-α: a novel, long-acting nanomedicine
for idiopathic pulmonary arterial hypertension (IPAH). American Journal of Respiratory and
Critical Care Medicine 175(Supplement): A514, 2007.
Desai ES, Onyuksel H, Rubinstein I. Human neuropeptide Y-α: a novel, long-acting
biocompatible and biodegradable intra-nasal orixogenic nanomedicine for COPD-associated
cachexia. American Journal of Respiratory and Critical Care Medicine 175(Supplement):
A514, 2007.
Onyuksel H, Sethi V, Rubinstein I. Human VIP-alpha: a novel, long-acting, biocompatible,
biodegradable and safe disease modifying nanomedicine for rheumatoid arthritis. Journal of
Molecular Neuroscience 33: 323-324, 2007.
Cesur H, Rubinstein I, Pai A, Onyuksel HA. Lipid based nanomicelles for solubilization of a
sulfonamide anticancer drug. 2007 Annual Fall Meeting of the Biomedical Engineering
Society, Los Angeles, California, September 26-29, 2007; abstract book page 2.124.
Pai A, Onyuksel H, Artwohl J, Rubinstein I. Intranasal sterically stabilized nanomicellar VIP: a
novel nanomedicine for Alzheimer’s disease. Neuroscience 2007, Society for Neuroscience
Annual Meeting, San Diego, California, November 3-7, 2007; abstract book program#/Poster#:
886.13/M3.
Önyüksel H, Pai A, Artwohl J, Rubinstein I. Anti-amyloid efficacy of a novel intranasal lipid-
based peptide nanomedicine: A pilot study. AAPS Journal 9(Supplement 2):T3243, 2007.
Lim S, Rubinstein I, Önyüksel H. Lyophilization of self-associated peptide therapeutics with
sterically stabilized phospholipid nanomicelles. AAPS Journal 9(Supplememnt 2):T3297, 2007.
Pai A, Onyuksel H, Rubinstein I. PEGylated phospholipid nanomicelles protect Swedish
mutants APP695 and sweΔ9 N2a mouse neuroblastoma cells from β-amyloid induced
apoptosis. FASEB Journal 22: 716.6, 2008.
Cesur H, Rubinstein I, Mohanty P, Onyuksel H. Solubilization of water-insoluble drugs in
pegylated lipid-based nano-carriers: drug hydrophobicity and Solubilization. 6th
World Meeting
on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barcelona, Spain, April
7-10, 2008; abstract book page 63, poster 144.
Sadikot RT, Mohanty PS, Ornatowska M, Onyuksel H, Rubinstein I. Sterically stabilized
phospholipid nanomicellar 17-allylaminodemethoxygeldanamycin inhibits lipopolysaccharide-
induced activation of nuclear factor-κB in bone marrow-derived macrophages. American
Journal of Respiratory and Critical Care Medicine 177(Abstract Issue): A75, 2008.
Israel Rubinstein, M.D.
62 of 115
Rubinstein I, Onyuksel H, Pendland SI. Is human vasoactive intestinal peptide an antimicrobial
peptide? American Journal of Respiratory and Critical Care Medicine 177(Abstract Issue):
A685, 2008.
Brandenburg KS, Rubinstein I, Onyuksel H. A novel, long-acting, biocompatible and
biodegradable parenteral nanoformulation of polymyxin B for resistant microorganisms.
American Journal of Respiratory and Critical Care Medicine 177(Abstract Issue): A686, 2008.
Sadikot RT, Lim SB, Ornatskowa M, Onyuksel H, Rubinstein I. TREM-1 self-associated with
sterically stabilized phospholipid nanomicelles attenuates acute lung inflammation in mice.
American Journal of Respiratory and Critical Care Medicine 177(Abstract Issue): A982, 2008.
Pai A, Onyuksel H, Rubinstein I. Blood brain barrier permeability in AAPswe/PS1ΔE9 co-
expressing transgenic mice. Neuroscience 2008, Society for Neuroscience Annual Meeting,
Washington, D.C., November 15-19, 2008; abstract book program#/Poster#: 638.20/M5.
Önyüksel H, Sethi V, Krishnadas A and Rubinstein I. Long-circulating, biocompatible and
biodegradable lipid-based nanocarriers improve drug efficacy and safety. AAPS Journal
10(Supplement 2): M1181, 2008.
Lim SB, Rubinstein I, Sadikot RT and Önyüksel H. Long-circulating, biocompatible and
biodegradable sterically stabilized phospholipid nanomicelles attenuate NF-қB activation in
murine macrophages. AAPS Journal 10(Supplement 2): W4106, 2008.
Sadikot RT, Lim S, Wang X, Christman JW, Onyuksel H, Rubinstein I. Effects of long-
circulating nanomicellar GLP-1 on LPS-induced acute lung inflammation in mice. American
Journal of Respiratory and Critical Care Medicine 179(Supplement): A4015, 2009.
Sadikot RT, Lim S, Wang X, Christman JW, Onyuksel H, Rubinstein I. Salutary effects of
nanomicellar GLP-1 administered after onset of LPS-induced acute lung inflammation in mice.
American Journal of Respiratory and Critical Care Medicine 179(Supplement): A5646, 2009.
Lim S, Rubinstein I, Onyuksel H. Sterile filtration of nanomicellar human GLP-1(7-36)
peptide drug does not affect its biophysical properties. 2009 AAPS National Biotechnolgy
Conference, American Association of Pharmaceutical Scientists, Seattle, WA, June 21-24,
2009; abstract book #T2097, page 108.
Brandenburg KS, Rubinstein I, Onyuksel H. PEG 2000 coating on lipid nanomicelles hinders
polymyxin B interaction with Pseudomonas aeruginosa. Proceedings of 36th Annual Meeting
of Controlled Release Society, Copenhagen, Denmark, July 18-22, 2009; poster #850.
Rubinstein I, Berger E, McCllelan S, Hazlett L. Long-acting nanoformulation of vasoactive
intestinal peptide downregulates P. aeruginosa-induced tissue inflammation in mice. American
Journal of Respiratory and Critical Care Medicine 181(Abstract Issue): A747, 2010.
Israel Rubinstein, M.D.
63 of 115
Famuyiwa FI, Rubinstein I, Sadikot RT. Rapid resolution of leukocytoclastic-associated acute
respiratory distress syndrome with hydroxyurea. American Journal of Respiratory and Critical
Care Medicine 181(Abstract Issue): A4615, 2010.
Kuzmis A, Lim S, Desai E, Lee B-S, Rubinstein I, Onyuksel H. Peptide nanomedicine; human
neuropeptide Y self-associatedd with sterically stabilized phospholipid micelles. AAPS Journal
12(S2); W4033, 2010.
Weinberg G, Rubinstein I. Intravenous fat nanoemulsion: a novel antidote for local anesthetic-
induced systemic toxicity in humans. World Journal of Engineering 7 (Supplement 3): P1207-
P1208, 2010 (http://wjoe.hebeu.edu.cn)
Famuyiwa F, Rubinstein I. Chronic non-infectious respiratory diseases in adult patients with
IgE hypogammaglobulinemia residing in inner-city Chicago. American Journal of Respiratory
and Critical Care Medicine 183(Abstract Issue): A1363, 2011.
Rubinstein I, Weinberg G. Intravenous fat emulsion: an emerging antidote for acute local
anesthetic-induced cardiac toxicity in humans. American Journal of Respiratory and Critical
Care Medicine 183(Abstract Issue): A5837, 2011.
Feinstein DL, Kalinin S, Colca J, Rubinstein I. Thee potential of PPARɤ-sparing TZDs for
treatment of neurodegenerative diseases. 7th
International Symposium on Neuroprotection and
Neurorepair, Potsdam, Germany, May 2-5, 2012; abstract book.
Ericsoussi MB, Jaffe HA, Rubinstein I. Case report: Non-invasive positive pressure ventilation
prevents frequent acute COPD exacerbations in a patient with excessive dynamic airway
collapse. American Journal of Respiratory and Critical Care Medicine 185(Abstract Issue):
A2745, 2012.
Markos MA, Rubinstein I, Weinberg G. Pig is unsuitable model to investigate mechanisms
underlying lipid rescue of local anesthetic-induced cardiac arrest. American Journal of
Respiratory and Critical Care Medicine 185(Abstract Issue): A3154, 2012.
Rubinstein I, Reichstetter S, Castillo J, Bolotin E. Safety of nanomicellar vasoactive intestinal
peptide in mice – Implications for pulmonary arterial hypertension. American Journal of
Respiratory and Critical Care Medicine 185(Abstract Issue): A3412, 2012.
Markos M, Weinberg G, Rubinstein I. Lipid emulsion resuscitation of hydrophobic drug
overdose-induced toxicity in young children. Critical Care Medicine 40(Supplement 1): 591,
2012.
Rubinstein I, Reichstetter S, Castillo G, Bolotin E. Vasoactive intestinal peptide self-associated
with protected graft copolymer: a novel, long-acting nanoformulation of vasoactive intestinal
peptide for sarcoidosis and pulmonary hypertension. American Journal of Respiratory and
Critical Care Medicine 187(Abstract Issue): A1067, 2013.
Israel Rubinstein, M.D.
64 of 115
Fettiplace M, Weinberg G, Ripper R, Lis K, Feinstein D, Markos MA, Rubinstein I.
Intraosseous injection of Intralipid reverses bupivacaine-induced cardiovascular toxicity in rats.
American Journal of Respiratory and Critical Care Medicine 187(Abstract Issue): A4410, 2013.
Invited Lectures, Presentations and Visiting Professorships
06/13 Continuing Medical Education Lecture; Gottlieb Memorial Hospital, Melrose Park,
Illinois. “Tobacco Screening: Theory and Practice.”
04/13 Continuing Medical Education Lecture; Saint Joseph Regional Medical Center,
Mishawaka, Indiana. “Tobacco Screening: Theory and Practice.”
03/13 Preseantation, Jewish Medical Ethics Symposium, UIC Levine Hillel Center,
Chicago, Illinois. “To Eat or not to Eat: Whose Decision, Whose Risk?”
01/13 Faculty, Cardio/Pulmonary For Primary Care Physicians, Continuing Medical
Education Programs, Medical Education Resources, Inc., January 25-27, 2013, Las
Vegas, Nevada . Presentations: “Asthma”; “Controversies in the Treatment of
Common Respiratory Infections”; “Everything You Need to Know About COPD”;
“Case Presentations”.
12/12 Continuing Medical Education Lecture; Vanguard Weiss Memorial Hospital,
Chicago, Illinois. “Tobacco Screening: Theory and Practice.”
11/12 Continuing Medical Education Lecture; Norwegian American Hospital, Chicago,
Illinois. “Tobacco Screening: Theory and Practice.”
11/12 Continuing Medical Education Lecture; Health First Center for Learning, Holmes
Regional Medical Center, Melbourne, Florida. “Tobacco Screening: Theory and
Practice.”
07/12 Faculty, Cardio/Pulmonary For Primary Care Physicians, Continuing Medical
Education Programs, Medical Education Resources, Inc., July 20-22, 2012,
Mackinac Island, Michigan. Presentations: “Asthma”; “Controversies in the
Treatment of Common Respiratory Infections”; “Everything You Need to Know
About COPD”; “Case Presentations”.
07/12 General Grand Rounds, Trinity Medical Center, Rock Island, Illinois. “Smoking
Cessation: an Ongoing Performance Improvement Challenge.”
06/12 Continuing Medical Education Program, Delray Medical Center, Delray Beach,
Florida. “Smoking Cessation: an Ongoing Performance Improvement Challenge.”
06/12 Continuing Medical Education Progrma, Blessing Hospital, Quincy, Illinois.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
Israel Rubinstein, M.D.
65 of 115
06/12 Grand Rounds, Saints Mary and Elizabeth Medical Center, Resurrection Health
Care, Chicago, Illinois. “Smoking Cessation: an Ongoing Performance
Improvement Challenge.”
05/12 Co-Chair of the Mini Symposium: “Nanotech meets the lung.” ATS 2012
International Conference, American Thoracic Society, San Francisco, California.
03/12 Grand Rounds, Saint Joseph Hospital, Resurrection Health Care, Chicago, Illinois.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
01/12 Chairperson; Cambridge Healthtech Institute’s PepTalk 2012, Pipeline 1:
Formulation – Optimizing Biologics Formulation Development, Candidate
Profiling, Developtability Assessment, Screening and Optimization, San Diego,
California.
01/12 Invited Plenary Lecture; Cambridge Healthtech Institute’s PepTalk 2012, Pipeline 1:
Formulation – Optimizing Biologics Formulation Development, Candidate
Profiling, Developtability Assessment, Screening and Optimization, San Diego,
California. “Novel Nanoformulation of Polymyxin B, a Peptide Antibiotic.”
11/11 Continuing Medical Education, Lung Health Day, Hanover Hospital, Hanover,
Pennsylvania. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
11/11 Faculty, Cardio/Pulmonary For Primary Care Physicians, Continuing Medical
Education Programs, Medical Education Resources, Inc., November 11-13, 2011,
Las Vegas, Nevada. Presentations: “Asthma”; “Controversies in the Treatment of
Common Respiratory Infections’; Everything You Need to Know About COPD”;
“Case Presentations”.
11/11 Wisconsin’s Evidence Based Issues in Family Medicine Fall CME Conference;
Wisconsin Association of Osteopathic Physicians & Surgeons, Milwaukee,
Wisconsin. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
09/11 Continuing Medical Education Conference, Vista Medical Center East, Waukegan,
Illinois. “Improving the Medical Management of Community Acquired
Pneumonia.”
07/11 Oral Presentation; The Nineteenth Annual International Conference on
Composites/Nano Engineering, ICCE-19, Shanghai, People’s Republic of China,
July 24-30, 2011. “A Novel Antidote for Local Anesthetic-Induced Systsemic
Toxicity in Humans.”
05/11 Invited Lecture; 2nd
Annual Covenant HealthCare Respiratory Care Conference,
Saginaw, Michigan. “Differential Diagnosis, Mangaement and Treatment of
Chronic Obstructive Pulmonary Disease (COPD).”
Israel Rubinstein, M.D.
66 of 115
03/11 Grand Rounds; Cheboygan Memorial Health Center, Cheboygan, Michigan.
“Asthma and COPD in Primary Care: The Similarities, Differences, and Treatment
Options.”
09/10 Research-in-Progress seminar; Department of Industrial and Physical Pharmacy,
College of Pharmacy, Purdue, University, West Lafayette, Indiana. “Nanomedicine
– a nascent clinical discipline.”
08/10 Grand Rounds, Department of Internal Medicine, Kalamazoo Center for Medical
Studies, Michigan State University, Kalamaazoo, Michigan. “Nanomedicine – An
Emerging Clinical Discipline.”
07/10 Chairperson of a scientific session, 4th
International Meeting on Development in
Materials, Processes of Emerging Technologies (MPA-2010), University of Minho,
Braga, Portugal, July 28-30, 2010. “Commercialisation of Advanced Technologies.”
07/10 Visiting Professor, The Centre for Research in Health Technologies and Information
Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal
05/10 Medical/Surgical Grand Rounds; Swedish American Hospital, Rockford, Illinois.
“Swine Origin Influenza: An H1N1 Virus.”
05/10 Wisconsin’s Annual Family Medicine Spring 2010 CME Conference; Wisconsin
Association of Osteopathic Physicians & Surgeons, Brookfield, Wisconsin.
“Asthma.”
05/10 Continuing Medical Education Conference, Vista Medical Center East, Waukegan,
Illinois. “Smoking Cessation: an Ongoing Performance Improvement Challenge.”
04/10 Invited Lecture; South Shore Hospital, Chicago, Illinois. “Diagnosis and
Management of COPD: A treatable, Long-Term Progressive Disease.”
04/10 Faculty, Cardio/Pulmonary For Primary Care Physicians, Continuing Medical
Education Programs, Medical Education Resources, Inc., April 23-25, 2010,
Orlando, Florida. Presentations: “Asthma”, “Controversies in the Treatment of
Common Respiratory Infections’, Everthing You Need to Know About COPD”,
“Case Presentations”.
03/10 Continuing Medical Education Lecture, Wyoming Valley Health Care System,
Wilkes-Barre, Pennsylvania. “Smoking Cessation: an Ongoing Performance
Improvement Challenge.”
03/10 Continuing Medical Education Lecture, St. Mary Medical Center, Hobart, Indiana.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
03/10 Grand Rounds, Department of Psychiatry, Maine Medical Center, Portland, Maine.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
Israel Rubinstein, M.D.
67 of 115
03/10 Research-in-Progress seminar; Diabetes Endocrinology Research Center, University
of Washington School of Medicine, Seattle, Washington. “Long-Acting, Targeted
Nanomedicine for ARDS: a Paradigm Shift?”
01/10 Continuing Medical Education Lecture; Health First Center for Learning, Holmes
Regional Medical Center, Melbourne, Florida. “Influenza Disease and Vaccination
– an Ongoing Performance Improvement Challenge.”
01/10 Invited Plenary Lecture; Cambridge Healthtech Institute’s Ninth Annual PepTalk,
Pipelines 1&3, San Diego, California. “Lyophylization of Long-Acting,
Biocompatible and Biodegradable, Nanomicellar Human Glucagon-Like Peptide-
1(7-36) Amide Drug.”
01/10 Continuing Medical Education presentation; Adventist GlenOaks Hospital,
Glendale Hights, Illinois. “Smoking Cessation: Evidence-Basedd Methods for
Helping Your Patients Quit.”
12/09 Continuing Medical Education presentation, Valley View Hosdpital, Glenwood
Springs, Colorado. “Management of COPD in the Community.”
12/09 Continuing Medical Education presentation, Aurora Medical Center Oshkosh,
Oshakosh, Wisconsin. “ 2009 Pandemic Influenza A (H1N1) Virus Infection: A
Rational Approach.”
11/09 Wisconsin’s Evidence Based Issues in Family Medicine Fall CME Conference;
Wisconsin Association of Osteopathic Physicians & Surgeons, Sheboygan,
Wisconsin. “Management of COPD in the Community.”
11/09 Continuing Medical Education presentation, St. Mary’s Hospital, Streator, Illinois.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
11/09 Invited Plenary Lecture; 16th
Annual Northwestern Iowa Respiratory Conference,
Sioux City, Iowa. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
11/09 Invited Plenary Lecture; 16th
Annual Northwestern Iowa Respiratory Conference,
Sioux City, Iowa. “Management of COPD in the Community.”
11/09 Continuing Medical Education presentation; Kishwaukee Community Hospital,
DeKalb, Illinois. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
10/09 Reseach-in-Progress Seminar; Diagnostic Center for Population and Animal Health,
Michigan State University, Lansing, Michigan. “Actively-Targeted Nanomedicine:
From Bench to Bedside.”
Israel Rubinstein, M.D.
68 of 115
10/09 Invited Plenary Lecture; American Society for Nanomedicine Inaugural Conference,
October 22-25, 2009, Bolger Center, Potomac, Maryland. “Novel, Long-Acting,
Biocompatible and Biodegradable Human Peptide Nanomedicines.”
10/09 Grand Rounds; St. Catherine Hospital, East Chicago, Indiana. “H1N1 Influenza
Virus Infection: The Devil is in the Details.”
09/09 Medical/Surgical Grand Rounds; Swedish American Hospital, Rockford, Illinois.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
09/09 Continuing Medical Education presentation; John C. Lincoln Health Network,
Phoenix, Arizona. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
08/09 Grand Rounds; Trinity Medical Center, Rock Island, Illinois. “Smoking Cessation:
an Ongoing Performance Improvement Challenge.”
08/09 Visiting Professor Grand Rounds, St. Mary Medical Center, Community Healthcare
System, Hobart, Indiana. “Asthma Update 2009. New NHLBI Guidelines.”
07/09 Grand Rounds; University Medical Center, Las Vegas, Nevada. “Smoking
Cessation: an Ongoing Performance Improvement Challenge.”
07/09 Grand Rounds; St. Luke’s Magic Valley Medical Center, Twin Falls, Idaho.
“Smoking Cessation: an Ongoing Performance Improvement Challenge.”
06/09 Grand Rounds; Adventist La Grange Memorial Hospital, La Grange, Illinois.
“Smoking Cessation: Evidence-Basedd Methods for Helping Your Patients Quit.”
05/09 Continuing Medical Education presentation; Sierra Vista Regional Health Center,
Sierra Vista, Arizona. “Healthcare-Associated Pneumonia: an Ongoing Quality
Improvement Challenge.
05/09 Wisconsin’s Evidence Based Issues in Family Medicine Spring CME Conference;
Wisconsin Association of Osteopathic Physicians & Surgeons, Brookfield,
Wisconsin. “Smoking Cessation: an Ongoing Performance Improvement
Challenge.”
05/09 Invited Lecture; Internal Medicine Residency Program, Mt. Sinai Hospital, Chicago,
Illinois. “Managing Asthma in the Hospital: A Case-Based Approach.”
05/09 Continuing Medical Education presentation; Provena United Samaritans Medical
Center, Danville, Illinois. “Smoking Cessation: an Ongoing Performance
Improvement Challenge.”
Israel Rubinstein, M.D.
69 of 115
04/09 Invited Lecture; 38th
Annual Spring Symposium & Medical Expo, Lake Michigan
College Mendel Center, Benton Harbor, Michigan. “Smoking Cessation: an
Ongoing Performance Improvement Challenge.”
04/09 Continuing Medical Education presentation; Norman Regional Hospital, Norman,
Oklahoma. “Smoking Cessation Performance Improvement Roundtable
Discussion.”
04/09 Continuing Medical Education Lecture; St. Mary’s Hospital, Streator, Illinois.
“Management of COPD in the Community.”
03/09 Grand Rounds; Adventist Hinsdale Hospital, Hinsdale, Illinois. “Smoking
Cessation: Evidence-Basedd Methods for Helping Your Patients Quit.”
03/09 Invited Lecture; Pri-Med Access; March 18-19, 2009, San Diego Convention
Center, San Diego, CA. “Optimizing the Management of Chronic Obstructive
Pulmonary Disease (COPD).”
03/09 Invited Lecture; Pri-Med Access; March 13-14, 2009, Saint Paul RiverCentre, St.
Paul, MN. “Optimizing the Management of Chronic Obstructive Pulmonary Disease
(COPD) .”
03/09 Grand Rounds; Adventist Bolingbrook Hospital, Bolingbrook, Illinois. “Smoking
Cessation: Evidence-Basedd Methods for Helping Your Patients Quit.”
03/09 Continuing Medical Education Lecture; Health First Center for Learning, Holmes
Regional Medical Center, Melbourne, Florida. “Smoking Cessation: an Ongoing
Performance Improvement Challenge.”
02/09 Family Practice Grand Rounds; MidMichigan Medical Center, Midland, Michigan.
“Update on New NIH Asthma Guidelines.”
02/09 Research-in-Progress Seminar; ADAMAS Pharmaceuticals, Emeryville, California.
“Healthcare-Associated Infections.”
02/09 Grand Rounds; Jupiter Medical Center, Jupiter, Florida. “Healthcare-Associated
Infections – an Ongoing Quality Improvement Challenge.”
02/09 Grand Rounds; Bloomington Hospital, Bloomington, Indiana. “Healthcare-
Associated Pneumonia – an Ongoing Quality Improvement Challenge.”
01/09 Continuing Medical Education Program; Flagler Hospital, St. Augustine, Florida.
“Update on New NIH Asthma Guidelines.”
12/08 Grand Rounds; Ball Memorial Hospital, Muncie, Indiana. “The New NIH Asthma
Guidelines.”
Israel Rubinstein, M.D.
70 of 115
11/08 Continuing Medical Education presentation; Norman Regional Hospital, Norman,
Oklahoma. “New Guidelines for Asthma Management and Control in the
Community.”
10/08 Invited Lecture; Congdon Lecture Series: “Update – General Medicine”; Genesys
Learning Institute, Genesys Regional Medical Center, Grand Blanc, MI. “Rationale
Approach to Antibiotic Therapy-Another Case of Cimmunity-Acquired
Pneumonia?”
08/08 Grand Rounds; St. Luke’s Magic Valley Regional Medical Center, Twin Falls,
Idaho. “Update on Current NIH Treatment Guidelines for Asthma Management.”
07/08 Invited Lecture; Hospital Medicine, Rockford Memorial Hospital, Rockford,
Illinois. “Diagnosis and Management of COPD: A Treatable, Long-term Progressive
Disease.”
07/08 Grand Rounds; Mercy Medical Center, Sioux City, Iowa. “The New NIH Asthma
Guidelines.”
06/08 Grand Rounds; Provena United Samaritans Medical Center, Danville, Illinois.
“2007 NHLBI Asthma Guidelines.”
05/08 Invited Lecture; Family Medicine Residency Program, Saint Mary of Nazareth,
Chicago, Illinois. “Diagnosis and Management of COPD: A Treatable, Long-term
Progressive Disease.”
05/08 Grand Rounds; Prince George’s Hospital Center, Cheverly, Maryland.
“Management of COPD in the Community.”
04/08 Grand Rounds; Provena Covenant Medical Center, Urbana, Illinois. “2007 NHLBI
Asthma Guidelines.”
04/08 Continuing Medical Education Program; Bluefield Regional Medical Center,
Bluefield, West Virginia. “Rational Approach to Antibiotic Therapy – Just Another
Case of CAP.”
02/08 Continuing Medical Education Lecture; Health First Center for Learning Holmes
Regional Medical Center, Melbourne, Florida. “Alpha-1 Antitrypsin Deficiency: An
Underrecognized, Underdiagnosed Cause of Obstructive Airway Disease.”
01/08 Grand Rounds; St. Luke’s Magic Valley Regional Medical Center, Twin Falls,
Idaho. “Rational Approach to Antibiotic Therapy in the Era of Increased
Resistance.”
01/08 Research-in-Progress Seminar; Department of Cellular and Integrative Physiology,
University of Nebraska Medical Center, Omaha, Nebraska. “Active Targeting of
Nanomedicines to Inflammation; an Integrated Approach.”
Israel Rubinstein, M.D.
71 of 115
11/07 Invited Plenary Lecture; Wisconsin Association of Osteopathic Physicians &
Surgeons Fall 2007 CME Convention, Wausau, Wisconsin. “Managing Asthma in
the Hospital: A Case-Based Approach.”
11/07 Invited Plenary Lecture; Wisconsin Association of Osteopathic Physicians &
Surgeons Fall 2007 CME Convention, Wausau, Wisconsin. “New Insights on
Inhaled Insulin.”
11/07 Grand Rounds; John C. Lincoln Health Network, Phoenix, Arizona. “New Insights
on Inhaled Insulin.”
11/07 Grand Rounds; Department of Medicine, Berkshire Medical Center, Pittsfield,
Massachusetts. “The Immunomodulatory Effects of Macrolide Antibiotics in
Human Diseases.”
10/07 Invited Plenary Lecture; 5th
Annual Fall Primary Care CME Symposium,
Kalamazoo Center for Medical Studies, Kalamazoo, Michigan. “Inhaled
Corticosteroids: The Mainstay of Treatment in Mild Persistent Asthma.”
10/07 Grand Rounds; University Medical Center, Las Vegas, Nevada. “Alpha-1
Antitrypsin Deficiency.”
10/07 Invited Lecture; Association of Russian-American Physicians in Chicago, Glenview,
Illinois. “Management of COPD in the Community.”
10/07 Grand Rounds; Huron Hospital, East Cleveland, Ohio. “Alpha-1 Antitrypsin
Deficiency: An Underrecognized, Underdiagnosed Cause of Obstructive Airway
Disease.”
10/07 Invited Lecture; Internal Medicine Residence Lecture Series. Providence-St. John
Health Hospital, Southfield, Michigan. “Managing Asthma in the Hospital: A Case-
Based Approach.”
10/07 Invited Lecture; Family Medicine Residence Lecture Series. Oakwood Hospital
Annapolis Center, Wayne, Michigan. “Managing Asthma in the Hospital: A Case-
Based Approach.”
09/07 Grand Rounds; Broughton Hospital, Morganton, North Carolina. “New Insights on
Inhaled Insulin.”
09/07 Invited Lecture; Symposium: Insulin Therapy in 2007. Hackettstown Regional
Medical Center, Hackettstown, New Jersey. “New Insights on Inhaled Insulin.”
09/07 Grand Rounds; Stephens Memorial Hospital, Norway, Maine. “New Insights on
Inhaled Insulin.”
Israel Rubinstein, M.D.
72 of 115
09/07 Invited Lecture; Calhoun County Medical Society Meeting, Marshall, Michigan.
“Inhaled Corticosteroids: The Mainstay of Treatment in Mild Persistent Asthma.”
09/07 Invited Plenary Lecture; 8th
International Symposium on VIP, PACAP and Related
Peptides, Manchester Village, Vermont. “Human VIP-alpha: a novel, long-acting,
biocompatible, biodegradable and safe disease modifying nanomedicine for
rheumatoid arthritis.”
08/07 Grand Rounds; Vista Medical Center East, Waukegan, Illinois. “New Insights on
Inhaled Insulin.”
07/07 Grand Rounds; Mary Free Bed Rehabilitation Hospital, Grand Rapids, Michigan.
“Prevention, Recognition and Treatment of Health Care-Associated Pneumonia.”
06/07 Grand Rounds; Halifax Medical Center, Daytona Beach, Florida. “Prevention,
Recognition and Treatment of Health Care-Associated Pneumonia.”
06/07 Grand Rounds; Bayshore Community Hospital, Holmdel, New Jersey. “New
Insights on Inhaled Insulin.”
06/07 Grand Rounds; St. Mary Medical Center, Langhorne, Pennsylvania. “Prevention,
Recognition and Treatment of Health Care-Associated Pneumonia.”
05/07 Grand Rounds; Integris Southwest Medical Center, Oklahoma City, Oklahoma..
“Prevention, Recognition and Treatment of Health Care-Associated Pneumonia.”
05/07 Grand Rounds; Integris Baptist Medical Center, Oklahoma City, Oklahoma.
“Prevention, Recognition and Treatment of Health Care-Associated Pneumonia.”
05/07 Grand Rounds; Elkhart General Hospital, Elkhart, Indiana. “Prevention,
Recognition and Treatment of Health Care-Associated Pneumonia.”
04/07 Grand Rounds; St. Luke’s Magic Valley Regional Medical Center, Twin Falls,
Idaho. “Prevention, Recognition and Treatment of Health Care-Associated
Pneumonia.”
04/07 Grand Rounds; Department of Medicine, Mercer University School of Medicine,
Macon, Georgia. “Prevention, Recognition and Treatment of Health Care-
Associated Pneumonia.”
04/07 Invited Plenary Lecture; Wisconsin Association of Osteopathic Physicians &
Surgeons Spring 2007 Environmental Medicine/Family Practice Update CME
Conference, Pewaukee, Wisconsin. “Health Care-Associated Pneumonia.”
03/07 Grand Rounds; Vista Medical Center East, Waukegan, Illinois. “Alpha-1
Antitrypsin Deficiency: An Underrecognized, Underdiagnosed Cause of Obstructive
Airway Disease.”
Israel Rubinstein, M.D.
73 of 115
02/07 Invited Lecture; 2007 Winter CME Symposium & Recertification Conference,
Florida Academy of Physician Assistants, Orlando, Florida. “RTI: Treatment
Choices Rooted in Clinical Evidence. Predictable Outcomes for all Seasons.”
02/07 Grand Rounds; Department of Medicine, Christiana Care Health System, Newark,
Delaware. “The Immunomodulatory Effects of Macrolide Antibiotics in Human
Diseases.”
01/07 Grand Rounds; Midland Memorial Hospital, Midland Texas. “Prevention,
Recognition and Treatment of Health Care-Associated Pneumonia.”
01/07 Grand Rounds; Bloomington Hospital, Bloomington, Indiana. “Prevention,
Recognition and Treatment of Health Care-Associated Pneumonia.”
01/07 Invited Lecture; Vista Medical Center East, Waukegan, Illinois. “RTI: Treatment
Choices Rooted in Clinical Evidence. Predictable Outcomes for all Seasons.”
01/07 Grand Rounds; Huron Hospital, East Cleveland, Ohio. “Prevention, Recognition
and Treatment of Health Care-Associated Pneumonia.”
01/07 Grand Rounds; Salem Hospital Regional Health Services, Salem, Oregon.
“Prevention, Recognition and Treatment of Health Care-Associated Pneumonia.”
10/06 Research-in-Progress Seminar; FILT Lungen- und Thoraxdiagnostik GmbH, Berlin,
Germany. “The Future of Exhaled Breath Condensate.”
10/06 Research-in-Progress Seminar; Capsulution NanoScience AG, Berlin, Germany.
“Novel Targeted Nanomedicine for Breast Cancer.”
10/06 Invited Plenary Lecture; 4th
Annual Autumn Primary Care Symposium, Michigan
State University-Kalamazoo Center for Medical Studies, Kalamazoo, Michigan.
“Rational Approach to Antibiotic Therapy in the Era of Increased Resistance.”
09/06 Grand Rounds; Chambersburg Hospital, Chambersburg, Pennsylvania. “Recognition
and Management of COPD in the Community for Patient Safety.”
09/06 Grand Rounds; Innovis Health, Fargo, North Dakota. “New Approaches to an Old
Disease: Bronchiectasis.”
09/06 Grand Rounds; Alvarado Hospital Medical Center, San Diego, California. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
09/06 Invited Instruction Course; 65th
Annual Meeting, American Academy of Otolaryngic
Allergy, Inc., Toronto, Ontario, Canada. “The Immunomodulatory Effects of
Macrolide Antibiotics in Otolaryngic Disorders.”
Israel Rubinstein, M.D.
74 of 115
08/06 Grand Rounds; St. John Medical Center, Longview, Washington. “Rational
Approach to Antibiotic Therapy in the Era of Increased Resistance.”
06/06 Presentation, General Session, International Congress of Nanobiotechnology &
Nanomedicine, International Association of Nanotechnology, San Francisco,
California. “Sterically Stabilized Phospholipid Micellar Human Vasoactive
Intestinal Peptide: A Novel Disease-Modifying Drug for Rheumatoid Arthritis.”
06/06 Invited Lecture; Medical Society County of Orange, Inc., Newburgh, New York.
“Understanding, Preventing and Managing COPD in the Community.”
06/06 Research-in-Progress Seminar; PharmaIn, Ltd., Seattle, Washington. “Sterically
stabilized phospholipid micellar human vasoactive intestinal peptide: A novel
disease-modifying drug for rheumatoid arthritis.”
06/06 Grand Rounds; Christ Hospital, Cincinnati, Ohio. “New Approaches to an Old
Disease: Bronchiectasis.”
05/06 Invited Plenary Lecture; American College for Advancement in Medicine; ACAM
DALLAS: Infection and Chronic Illness: Integrative Approaches to Lyme Disease,
Stealth Infections, and Inflammation, Dallas, Texas. “The Immunomodulatory
Effects of Macrolides in Human Diseases.”
04/06 Grand Rounds; Bayfront Medical Center, St. Petersburg, Florida. “Bronchiectasis: A
Not So Orphan Disease.”
03/06 Research-in-Progress Seminar; Division of Rheumatology, Department of Medicine,
New York University Medical Center, New York, New York. “Sterically Stabilized
Phospholipid Micellar Human Vasoactive Intestinal Peptide: A Novel Disease-
Modifying Drug for Rheumatoid Arthritis.”
03/06 Invited Plenary Lecture; Coalition of Advanced Practice Nurses of Indiana
Continuing Education Day and Annual Meeting, Plymouth, Indiana. “Rational
Approach to Antibiotic Therapy in the Era of Increased Resistance.”
02/06 Invited Lecture; Northeastern Illinois Physician Assistant Chapter CME meeting,
Highland Park, Illinois. “Current Issues in Respiratory Infections.”
02/06 Invited Plenary Lecture; 2006 Annual Scientific Assembly, New York State
Thoracic Society and the American Thoracic Society, West Point, New York. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
01/06 Pediatric Grand Rounds; Miller Children’s at Long Beach Memorial Medical
Center, Long Beach, California. “Antibiotics: not just antimicrobials but also
immunomodulators.”
01/06 Pulmonary & Critical Care Grand Rounds; Pulmonary and Critical Care Medicine
Division, University of California Irvine Medical Center, Orange, California.
Israel Rubinstein, M.D.
75 of 115
“Management of Lower Respiratory Tract Infections in the Mechanically-Ventilated
Patient: the Role of Aerosolized Antibiotic Therapy.”
01/06 Grand Rounds; Allegheny General Hospital, Pittsburgh, Pennsylvania. “Alpha-1
Antitrypsin Deficiency: An Underrecognized, Underdiagnosed Cause of Obstructive
Airway Disease.”
01/06 Research-in-Progress Seminar; Department of Pharmacy and Pharmacology,
University of Bath, Bath, United Kingdom. “A novel targeted nanomedicine for
breast cancer.”
01/06 Research-in-Progress Seminar; Kennedy Institute of Rheumatology Division,
Imperial College, London, United Kingdom. “Sterically stabilized phospholipid
micellar human vasoactive intestinal peptide: A novel disease-modifying drug for
rheumatoid arthritis.”
12/05 Invited Plenary Lecture; 21st Annual Infectious Disease Conference, Providence
Everett Medical Center, Seattle, Washington. “Practical Implications of Increased
Bacterial Resistance to Anti-Infectives in the Community.”
12/05 Invited Plenary Lecture; 21st Annual Infectious Disease Conference, Providence
Everett Medical Center, Seattle, Washington. “The Immunomodulatory Effects of
Macrolides in Human Disease.”
12/05 Invited Plenary Lecture; Pri-Med Update Symposium, Pittsburgh, Pennsylvania.
“Predictable Patient Outcomes for All Seasons: RTI Treatment Choices Rooted in
Clinical Evidence.”
11/05 Oral Presentation; ACR Concurrent Super Session. Rheumatoid Arthritis: From
Bench to Bedside; 2005 American College of Rheumatology Annual Scientific
Meeting, San Diego, California. “Sterically Stabilized Phospholipid Micellar
Human Vasoactive Intestinal Peptide: A Novel Disease-Modifying Drug for
Rheumatoid Arthritis.”
10/05 Invited Lecture; Update in Allergy and Immunology, American College of Allergy,
Asthma and Immunology and Nassau University Medical Center, East Meadow,
New York. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/05 Grand Rounds; Charlton Memorial Hospital, Fall River, Massachusetts. “Ventilator-
Associated Pneumonia.”
10/05 Grand Rounds; La Porte Hospital & Health Services, La Porte, Indiana. “Managing
Patients with Pleural Effusion – an Update.”
Israel Rubinstein, M.D.
76 of 115
10/05 Invited Plenary Lecture; All Alaska Medical Conference, Fall 2005, Alaska
Academy of Physician Assistants, Anchorage, Alaska. “The Immunomodulatory
Effects of Macrolides in Human Diseases.”
10/05 Invited Plenary Lecture; All Alaska Medical Conference, Fall 2005, Alaska
Academy of Physician Assistants, Anchorage, Alaska. “Rational Approach to
Antibiotic Therapy in the Era of Increased Resistance.”
09/05 Grand Rounds; Sarasota Memorial Hospital, Sarasota, Florida. “Aerosolized
Antibiotics in the 21st Century.”
09/05 Grand Rounds; Midland Memorial Hospital, Midland, Texas. “Rational Approach
to Antibiotic Therapy in the Era of Increased Resistance.”
09/05 Invited Plenary Lecture; Indiana Society for Respiratory Care Fall Seminar,
Indianapolis, Indiana. “Rational Approach to Antibiotic Therapy in the Era of
Increased Resistance.”
09/05 Robert E. Glass Honorary Lecture; Indiana Society for Respiratory Care Fall
Seminar, Indianapolis, Indiana. “Understanding, Preventing and Managing COPD
in the Community.”
09/05 Grand Rounds; Department of Medicine, Provena Covenant Medical Center,
Urbana, Illinois. “The Immunomodulatory Effects of Macrolides in Human
Diseases.”
09/05 Grand Rounds; Enloe Medical Center, Chico, California. “Rational Approach to
Antibiotic Therapy in the Era of Increased Resistance.”
05/05 Grand Rounds; Methodist Hospital, Henderson, Kentucky. “Rational Approach to
Combat Lung Injury and Inflammation in Cystic Fibrosis.”
05/05 Pediatric Grand Rounds; Department of Pediatrics, The Children’s Hospital at Sinai
Hospital of Baltimore, Baltimore, Maryland. “The Immunomodulatory Effects of
Macrolides in Human Diseases.”
05/05 Invited Lecture; Cherry Street Health Services, Spectrum Health, Grand Rapids,
Michigan. “Recognition and Management of COPD in the Community.”
04/05 Grand Rounds; Dominican Santa Cruz Hospital, Catholic Health West, Santa Cruz,
California. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
04/05 Invited Plenary Lecture; Neuromuscular Disorders, Family Practice Issues Annual
Convention, Wisconsin Association of Osteopathic Physicians & Surgeons,
Brookfield, Wisconsin. “Recognition and Management of COPD in the
Community.”
Israel Rubinstein, M.D.
77 of 115
04/05 Keynote Address; Eighth Annual Eastern Regional Conference, Pennsylvania
Society for Respiratory Care, Inc, King of Prussia, Pennsylvania. “Aerosolized
Antibiotics in the 21st Century.”
04/05 Invited Plenary Lecture; Seventeenth Regional Conference Toward Excellence in
Advanced Practice Nursing, The Kentucky Coalition of Nurse Practitioners/Nurse
Midwives, Lexington, Kentucky. Session 203. “Rational Approach to Antibiotic
Therapy in the Era of Increased Resistance.”
04/05 Invited Lecture; San Diego Vietnamese Physician Association Monthly Meeting,
San Diego, California. “Recognition and Management of COPD in the
Community.”
04/05 Grand Rounds; Alvarado Hospital Medical Center, San Diego, California.
“Recognition and Management of COPD in the Community.”
03/05 Invited Plenary Lecture; Michigan Society for Respiratory Care 2005 Spring
Seminar, Grand Rapids, Michigan. “Aerosolized Antibiotics in the 21st Century.”
02/05 Grand Rounds; Alaska Family Practice Residency, Providence Health System,
Anchorage, Alaska. “Rational Approach to Antibiotic Therapy in the Era of
Increased Resistance.”
02/05 Invited Lecture; Iron County’s Medical Education Corporation, Iron River,
Michigan. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
02/05 Grand Rounds; Department of Medicine, Pennsylvania Hospital, University of
Pennsylvania Health System, Philadelphia, Pennsylvania. “Recognition and
Management of COPD in the Community.”
01/05 Invited Lecture; Respiratory Therapy Department, The Ohio State University
Medical Center, Columbus, Ohio. “Recognition and Management of COPD in the
Community.”
01/05 Invited Lecture; Respiratory Therapy Department, The Ohio State University
Medical Center, Columbus, Ohio. “Ventilator-Associated Pneumonia and
Tracheobronchitis: Shifting Paradigm in Diagnosis and Treatment.”
01/05 Grand Rounds; The Medical Educational Council of Pensacola, Pensacola, Florida.
“Rational Approach to Antibiotic Therapy in the Era of Increased Resistance.”
01/05 Invited Lecture; The DeKalb Medical Society, Auburn, Indiana. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
12/04 Invited Lecture; Valley Medical Center, Wasilla, Alaska. “Current Issues in
Respiratory Infections.”
Israel Rubinstein, M.D.
78 of 115
11/04 Invited Plenary Lecture; The New Hampshire Allergy Society, Manchester, New
Hampshire. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/04 Grand Rounds; Good Samaritan Regional Medical Center, Corvallis, Oregon.
“Rational Approach to Antibiotic Therapy in the Era of Increased Resistance.”
10/04 Invited Lecture; The Asthma and Allergy Society of Delaware, Newark, Delaware.
“The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/04 Grand Rounds; Department of Medicine, Alaska Regional Hospital, Anchorage,
Alaska. “Ventilator-Associated Pneumonia and Tracheobronchitis: Shifting
Paradigm in Diagnosis and Treatment.”
10/04 Grand Rounds; Department of Medicine, Providence Hospital, Anchorage, Alaska.
”Bronchiectasis: A not so Orphan Disease.”
10/04 Grand Rounds; Department of Medicine, Alaska Native Medical Center,
Anchorage, Alaska. ”Bronchiectasis: A not so Orphan Disease.”
10/04 Grand Rounds; Department of Medicine, Royal Ball Memorial Hospital, Inc.,
Muncie, Indiana. “The Immunomodulatory Effects of the Macrolide Class when
Treating Respiratory Infections.”
10/04 Invited Lecture; Bartholomew-Brown Medical Society, Columbus, Indiana. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
10/04 Medical Grand Rounds; Department of Medicine, Royal Alexandra Hospital,
Edmonton, Alberta, Canada. “The Immunomodulatory Effects of Macrolides in
Human Diseases.”
10/04 Invited Plenary Lecture; Pandora’s Box Annual Meeting, American Lung
Association of Santa Barbara & Ventura Counties, Santa Barbara, California.
”Bronchiectasis: A not so Orphan Disease.”
10/04 Invited Plenary Lecture; Eleventh Annual Pulmonary & Critical Care Symposium.
Clinical Advances, Mercy Pulmonary Institute and California Society for
Respiratory Care, Northern Chapter, Sacramento, California. “Recognition and
Management of COPD in the Community.”
09/04 Invited Lecture; The Medical Society County of Orange, Inc., Newburgh, New
York. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
09/04 Residents Conference, Department of Pediartics, The University of Tennessee
Health Science Center, Chattanooga Unit of the College of Medicine, Chattanooga,
Tennessee. “Rational Approach to Antibiotic Therapy in the Era of Increased
Bacterial Resistance.”
Israel Rubinstein, M.D.
79 of 115
09/04 Grand Rounds, Department of Pediartics, The University of Tennessee Health
Science Center, Chattanooga Unit of the College of Medicine, Chattanooga,
Tennessee. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
09/04 Visiting Professor, Department of Pediatrics, The University of Tennessee Health
Science Center, Chattanooga Unit of the College of Medicine, Chattanooga,
Tennessee.
09/04 Grand Rounds, Department of Pediatrics, Faculty of Medicine, Queen’s University,
Kingston, Ontario, Canada. “Immunomodulatory Effects of Aminoglycoside
Antibiotics: Implications in Cystic Fibrosis and Bronchiectasis.”
09/04 Henry Ford Hospital Infectious Diseases Seminar, Henry Ford Hospital, Detroit,
Michigan. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
09/04 Invited Plenary Lecture; South Carolina Society for Respiratory Care 33rd
Annual
Convention, Myrtle Beach, South Carolina. “Ventilator-Associated Pneumonia and
Tracheobronchitis: Shifting Paradigm in Diagnosis and Treatment.”
08/04 Grand Rounds; Department of Medicine, Joan C. Edwards School of Medicine,
Marshall University, Huntington, West Virginia. “The Immunomodulatory Effects
of Macrolides in Human Diseases.”
08/04 Grand Rounds; Department of Internal Medicine, Synergy Medical Education
Alliance, Saginaw, Michigan. “Pulmonary Arterial Hypertension: A Shifting
Therapeutic Paradigm.”
07/04 Visiting Professor, Section of Respiratory Diseases and Thoracic Surgery,
Department of Medicine, Faculty of Medicine, University of Manitoba, Winnipeg,
Manitoba, Canada. “Immunomodulatory Effects of Aminoglycoside Antibiotics:
Implications in Cystic Fibrosis and Bronchiectasis.”
07/04 Research in Progress, Section of Respiratory Diseases and Thoracic Surgery,
Department of Medicine, Faculty of Medicine, University of Manitoba, Winnipeg,
Manitoba, Canada. “Immunomodulatory Effects of Aminoglycoside Antibiotics:
Implications in Cystic Fibrosis and Bronchiectasis.”
07/04 Research-in-Progress Seminar, Centre for Microbial Disease and Immunity
Research, The University of British Columbia, Vancouver, British Columbia,
Canada. “The Immunomodulatory Effects of Aminoglycosides.”
07/04 Invited Lecture, Vancouver Adult Cystic Fibrosis Clinic, St Paul’s Hospital,
Vancouver, British Columbia, Canada. “Immunomodulatory Effects of
Aminoglycosides Antibiotics: Implications in Cystic Fibrosis and Bronchiectasis.”
Israel Rubinstein, M.D.
80 of 115
07/04 Grand Rounds, Department of Medicine, Mercy Medical Center, Des Moines, Iowa.
“Rational Management of Community-Acquired Respiratory Tract Infections in the
Era of Antibiotic Resistance.”
06/04 Grand Rounds; Ball Memorial Hospital, Muncie, Indiana. “The Immunomodulatory
Effects of Macrolides in Human Diseases.”
06/04 Grand Rounds, Miami Children’s Hospital, Miami, Florida. “Aerosolized
Antibiotics in the 21st Century.”
05/04 Invited Plenary Lecture; Virginia Society for Respiratory Care, VSRC –
“Symposium by the Sea” Current Trends In Respiratory Care 27th
Annual Seminar
and Trade Show, Virginia Beach, Virginia. “Aerosolized Antibiotics in the 21st
Century.”
05/04 Invited Plenary Lecture; Blue Cross Blue Shield of Illinois Managed Care
Roundtable, Chicago, Illinois. “Rational Management of Community-Acquired
Respiratory Tract Infections in the Era of Antibiotic Resistance.”
04/04 Invited Plenary Lecture; The Montana Society for Respiratory Care, The 30th
Annual Convention of Respiratory Care, Bozeman, Montana. “Aerosolized
Antibiotics in the 21st Century.”
04/04 Medical Grand Rounds; University Medical Center, Las Vegas, Nevada. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
04/04 Invited Plenary Lecture; Michiana Medical Expo. Thirty-Third Annual CME
Seminar, Lakeland Health and Healing, St. Joseph, Michigan. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
04/04 Grand Rounds; Alvarado Hospital Medical Center, San Diego, California.
“Immunomodulatory Effects of Macrolides in Human Diseases.”
04/04 Grand Rounds; Department of Medicine, Hahnemann University Hospital and
Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania.
“Aerosolized Antibiotics in the 21st Century.”
04/04 Visiting Professor; Department of Medicine, Drexel University College of
Medicine, Philadelphia, Pennsylvania.
04/04 Invited Plenary Lecture; Maine Society for Cardiovascular & Pulmonary
Rehabilitation Annual Education Symposium “Keeping Pace with the Latest
Trends”, Lewiston, Maine. “Aerosolized Antibiotics in the 21st Century.”
03/04 Invited Speaker; Workshop – Q&A: Collection and Utility of Exhaled Breath
Condensate, 60th
American Academy of Allergy, Asthma & Immunology, March
19-23, 2004; San Francisco, California. “The Future of Exhaled Breath
Condensate.”
Israel Rubinstein, M.D.
81 of 115
03/04 Grand Rounds; Department of Internal Medicine, Wayne State University School of
Medicine, Detroit, Michigan. “Bronchiectasis: A not so Orphan Diseases.”
03/04 Grand Rounds; Department of Internal Medicine, School of Medicine and Allied
Sciences, University of North Dakota, Fargo, North Dakota. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
03/04 Grand Rounds; Department of Medicine, Deaconess Hospital, Evansville, Indiana.
“The Management of Respiratory Tract Infections in the Era of Resistance.”
02/04 Grand Rounds; Department of Medicine, NYU Downtown Hospital, New York,
New York. “The Management of Respiratory Tract Infections in the Era of
Resistance.”
02/04 Grand Rounds; Department of Medicine, Provena Covenant Medical Center,
Urbana, Illinois. “Differentiating Acute Decompensation of Heart Failure from
Community-Acquired Pneumonia – an Evolving Paradigm.”
02/04 Invited Plenary Lecture; West Virginia Society for Respiratory Care 13th
Annual
Winter Conference, Davis, West Virginia. “Aerosolized Antibiotics in the 21st
Century.”
01/04 Grand Rounds; Department of Medical Education, University of Texas Health
Center at Tyler, Tyler, Texas. “The Immunomodulatory Effects of Macrolides in
Human Diseases.”
01/04 Grand Rounds; Department of Internal Medicine, Texas Tech University Health
Sciences Center, Lubbock, Texas. “The Immunomodulatory Effects of Macrolides
in Human Diseases.”
01/04 Grand Rounds; Memorial Hospital, York, Pennsylvania. “The Immunomodulatory
Effects of Macrolides in Human Diseases.”
01/04 Grand Rounds; Riverside Methodist Hospital, Columbus, Ohio. “Rational
Management of Respiratory Tract Infections in the Era of Resistance.”
01/04 Invited Lecture; National Meeting, Belgian Respiratory Infectiology Committee
(BRIC), Brussels, Belgium. “The Immunomodulatory Effects of Macrolides in
Human Diseases.”
12/03 Grand Rounds; Sparrow Health System, Lansing, Michigan. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
12/03 Invited Lecture; Section of Allergy/Immunology, Department of Pediatrics,
Children’s Hospital of Milwaukee and Medical College of Wisconsin, Milwaukee,
Wisconsin. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
Israel Rubinstein, M.D.
82 of 115
11/03 Grand Rounds; Beloit Memorial Hospital, Beloit, Wisconsin. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
11/03 Invited Lecture; The Internal Medicine Research Seminar Series, East Tennessee
State University, James H. Quillen College of Medicine, Johnson City, Tennessee.
“The Immunomodulatory Effects of Macrolides in Human Diseases.”
11/03 Medicine Grand Rounds; Department of Veterans Affairs VA Eastern Kansas
Health Care System, Topeka, Kansas. “New Therapeutic Options in the
Management of Acute Respiratory Tract Infections in an Era of Resistance.”
11/03 Grand Rounds; INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma.
“Aerosolized Antibiotics in the 21st Century.”
11/03 Invited Plenary Lecture; Infectious Disease Update for the Primary Care Physician,
Wisconsin Association of Osteopathic Physicians & Surgeons, Brookfield,
Wisconsin. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/03 Continuing Medical Education Lecture; Health First Center for Learning, Holmes
Regional Medical Center, Melbourne, Florida. “The Immunomodulatory Effects of
Macrolides in Human Diseases.”
10/03 Invited Lecture; Department of Medical Education, Saint Joseph Regional Medical
Center, South Bend, Indiana. “The Immunomodulatory Effects of Macrolides in
Human Diseases.”
10/03 Grand Rounds, Clearfield Hospital, Clearfield, Pennsylvania. “Trends in the
Management of Acute Respiratory Tract Infections in an Era of Resistance.”
10/03 Invited Lecture; ENT and Allergy Associates, LLP, Tarrytown, New York. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
10/03 Invited Lecture; The 9th
Annual J. Robert Wilson Memorial Lecture, Akron General
Medical Center, Akron, Ohio. “Aerosolized Antibiotics in the 21st Century.”
10/03 Internal Medicine Grand Rounds; Eastern Virginia Medical School, Norfolk,
Virginia. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/03 Invited Lecture; Porter Memorial Hospital, Valparaiso, Indiana. “Update on
Antibiotic Resistant Organisms.”
10/03 Grand Rounds; The Children’s Hospital of Buffalo, Kaleida Health, Buffalo, New
York. “The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/03 Invited Lecture; Madison County Medical Society, Jackson, Tennessee. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
Israel Rubinstein, M.D.
83 of 115
10/03 Grand Rounds; Jackson-Madison County General Hospital, Jackson, Tennessee.
“The Immunomodulatory Effects of Macrolides in Human Diseases.”
10/03 Invited Lecture, Alberta & Saskatchewan Respiratory Medicine Meeting, Emerald
Lake, Field, British Columbia, Canada. “The Immunomodulatory Effects of
Macrolides in Human Diseases.”
10/03 Grand Rounds; St. Vincent’s Hospital Manhattan, New York, New York. “The
Immunomodulatory Effects of Macrolides in Human Diseases.”
09/03 Invited Lecture; Loma Linda Cystic Fibrosis Day, Department of Pediatrics, Cystic
Fibrosis Center, Loma Linda University School of Medicine, Loma Linda,
California. “Immunomodulatory Effects of Aminoglycosides.”
09/03 Invited Lecture; Update on Cystic Fibrosis Care & Research, Department of
Pediatrics, Cystic Fibrosis Center, University of Nevada School of Medicine, Las
Vegas, Nevada. “Immunomodulatory Effects of Aminoglycosides.”
09/03 Grand Rounds; Department of Respiratory Care, Sunrise Hospital and Medical
Center, Sunrise Children’s Hospital, Las Vegas Nevada. “Aerosolized Antibiotics in
the 21st Century.”
09/03 Invited Plenary Lecture; Indiana Society for Respiratory Care Fall Seminar,
Indianapolis, Indiana. “Aerosolized Antibiotics in the 21st Century.”
09/03 Grand Rounds; Exempla Saint Joseph Hospital, Denver, Colorado. “New
Therapeutic Options in the Management of Acute Respiratory Tract Infections in an
Era of Resistance.”
09/03 Grand Rounds; Department of Internal Medicine, Synergy Medical Education
Alliance, Saginaw, Michigan. “Aerosolized Antibiotics in the 21st Century.”
09/03 Invited Lecture; Fall Respiratory Update, Provena Covenant Medical Center,
Champaign, Illinois. “Emerging Antibiotic Resistance and Community-Acquired
Respiratory Tract Infections.”
09/03 Pediatric Grand Rounds; Spectrum Health-DeVos Children Hospital and Grand
Rapids Medical Education & Research Center for Health Professionals, Grand
Rapids, Michigan. “The Immunomodulatory Effects of Macrolides in Human
Diseases.”
08/03 Internal Medicine Grand Rounds; Michigan State University/Kalamazoo Center for
Medical Studies, Kalamazoo, Michigan. “The Immunomodulatory Effects of
Macrolides in Human Diseases.”
Israel Rubinstein, M.D.
84 of 115
08/03 Cystic Fibrosis Center Grand Rounds; Kaiser Permanente Panorama City Medical
Center, Panorama City, California. “Aerosolized Antibiotics in the 21st Century.”
08/03 Grand Rounds; Community Health Carte Wausau Hospital, Wausau, Wisconsin.
“The Immunomodulatory Effects of Macrolides in Human Diseases.”
05/03 Invited Plenary Lecture; Minnesota Society for Respiratory Care Spring Forum
2003, Brainerd, Minnesota. “Aerosolized Antibiotics in the 21st Century.”
05/03 Grand Rounds; St. Mary Medical Center, Hobart, Indiana. “A New Approach in
Antimicrobial Therapy for Community-Acquired Respiratory Tract Infections.”
05/03 Invited Lecture; Sixth Annual International Conference of Infectious Disease
Pharmacotherapy, Making a Difference 2003 (MAD), Orlando, Florida. Session:
“Application of Non-Antimicrobial Effects of Antibiotics“; “The
Immunomodulatory Effects of Macrolide Antibiotics.”
04/03 Grand Rounds; Northwest Community Hospital, Arlington Heights, Illinois.
“Treatment of Community-Acquired Pneumonia.”
04/03 Invited presentation; Southern California and Nevada (SCAN) Consortium of Cystic
Fibrosis Centers, Santa Monica, California. “The Immunomodulatory Effects of
Aminoglycosides.”
04/03 Invited presentation; Satellite Symposium “New Approaches to the Treatment of
RTI: What Lies Ahead?”, 10th
National Congress “Man and Drug”, Moscow,
Russia. “Immunomodulatory Effects of Clarithromycin: Unusual Feature and it’s
Practical Use.”
03/03 Grand Rounds; La Porte Hospital & Health Services, La Porte, Indiana. “A New
Approach in Antimicrobial Therapy for Community-Acquired Respiratory Tract
Infections.”
02/03 Visiting Professor, Puget Sound Allergy & Asthma Society Meeting, Seattle,
Washington. “Immunomodulatory Effects of Macrolides in Sino-Pulmonary
Diseases in Humans.”
01/03 Combined Grand Rounds; Kansas Medical Education Foundation, Topeka, Kansas.
“Drug Resistance and Respiratory Infections” and “Optimizing Antibiotic Therapy
for Acute Exacerbations of Chronic Bronchitis (AECB).”
01/03 Grand Rounds; Gaston Memorial Hospital, Gastonia, North Carolina. “Appropriate
Utilization of Respiratory Antibiotics.”
Israel Rubinstein, M.D.
85 of 115
01/03 Visiting Professor, Ohio Society for Respiratory Care, Columbus, Ohio. “Is There a
Role for Inhaled Antibiotics in the Treatment of Patients with COPD?” and “Role of
Inhaled Antibiotics in the Treatment of COPD and Ventilator-Associated
Pneumonia.”
12/02 Grand Rounds; Oak Park Hospital, Oak Park, Illinois. “Emerging Trends in the
Treatment of Respiratory Tract Infections in the Era of Increased Bacterial
Resistance.”
12/02 Visiting Professor, Ohio Society for Respiratory Care, Columbus, Ohio. “Is There a
Role, for Inhaled Antibiotics in the Treatment of Patients with COPD?” and “Role
of Inhaled Antibiotics in the Treatment of COPD and Ventilator-Associated
Pneumonia.”
10/02 Pulmonary Grand Rounds, Division of Pulmonary and Critical Care Medicine,
Lenox Hill Hospital, New York, New York. ”Is There a Role for Aerosolized
Antibiotics in COPD Patients?”
10/02 Grand Rounds; Department of Continuous Medical Education, Howard Community
Hospital, Kokomo, Indiana. "The Immunomodulatory Effects of Macrolides in
Sinopulmonary Disorders in Humans."
10/02 Visiting Professor, Turkish Society for Respiratory Investigations, Izmir, Ankara
and Istanbul, Turkey. “Immunomodulatory effects of Macrolides.”
10/02 Invited lecture; The Ohio Society for Respiratory Care, Columbus, Ohio.
“Applications of Aerosolized Antibiotics.”
10/02 Grand Rounds; Medical Education Department, Medical Center of Independence,
Independence, Missouri. “Impact of Emerging Antibiotic Resistance on the
Treatment of Respiratory Tract Infections.”
09/02 Invited lecture, 6th Annual Infectious Disease Pharmacotherapy Conference,
Clinical Pharmacy Programs at San Antonio, College of Pharmacy, University of
Texas at Austin and Graduate School of Biomdical Engineering, University of
Texas Health Sciences Center at San Antonio, San Antonio, Texas "The
Immunomodulatory Effects of Macrolides in Chronic Sinopulmonary Diseases in
Humans."
07/02 Research-in-Progress Seminar; Department of Oral & Maxillofacial Surgery,
College of Dentistry, University of Washington, Seattle, Washington. “Bradykinin
and Proteinases Mediate Chewing Tobacco-Induced Oral Mucosa Injury In Vivo.”
07/02 Invited lecture at the 8th World Congress on Heart Failure - Mechanisms and
Management, Washington, D.C. "Novel Aspects of Hypertension Control by
Vasoactive Intestinal Peptide."
Israel Rubinstein, M.D.
86 of 115
07/02 Visiting Professor Program; West Suburban Hospital Medical Center, Oak Park,
Illinois. “Treatment of Community-Acquired Pneumonia.”
07/02 Research-in-Progress Seminar; Division of Preclinical Research, EGIS
Pharmaceuticals LTD., Budapest, Hungary. “Novel Active In Situ Drug Targeting
and Imaging of Breast Cancer in Rats.”
07/02 Grand Rounds; Department of Pulmonology, Semmelweis University Faculty of
Medicine, Budapest, Hungary. “The Immunomodulatory Effects of Macrolides in
Pulmonary Disorders.”
06/02 Research-in-Progress Seminar; Second Department of Dermatology, Instituto
Dermopatico Dell’Immacolata, Rome, Italy. “Effects of Phospholipids on VIP
Bioactivity In Vivo.”
05/02 Participant; Meeting of the Joint European Respiratory Society/American Thoracic
Society Task Force on Exhaled Breath Condensate; 2002 International Conference,
American Thoracic Society, Atlanta, Georgia.
05/02 Research-in-Progress Seminar; Department of Biochemistry and Molecular Biology,
University of Nebraska Medical Center, Omaha, Nebraska. “Novel Active In Situ
Drug Targeting and Imaging of Breast Cancer in Rats.”
05/02 Grand Rounds; Medical Staff, Norwegian American Hospital, Chicago, Illinois.
“Antibiotic Treatment Update.”
04/02 Toronto City Wide Rounds; Division of Respirology, Department of Medicine,
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. “The
Immunomodulatory Effects of Macrolides in Pulmonary Diseases.”
04/02 Research-in-Progress Seminar; Division of Respirology, Department of Medicine,
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. “Collection
and Analysis of Exhaled Breath Condensate in Pulmonary Disease – the Next
Frontier?”
04/02 Grand Rounds; Division of Pulmonary and Critical Care Medicine, Department of
Medicine, UCLA School of Medicine. “Is Analysis of Exhaled Breath Condensate
the Next Non-invasive Frontier of Pulmonary Medicine?”
04/02 Grand Rounds; Division of Respirology, Department of Medicine, London Health
Sciences Center, University of Western Ontario, London, Ontario, Canada.
“Collection and Analysis of Exhaled Breath Condensate in Pulmonary Disease – the
Next Frontier?”
04/02 Research-in-Progress Seminar; Program in Vascular Biology/Inflammation, Lawson
Health Research Institute, University of Western Ontario, London, Ontario, Canada.
Israel Rubinstein, M.D.
87 of 115
“The Anti-Inflammatory Effects of Macrolides in Chronic Sino-Pulmonary
Disorders.”
04/02 Visiting Professor; Program in Vascular Biology/Inflammation, Lawson Health
Research Institute, University of Western Ontario, London, Ontario, Canada.
04/02 Grand Rounds; Division of Pulmonary and Critical Care Medicine, Department of
Medicine, UCLA School of Medicine. “New Developments in the Diagnosis and
Treatment of Bronchiectasis.”
04/02 Grand Rounds; Division of Pulmonary Medicine, Department of Pediatrics,
Stanford University School of Medicine. “Collection and Analysis of Exhaled
Breath Condensate in Patients with Cystic Fibrosis and Bronchiectasis.”
03/02 Grand Rounds; Division of Pulmonary and Critical Care Medicine, Department of
Medicine, St. Elizabeth’s Medical Center, Boston, Massachusetts. “The
Immunomodulatory Effects of Macrolides in Humans.”
02/02 Pneumoclub; Division of Respirology, Department of Medicine, Ottawa Hospital
General Campus, University of Ottawa, Faculty of Medicine, Ottawa, Ontario,
Canada. “Analysis of Exhaled Breath Condensate in Pulmonary Diseases.”
01/02 Progress in Medicine, St. Catherine Hospital, East Chicago, Illinois. “Acute
Exacerbations of Chronic Bronchitis: New Approaches to Antimicrobial Therapy.”
01/02 Research-in-Progress Seminar; Laboratory of Industrial Toxicology, Department of
Clinical Medicine, Nephrology and Preventive Sciences, University of Parma,
Faculty of Medicine and Surgery, Parma, Italy. “Exhaled Breath Condensate: A
New Tool for the Evaluation of Airway Inflammation.”
12/01 Hub Meeting; In Patient Consultants of Illinois, Westmont, Illinois. “Anti-
Inflammatory Effects in Macrolides and their Effect in Treating Respiratory
Infections.”
12/01 Grand Rounds; Department of Medicine, Michael Reese Hospital, Chicago, Illinois.
“Anemia and Blood Transfusion in the Critically Ill Patient: The Role of
Erythropoietin.”
10/01 Grand Rounds; Department of Medicine, St. Joseph Hospital Resurrection Health
Care, Chicago, Illinois. “Anemia and Blood Transfusion in the Critically Ill Patient:
The Role of Erythropoietin.”
10/01 Guest Speaker; Fall Banquet, The Beta Chapter of West Virginia of Alpha Omega
Alpha at Joan C. Edwards School of Medicine, Marshall University, Huntington,
West Virginia. “Buyer be Ware: Bacillus Species are Present on Chewing Tobacco.”
Israel Rubinstein, M.D.
88 of 115
10/01 Grand Rounds; Department of Internal Medicine, Joan C. Edwards School of
Medicine, Marshall University, Huntington, West Virginia. “Mechanisms
Underlying Smokeless Tobacco-Induced Oral Mucosa Injury in Humans.”
10/01 Invited Lecture at the New Jersey Society for Respiratory Care Annual Shore
Conference 2001, Atlantic City, New Jersey. “Aerosolized Antibiotics in Ventilator-
Associated Pneumonia: The New Frontier.”
10/01 Grand Rounds; Department of Medicine, Providence Hospital, Southfield,
Michigan. “Treatment of Ventilator-Associated Pneumonia with Aerosolized
Antibiotics.”
10/01 Invited Lecture in the symposium: “Understanding and Management of Upper and
Lower Airway Inflammation”; University of Pittsburgh School of Medicine,
Department of Otolaryngology, Pittsburgh, Pennsylvania. “Sampling Exhaled Air
Condensate.”
10/01 Lecture, San Diego Pulmonary Society/American Lung Association, San Diego,
California. “Is There a Role for Aerosolized Antibiotics in COPD Patients?”
09/01 Invited Lecture in the symposium: “Role of Macrolide Antibiotics in Airway
Infections”; European Respiratory Society Annual Congress 2001, Berlin, Germany.
“Macrolides Antibiotics as Biological Response Modifiers.”
07/01 Grand Rounds; Department of Medicine, University of Illinois at Chicago, Chicago,
Illinois. “Analysis of Exhaled Breath Condensate in Pulmonary Disease: The Next
(Non-Invasive) Frontier.”
07/01 Research-in-Progress Seminar; Division of Pulmonary and Critical Care Medicine,
Department of Medicine, University of Kentucky School of Medicine, Lexington,
Kentucky. “Immunomodulatory Effects of Macrolides in Pulmonary Diseases.”
05/01 Plenary Lecture; First International Meeting of Asia Minor Branch of the
International Neuropeptide Society (INPS). Neuropeptides and Immune Cells:
Neuropeptides in Regulation of the Immune Response, Antalya, Turkey. “The
Biological Effects of Alpha Helix Vasoactive Intestinal Peptide.”
05/01 Chairman of the Symposium: “Exhaled Breath Condensate: A New Technique to
Evaluate the Lower Respiratory Tract.” ATS 2001, The 97th International
Conference, American Thoracic Society, San Francisco, California.
04/01 Merck Distinguished Speaker, Research Rounds; Firestone Institute for Respiratory
Health, St. Joseph’s Healthcare-McMaster University, Hamilton, Ontario, Canada.
“The Tissue Reparative Effects of Macrolides in Chronic Sinopulmonary
Inflammation in Humans.”
Israel Rubinstein, M.D.
89 of 115
04/01 Research-in-Progress Seminar; Lung Inflammation Club, Section of Infectious
Diseases, Department of Pediatrics, University of Texas Southwestern Medical
Center, Dallas, Texas. “Future Directions of Inhaled Tobramycin Therapy.”
03/01 Special Lecture; Department of Thoracic Surgery, Kyoto University, School of
Medicine, Kyoto, Japan. “The Anti-Inflammatory Effects of Macrolides in Chronic
Sino-pulmonary Diseases in Humans.”
03/01 Special Lecture; Department of Internal Medicine, Shinshu University, School of
Medicine, Matsumoto, Japan. “The Anti-Inflammatory Effects of Macrolides in
Chronic Sino-pulmonary Diseases in Humans.”
03/01 Plenary Lecture; The 28th Annual Scientific Meeting of the Japanese Society of
Intensive Care Medicine, Tokyo, Japan. “New Developments if the Treatment of
Pulmonary Hypertension.”
03/01 Special Lecture; Departments of Laboratory Medicine and Internal Medicine,
Faculty of Medicine, University of Tokyo Graduate Medical School, Tokyo, Japan.
“The Anti-Inflammatory Effects of Macrolides in Chronic Sino-pulmonary Diseases
in Humans.”
02/01 Invited Speaker, Alpha One Foundation, Critical Issues Workshop Series No. 4.
Application of Lung Parenchyma Inflammatory Factors as Markers of Lung
Destruction in Alpha1-Antitrypsin Deficient Individuals. Session VI: “Methods of
Evaluation of Lung Inflammation: Sputum, BAL, Breath Condensate.”
02/01 Grand Rounds, Provena St. Therese Medical Center, Waukegan, Illinois.
"Treatment of Anemia in the Intensive Care Unit."
02/01 Research Seminar; Division of Pulmonary and Critical Care Medicine, SUNY Stony
Brook Health Sciences Center, Stony Brook, New York. "The Anti-Inflammatory
Properties of Macrolides in Sinopulmonary Diseases."
01/01 Pulmonary Grand Rounds; Edgewater Medical Center, Chicago, Illinois. "The Anti-
Inflammatory Properties of Macrolides in Sinopulmonary Disease."
01/01 Medical Grand Rounds; Riverside Regional Medical Center, Newport News,
Virginia. "Immunomodulatory Effects of Antibiotics."
11/00 Grand Rounds; Division of Pulmonary and Critical Care Medicine, University of
Texas Southwestern Medical Center, Dallas, Texas. "Anti-Inflammatory Effects of
Macrolides."
11/00 Director and Lecturer, University of Illinois at Chicago College of Medicine
Continuing Medical Education Activity (2 hours of Category 1 CME credit),
Chicago, Illinois. “New Developments in the Diagnosis and Treatment of
Bronchiectasis.”
Israel Rubinstein, M.D.
90 of 115
10/00 Faculty, Chest 2000 Satellite Symposium: “Aerosolized Antibiotics: A New
Paradigm for the Treatment of Lung Infections.” Plenary presentation: ”Is There a
Role for Aerosolized Antibiotics in COPD Patients?”
10/00 Grand Rounds, Department of Internal Medicine, The Jewish Hospital, Cincinnati,
Ohio. “Anti-Inflammatory Effects of Macrolides.”
09/00 Combined Grand Rounds, Division of Pulmonary Medicine, Rush-Presbyterian-St.
Luke’s Medical Center/Cook County Hospital, Chicago, Illinois. “Anti-
Inflammatory Effects of Macrolides in Chronic Sinopulmonary Diseases.”
09/00 Abbott Platinum Sponsored Breakfast, 2000 Fall Meeting, Kentucky Society of
Health-System Pharmacists, Lexington, Kentucky. “The Anti-Inflammatory Effects
of Antibiotics.”
07/00 Grand Rounds, Division of Pulmonary and Critical Care Medicine, Mount Sinai
Medical Center, Mount Sinai School of Medicine, New York, New York.
“Macrolides: Biologic Response Modifiers in Chronic Sinopulmonary Diseases.”
07/00 Research-in-Progress Seminar, Division of Clinical Sciences, University of
Sheffield, Medical School, Sheffield, U.K. “Novel Concepts on the Vasoactivity of
Vasoactive Intestinal Peptide In Vivo - a Non-Conformational View.”
07/00 Pulmonary Grand Rounds, Department of Respiratory Diseases, University Hospital
of Montpellier, Montpellier, France. “The Anti-Inflammatory Effects of
Clarithromycin.”
05/00 Grand Rounds, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai
Medical Center, Los Angeles, California. “Macrolides: Biological Response
Modifiers in the Lung.”
05/00 Grand Rounds, Department of Pediatrics, University of Chicago Children’s
Hospital, Chicago, Illinois. “Macrolides: Biologic Response Modifiers in the
Lung.”
05/00 Invited lecture in the Symposium (A75): “Noninvasive Markers of Inflammation in
the Lower Respiratory Tract.” ATS 2000, The 96th International Conference,
American Thoracic Society, Toronto, Ontario, Canada. “Analysis of Breath
Condensate.”
04/00 Grand Rounds, Department of Medicine, Santa Clara Valley Medical Center, San
Jose, California. “Macrolides - Beyond Bactericidal.”
03/00 Respiratory Conference, Respiratory Sciences, University of Arizona Medical
Center, Tucson, Arizona. “Bioactivity of Vasoactive Intestinal Peptide - the
Conformation Approach.”
Israel Rubinstein, M.D.
91 of 115
03/00 Management Conference, Medical Service, Tucson VA Medical Center, Tucson,
Arizona. “The Anti-Inflammatory Effects of Macrolides in the Lung.”
03/00 Merck Frosst Distinguished Speaker, Division of Respirology, Department of
Medicine, University of Toronto, Toronto, Ontario, Canada. “Phospholipid
Modulation of Vasoactive Intestinal Peptide Bioactivity.”
01/00 Grand Rounds, Department of Medicine, University of Illinois at Chicago, Chicago,
Illinois. “Treatment of Influenza - the Next Millennium.”
12/99 Research-in-Progress Seminar, Section of Allergy/Immunology, Children’s Hospital
of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA. “Anti-
Inflammatory Effects of Macrolides in the Lungs.”
11/99 Research-in-Progress Seminar, Division of Infectious Diseases and Pharmacy, The
Hartford Hospital, Hartford, CT. “Modulation of Plasma Exudation During
Infection.”
11/99 Grand Rounds, Kona Community Hospital, Kealakekua, Hawaii. “Anti-
Inflammatory Effects of Macrolides in the Lungs.”
07/99 Plenary presentation, Anti-Infective Advisory Meeting, Abbott Laboratories, Lake
Geneva, Wisconsin. “Biaxin - Beyond Bactericidal.”
07/99 Faculty, Anti-Infective Advisory Meeting, Abbott Laboratories, Lake Geneva,
Wisconsin.
07/99 Research-in-Progress Seminar, G.D. Searle&Co., Skokie, Illinois. “Amphipathic
Peptides/Proteins: a Novel Targeted Drug Delivery System.”
06/99 Faculty, The Osler Institute 31st Family Practice Board Review Course, Northbrook,
Illinois. Two plenary presentations: “Asthma and Emphysema” and “Pulmonary
Infections.”
05/99 Co-Chairman of a plenary session at the Ist International Congress on Heart Disease
- New Trends in Research and Diagnosis, Washington, D.C. "Hypertension, Basic
and Clinical."
05/99 Invited lecture at the Ist International Congress on Heart Disease - New Trends in
Research and Diagnosis, Washington, DC.. "The Halls Harbour Spontaneously
Hypertensive Hamster (4H): a New Rodent Model of Essential Hypertension.”
04/99 Research-in-Progress Seminar, CURE/Digestive Disease Research Center West Los
Angeles VA Medical Center and Department of Medicine, University of California,
Los Angeles, Los Angeles, California. “Conformation-Dependent bioactivity of
vasoactive intestinal peptide.”
Israel Rubinstein, M.D.
92 of 115
04/99 Research-in-Progress Seminar, Department of Medicine, University of California,
San Diego and VA San Diego Health care System, San Diego, California. “VIP-
Phospholipid Interactions: Implications for Peptide Bioactivity.”
03/99 Pulmonary Grand Rounds, Edgewater Medical Center, Chicago, Illinois. “Diagnosis
and Management of Pleural Effusion.”
03/99 Research-in-Progress Seminar, Aradigm Corporation, Hayward, California. “An
Innovative Approach to Deliver Peptides and Proteins.”
01/99 Research-in-Progress Seminar, Department of Internal Medicine, University of
Texas and M.D. Anderson Cancer Center, Houston, Texas. “αVIP - Autologous
Targeted Drug Delivery System.”
09/98 Pulmonary Grand Rounds, Edgewater Medical Center, Chicago, Illinois. “COPD
Update.”
06/98 Research-in-Progress Seminar, Research Service, Edward Hines, Jr., VA hospital,
Hines, Illinois. “Vasoactive Intestinal Peptide - Biology Revisited.”
06/98 Research-in-Progress Seminar, Pharmaceutical Discovery, Abbott Laboratories,
Abbott Park, Illinois. “Vasoactive Intestinal Peptide (VIP) - Biology Revisited.”
05/98 Visiting Professor, Pediatric Neurology Service & INSERM CRI 97-01, Hopital
Robert-Debre, Faculty of Medicine Xavier-Bichat, University of Paris 7 - Denis
Diderot, Paris, France.
05/98 Research-in Progress Seminar, Pediatric Neurology Service & INSERM CRI 97-01,
Hopital Robert-Debre, Faculty of Medicine Xavier-Bichat, University of Paris 7 -
Denis Diderot, Paris, France. “Biologic Effects of Novel Phospholipid Formulations
of VIP.”
05/98 Chairman of a plenary session at the 6th World Congress on Heart Failure -
Mechanisms and Management, Geneva, Switzerland. "Pulmonary Aspects."
04/98 Organizer, “Chicago colloquium on VIP-lipid interactions”, University of Illinois at
Chicago, Chicago, Illinois.
04/98 The Dean Arthur A. Dugoni Enrichment Program, University of the Pacific School
of Dentistry, San Francisco, California. “Vasoactive Intestinal Peptide (VIP) -
Phospholipid Interactions: Biological Implications.”
04/98 Pulmonary Grand Rounds, Edgewater Medical Center, Chicago, Illinois. “Rare and
Unusual Pulmonary Diseases.”
Israel Rubinstein, M.D.
93 of 115
01/98 Research-in Progress Seminar, M.D./Ph.D. Scholars Program, University of
Nebraska Medical Center, Omaha, Nebraska. “Mechanisms of Smokeless Tobacco-
Induced Oral Mucosa Inflammation.”
12/97 Research-in-Progress Seminar; Department of Pharmacology, Tulane University
Medical Center, New Orleans, Louisiana. "VIP - Back to the Basics."
05/97 Co-Chairman of a plenary session at the 5th World Congress on Heart Failure -
Mechanisms and Management, Washington, D.C. "Hypertension, LVH and Heart
Failure."
05/97 Invited lecture at the 5th World Congress on Heart Failure - Mechanisms and
Management, Washington, D.C. "Neurogenic Vasodilation in Hypertension."
03/97 Visiting Professor, Department of Medicine, Pennsylvania State College of
Medicine, Hershey, Pennsylvania.
02/97 Co-Chairman of a session at the International Congress on Cilia, Mucus and
Mucociliary Interactions, Jerusalem, Israel. "Clinical and Experimental Approaches
to Evaluation of Mucociliary Function" (unable to attend for personal reasons).
01/97 Advisory Board Meeting, Integrated Therapeutics Group, Inc., Palo Alto, California.
“Upper Airway Inflammation in Patients with Obstructive Sleep Apnea.”
10/96 Research-in-Progress Seminar; Department of Physiology and Biophysics,
University of Nebraska Medical Center, Omaha, Nebraska. "Biologic Effects of
Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes."
06/96 Co-Moderator of a session at the American College of Angiology 43rd Annual
World Assembly, Barcelona, Spain. "Heart/Cardiomyopathies."
05/96 Co-Chairman of a session at the International Society of Heart Failure 4th World
Congress on Heart Failure – Mechanisms and Management, Jerusalem, Israel.
"Pulmonary Aspects, Exercise."
02/96 Research-in-Progress Seminar; SEQUUS Pharmaceuticals, Inc., Menlo Park,
California. "Restoration of Smooth Muscle Contractility by Vasoactive Intestinal
Peptide Encapsulated into Liposomes."
11/95 Research-in-Progress Seminar; Department of Physiology and Biophysics,
University of Nebraska Medical Center, Omaha, Nebraska. "Restoration of Smooth
Muscle Reactivity by VIP in Liposomes."
09/95 Research-in-Progress Seminar; IGEN, Inc., Gaithersburg, MD. "Restoration of
Smooth Muscle Reactivity by VIP Encapsulated into Liposomes: Pre-Clinical
Studies."
Israel Rubinstein, M.D.
94 of 115
08/95 Visiting Professor; Pulmonary Institute, Chaim Sheba Medical Center, Tel-
Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
07/95 Research-in-Progress Seminar; First Department of Anatomy, University of Vienna,
Vienna, Austria. "Mechanisms of Microvascular Injury in the Upper Airway."
06/95 Research-in-Progress Seminar; Ciba-Geigy Limited, Basel, Switzerland. "New
Insights on the Role of Inflammatory Peptides in Upper Airway Inflammation."
06/95 Research-in-Progress Seminar; Cardiopulmonary Research Institute, Winthrop-
University Hospital, State University of New York at Stony Brook, Mineola,
New York. "Mechanisms of Upper Airway Inflammation."
05/95 Co-Chairman of a session at the International Society of Heart Failure 3rd World
Congress on Heart Failure – Mechanisms and Management, Geneva, Switzerland.
"Basic Research."
04/95 Research-in-Progress Seminar; Sleep Disorder Center, Rush-St. Luke's Medical
Center, Chicago, Illinois. "Mechanisms of Upper Airway Inflammation in Sleep
Apnea."
03/95 Research-in-Progress Seminar; Division of Pulmonology and Pulmonary
Occupational Medicine, St. Louis University Health Sciences Center, St. Louis,
Missouri. "Mechanisms of Upper Airways Inflammation."
02/95 Research-in Progress Seminar; Genentech, Inc., South San Francisco, California.
"Mechanisms of Upper Airway Inflammation in Obstructive Sleep Apnea."
11/94 Research-in-Progress Seminar; Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, Connecticut. "Mechanisms of Upper Airway Inflammation."
10/94 Research-in-Progress Seminar; Department of Physiology and Biophysics,
University of Nebraska Medical Center, Omaha, Nebraska. "Microvascular
Responses in the Upper Airway."
10/94 Research-in-Progress Seminar; Department of Medicine, University of Indiana
Medical Center, Indianapolis, Indiana. "Upper Airway Inflammation-Mechanisms
and Clinical Implications."
09/94 Research-in-Progress Seminar; Department of Medicine, Texas Medical Center,
Baylor College of Medicine, Houston, Texas. "The Role of Nitric Oxide in Airway
Inflammation."
09/94 Co-Chairman of a session at the Central Society for Clinical Research Annual
Meeting, Chicago, Illinois. "Electrophysiology/Arrhythmias."
06/94 Research-in-Progress Seminar; Department of Pharmacology, Rush Medical
College, Chicago, Illinois. "Role of Nitric Oxide in Airway Inflammation."
Israel Rubinstein, M.D.
95 of 115
06/94 Research-in-Progress Seminar; University of Antwerpen, Antwerpen, Belgium.
"The Role of Nitric Oxide in Modulating Upper Airway Inflammation."
06/94 Research-in-Progress Seminar; University Hospital, State University of Groningen,
Groningen, the Netherlands. "Mechanisms of Neuropeptide Regulation of the
Microcirculation: Role in Obstructive Sleep Apnea?"
04/94 Research-in-Progress Seminar; Gensia, Inc., San Diego, California. "Regulation of
Microvascular Responses."
04/94 Research-in-Progress Seminar; Air Pollution Health Effects Laboratory, Department
of Community and Environmental Medicine, University of California, Irvine,
California. "Peptide and Peptidase Control of Microcirculation: Role in Sleep
Apnea?"
04/94 Research-in-Progress Seminar; Division of Pulmonary Research, University of
Texas Southwestern Medical Center, Dallas, Texas. "Peptide Interactions in the
Microcirculation."
03/94 Research-in-Progress Seminar; Division of Pulmonary and Critical Care Medicine,
Medical College of Wisconsin, Milwaukee, Wisconsin. "Peptide Control of the
Microcirculation."
02/94 Research-in-Progress Seminar; Meakins-Christie Laboratories, McGill University,
Montreal, Quebec, Canada. "Nitric Oxide-Induced Tissue Injury."
02/94 Research-in-Progress Seminar; Merck-Frosst Canada, Inc., Pointe-Claire-Dorval,
Quebec, Canada. "Kinin control of plasma extravasation: Role of Nitric Oxide."
11/93 Regional Respirology Rounds; McMaster University, Hamilton, Ontario, Canada.
“Nitric Oxide and Tissue Inflammation.”
06/93 Research-in-Progress Seminar; University of Alberta, Edmonton, Alberta, Canada.
"The Role of Nitric Oxide in Tissue Injury and Inflammation."
06/93 Medical Staff Meeting; Department of Veterans Affairs Medical Center, Lincoln,
Nebraska. "Sleep Apnea."
05/93 Medical Grand Rounds; Santa Clara Valley Medical Center, San Jose, California.
"Upper Airway Function in Obstructive Sleep Apnea."
05/93 Research-in-Progress Seminar; California Primate Research Center, University of
California, Davis, California. "Nitric Oxide - a Pro-Inflammatory Mediator?"
04/93 Pulmonary Grand Rounds; Long Island Jewish Medical Center, New Hyde Park,
New York. "Modulation of Upper Airway Inflammation by Nitric Oxide."
Israel Rubinstein, M.D.
96 of 115
03/93 Research-in-Progress Seminar; University of Illinois at Chicago, Chicago, Illinois.
"The Role of Nitric Oxide in Tissue Injury and Inflammation."
03/93 Research-in-Progress Seminar; Minneapolis DVA Medical Center, Minneapolis,
Minnesota. "Modulation of Inflammatory Responses by Nitric Oxide."
02/93 Pulmonary Grand Rounds; New York University Medical Center, New York, New
York. "Peptide and Peptidase Control of Airway Epithelial Cell Function."
02/93 Research-in-Progress Seminar; Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, Connecticut. "Nitric Oxide - a Proinflammatory Mediator?"
01/93 Research-in-Progress Seminar; Creighton University School of Medicine, Omaha,
Nebraska. "Peptidase Control of the Microcirculation."
12/92 Research-in-Progress Seminar; University of Nevada-Las Vegas, University
Medical Center, Las Vegas, Nevada. "Assessment of Airway Caliber in Asthma:
The Acoustic Approach."
11/92 60th Annual Postgraduate Assembly of Omaha Mid-West Clinical Society, Omaha,
Nebraska. "Cardiopulmonary Effects of Sleep Apnea."
09/92 Research-in-Progress Seminar; Parke-Davis Pharmaceutical Research, Ann Arbor,
Michigan. "The Role of Angiotensin Converting Enzyme in Modulating Arteriolar
Reactivity In Vivo."
05/92 Research-in-Progress Seminar; Division of Pulmonary and Critical Care Medicine,
Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
"Peptidase Modulation of Microvascular Permeability."
04/92 Co-Chairman of a session at the FASEB Annual Meeting, Anaheim, California.
"Kinins II."
04/92 Pulmonary Physiology Seminar; Cardiovascular Research Institute, University of
California, San Francisco, California. "Upper Airway Function in Patients with
Sleep Apnea."
03/92 Research-in-Progress Seminar; Department of Biomedical Sciences, Creighton
University School of Medicine, Omaha, Nebraska. "Peptidase Control of the
Microcirculation.
03/92 Research-in-Progress Seminar; Division of Respiratory and Critical Care Physiology
and Medicine, Harbor-UCLA Medical Center, Los Angeles, California. "Airway
Geometry in Bronchial Asthma."
Israel Rubinstein, M.D.
97 of 115
03/92 Research-in-Progress Seminar; Wyeth-Ayerst Research, Princeton, New Jersey.
"The Role of Angiotensin Converting Enzyme and Neutral Endopeptidase in
Modulating Microvascular Permeability."
03/92 Research-in-Progress Seminar; Department of Physiology and Division of
Pulmonary and Critical Care Medicine, New York Medical College, Valhalla, New
York. "Peptidase Control of the Microcirculation in Hypertension."
01/92 Research-in-Progress Seminar; National Jewish Center for Immunology and
Respiratory Medicine, Denver, Colorado. "Role of Endotoxin in Modulating
Microvascular Responses in Situ."
10/91 Hypertension Conference; Midwest Hypertension Center, Creighton University,
Omaha, Nebraska. "Mast Cell Proteases and Vascular Responses."
07/91 Research-in-Progress Seminar; Cardiovascular Research Institute, University of
California, San Francisco, California. "The Role of Angiotensin Converting Enzyme
and Neutral Endopeptidase in Modulating Microvascular Responses."
Patents
Paul S, Noda Y, Rubinstein I. Method of delivering a vasoactive intestinal polypeptide, an
encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated
vasoactive intestinal polypeptide. United States of America Patent 5,770,570
Önyüksel H, Rubinstein I. Materials and methods for making improved liposome
compositions. United States of America Patent 6,197,333
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
United States of America Patent 6,217,886
Certain claims of this patent have been licensed to Baxter Healthcare Corporation,
Deerfield, Illinois, in September 2005
Two indications cited in this patent have been licensed to Vipogen LLC, Chicago,
Illinois, in June 2002
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
United States of America Patent 6,322,810
Two indications cited in this patent have been licensed to Vipogen LLC, Chicago,
Illinois
Önyüksel H, Rubinstein I. Materials and methods for making improved liposome
compositions. United States of America Patent 6,348,214
Israel Rubinstein, M.D.
98 of 115
Önyüksel H, Rubinstein I. Materials and methods for making improved liposome
compositions. Australian Patent 733212
Paul S, Noda Y, Rubinstein I. Method of delivering a vasoactive intestinal polypeptide, an
encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated
vasoactive intestinal polypeptide. Australian Patent 709559
Paul S, Noda Y, Rubinstein I. Method of delivering a vasoactive intestinal polypeptide, an
encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated
vasoactive intestinal polypeptide. International patents pending (WO09527496A1;
EPO0759768A4; CA02187322AA)
Önyüksel H, Rubinstein I. Materials and methods for making improved liposome
compositions. International, European, Canadian and Australian patents (WO9735561A1;
EPO0914094A4; CA 02250219AA; AU2426197A1, respectively)
Önyüksel H, Rubinstein I. Materials and methods for making improved echogenic liposome
compositions. International patents pending (WO09735560A1; AU2549297A1)
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
International and Canadian patent pending (WO044348A3; CA2355269)
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
International and Canadian patents pending (continuation in part; CA2468582)
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
United States of America Patent pending (continuation in part)
Önyüksel H, Rubinstein I. Materials and methods for making improved liposome
compositions. United States of America Patent pending (continuation in part)
Önyüksel H, Rubinstein I. Phospholipid micelles in liposomes as solubilizers for water-
insoluble compounds. PCT application number 60/387,982 filed June 12, 2002
Önyüksel H, Rubinstein I. Phospholipid micelles in liposomes as solubilizers for water-
insoluble compounds. International patent pending WO 2003/105765A3
Stec KJ, Rubinstein I, Eiznhamer D, Xu Z-Q, Flavin M. Use of 2,3 alkylcarbonyloxybenzoic
acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction,
damage and injury in mammals. International patent pending (WO2004010989; EP1539132 9
(A0); AU2003252178 (A1); PCT/US2003/023644)
Assigned to Advanced Life Sciences, Inc. in July 2003
Stec KJ, Rubinstein I, Eiznhamer D, Xu Z-Q, Flavin M. Use of 2,3 alkylcarbonyloxybenzoic
acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction,
Israel Rubinstein, M.D.
99 of 115
damage and injury in mammals. United States of America Patent pending (application
US20040019022 [A1])
Assigned to Advanced Life Sciences, Inc. in July 2003
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
European Patent 1 146 857 B1
Önyüksel H, Rubinstein I. Materials and methods for making improved micelle compositions.
European Patent pending (Divisional; EP 1 661 557 A1).
Önyüksel H, Rubinstein I. Hydrophilic polymer-conjugate lipids for peptide and protein folding
disorders. International patent pending (Application number 60/790,297 filed April 6, 2007;
PCT/US2007008660; EP2010223; WO/2008/054498).
Önyüksel H, Rubinstein I. Novel phospholipid micellar and liposomal formulations of
antibiotics and antitoxins. U.S. Provisional Patent Application 61/104,134
Önyüksel H, Rubinstein I. Phospholipid micellar and liposomal compositions and uses thereof.
International patent pending (WO/2010/045479; U.S. Patent Application 20110256213 A1)
Önyüksel H, Rubinstein I. Calibration materials for size measuring instruments at nanoscale
range. U.S. Provisional Patent Application 61/099,089
Weinberg G, Rubinstein I. Cyclodextrin reversal of local anesthetic toxicity. U.S. Provisional
Patent Application 61/379,533
Published audiovisual educational materials
Tino G, Barker AF, Fiel SB, O’Donnell A, Rubinstein I, Scheinberg PJ. Bronchiectasis: A not
so orphan disease. Bronchiectasis Educational Council and Metis BioScience Communications.
White Plains, New York; July 2003.
Published continuing education materials
Rubinstein I. Is there a role for aerosolized antibiotics in COPD patients. In: Aerosolized
antibiotics: a new paradigm for the treatment of lung infections. ACCP CHEST 2000 –
Symposia Highlights, p20.
Colice G, Canalis E, de Guehery L, File S, Gluck O, Martin R, Rubinstein I. Steroids and the
risk of osteoporosis. Considerations for pulmonologists. BioScience Communications, New
York, New York; Summer 2003.
Rubinstein I. Macrolides: anti-inflammatory properties and potential uses. Antibiotic Update,
Issue 3, November 4, 2004; pp. 1-4.
Israel Rubinstein, M.D.
100 of 115
Published computer software
Not applicable
Articles submitted for publication
Önyüksel H, Ashok B, Rubinstein I. Phospholipid micelles as solubilizers for water-insoluble
drugs. Advances in Drug Delivery (Submitted for publication)
Kirchhoff CF, Rubinstein I, Ludwig JD, Önyüksel H. Interaction of pegylated phospholipids
with a chimeric cytokine: a fluorescence and circular dichroism study. Pharmaceutical
Research (Submitted for publication)
Pai AS, Rubinstein I, Önyüksel H. New insights into mechanisms of inhibition of β-amyloid
aggregation by PEGylated phospholipid nanomicelles. Journal of Alzheimer’s Research
(Submitted for publication)
Önyüksel H, Krishnadas A, Rubinstein I. Vasoactive intestinal peptide-conjugated
phospholipid nanocarrier for breast cancer targeted drug delivery. (In preparation)
Kirchhoff CF, Rubinstein I, Önyüksel H. Pegylated phospholipids retard aggregation on
interleukin-2 near the isoelectric point. (In preparation)
Cesur H, Rubinstein I, Mohanty P, Önyüksel H. Investigation of a relationship between drug
hydrophobicity and solubilization in lipid nanocarriers. (In preparation)
Reviews, Consensus Statements, Editorials and Letters to the Editor
Rubinstein I. Fatal thrombosis of left internal carotid artery following diuretic abuse. Annals
of Emergency Medicine 14: 275, 1985.
Rubinstein I, Baum GL. The persistent need to improve our approach to sarcoidosis. Chest 87:
710-711, 1985.
Rubinstein I, Baum GL, Hiss Y. Selective IgA deficiency and sarcoidosis. Chest 88: 160,
1985.
Rubinstein I, Baum GL, Rosenthal T. Fungal infections complicating pulmonary sarcoidosis-
revisited. Journal of Infectious Diseases 152: 1360, 1985.
Rubinstein I. Central nervous system sarcoidosis. Journal of Neurosurgery 65: 265, 1986.
Rubinstein I, Baum GL. Colchicine therapy in sarcoid arthropathy. Pediatrics 78: 717-718,
1986.
Israel Rubinstein, M.D.
101 of 115
Rubinstein I, Baum GL. Role of mediastinoscopy in lung cancer. Annals of Thoracic Surgery
42: 601, 1986.
Rubinstein I, Zamel N, Hoffstein V. Dynamic upper airway narrowing in patients with
obstructive sleep apnea. American Journal of Roentgenology 147: 1330-1331, 1986.
Rubinstein I. Expanding spectrum of pulmonary disease caused by nontuberculous
mycobacteria. Radiology 159: 815-816, 1986.
Rubinstein I, Baum GL. Association of ulcerative colitis and sarcoidosis-A chance occurrence?
Chest 89: 618-619, 1986.
Rubinstein I. Bilateral granulomatous orchitis: manifestation of idiopathic systemic
granulomatosis. Journal of Urology 137: 317, 1987.
Rubinstein I, Hoffstein V. Pulmonary hamartoma: CT findings. Radiology 162: 878, 1987.
Rubinstein I, Hoffstein V. Angiotensin converting enzyme in neurosarcoidosis. Archives of
Neurology 44: 249-250, 1987.
Rubinstein I, Baum GL, Hiss Y, Solomon A. Hemoptysis as the presenting manifestation of
sarcoidosis. Chest 91: 931, 1987.
Rubinstein I, Baum GL, Racz I, Rosenthal T. Serum immunoglobulin levels in Jewish patients
with active pulmonary tuberculosis. Infection 16: 253, 1988.
Rennard SI, Rickard KA, Spurzem JR, Von Essen S, Rubinstein I, Sisson JH, Floreani AA,
Robbins RA, Romberger DJ, Thompson AB. Airways inflammation. Chest 101(Supplement):
30S-32S, 1992.
Belenky SN, Daughton DM, Rubinstein I, Rennard SI. Nicotine dependence and sleep
disturbances. International Journal of Smoking Cessation 3: 3-9, 1994.
Olopade CO, Rubinstein I. Salmetrol xinafoate vs albuterol in asthma: was a race a factor.
JAMA 272: 1576, 1994.
Rennard SI, Romberger DJ, Sisson JH, Von Essen SG, Rubinstein I, Robbins RA, Spurzem JR.
Airway epithelial cells: functional roles in airway disease. American Journal of Respiratory
and Critical Care Medicine 150(Part 2): S27-S30, 1994.
Crisostomo MI, Rubinstein I. Socioeconomic effects of health economics. In: European
Respiratory Monograph. Management of chronic obstructive pulmonary disease. 3(Monograph
7): 297-298, 1998.
Crisostomo MI, Rubinstein I. Pharmacotherapy of chronic pulmonary hypertension: a
contemporary overview. Clinical Pulmonary Medicine 5: 191-194, 1998.
Israel Rubinstein, M.D.
102 of 115
Alwani A, Rubinstein I. The nose and OSA. Current Opinion in Pulmonary Medicine 4: 361-
362, 1998.
Rubinstein I, Hong D. Circulating natriuretic peptides. A biologic marker of tissue injury?
Chest. 115: 7-8, 1999.
American Thoracic Society Statement. Recommendations for standardized procedures for the
online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide
in adults and children. American Journal of Respiratory and Critical Care Medicine 160: 2104-
2117, 1999.
Mutlu GM, Rubinstein I. Obstructive sleep apnea syndrome-associated nocturnal myocardial
ischemia. Chest 117: 1534-1535, 2000.
Rubinstein I. The biological effects of alpha helix vasoactive intestinal peptides. In: The First
International Meeting of Asia Minor Branch of the International Neuropeptides Society 21-25
May, 2001, Antalya, Turkey. Biomedical Reviews 12: 65-73, 2001.
Rubinstein I. Is there a role for aerosolized antibiotics in COPD patients. CHEST 2000 -
Symposia Highlights, 2001, pp. 21.
Mutlu GM, Garey KW, Robbins RA, Danziger, LH, Rubinstein I. Collection and analysis of
exhaled breath condensate in humans. American Journal of Respiratory and Critical Care
Medicine 164: 731-737, 2001.
Garey KW, Rubinstein I. Chlamydia pneumoniae, clarithromycin, and severe asthma. Chest
120: 1035-1036, 2001.
Mutlu GM, Rubinstein I. Pulmonary hypertension, part 1: The diagnostic workup. Journal of
Respiratory Diseases 22: 573-591, 2001.
Mutlu GM, Rubinstein I. Pulmonary hypertension, part 2: Current management strategies.
Journal of Respiratory Diseases 22: 641-645, 2001.
Kirchhoff CF, Rubinstein I, Ludwig JD, Önyüksel H. DSPE-PEG 5000 increases physical
stability of human interleukin-2 in vitro. Drug Delivery Technology 2: 71, 2002.
Rubinstein I. Upper airway inflammation in obstructive sleep apnea. American Journal of
Respiratory and Critical Care Medicine 165: 1023-1024, 2002.
Mutlu GM, Rubinstein I. Exhaled breath condensate: Current knowledge and potential
applications. Journal of Respiratory Diseases 23: 493-494, 2002.
Hatipoglu U, Rubinstein I. Pulmonary vasculitis: a clinical overview. Israel Medical
Association Journal 4: 1143-1148, 2002.
Israel Rubinstein, M.D.
103 of 115
Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide
antibiotics and chronic inflammatory sinopulmonary diseases. Chest 123: 261-265, 2003.
Krishnadas A, Önyüksel, Rubinstein I. Interactions of VIP, secretin and PACAP1-38 with
phospholipids: A biological paradox revisited. Current Pharmaceutical Design 9: 1005-1012,
2003.
Mutti A, Corradi M, Rubinstein I. Reporting data on exhaled breath condensate. American
Journal of Respiratory and Critical Care Medicine 168: 719, 2003.
Dagar S, Rubinstein I, Önyüksel H. Liposomes in ultrasound and gamma scintigraphic
imaging. Methods in Enzymology 373: 198-214, 2003.
Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a
working hypothesis. Respiration 70: 665-671, 2003.
Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, Danziger LH.
Effects of six-week calrithromycin therapy in subjects with corticosteroid-dependent asthma.
Current Therapeutic Research 65: 1-12, 2004.
Hatipoglu U, Rubinstein I. Low-dose, long-term macrolide therapy in asthma: an overview.
BMC Clinical and Molecular Allergy 2: 4-7, 2004.
Krishnadas A, Rubinstein I, Önyüksel H. Vasoactive intestinal peptide (VIP) conjugated
phospholipid nanocarrier for active targeted delivery of paclitaxel to breast cancer. Controlled
Release Society 31st Annual Meeting Transactions, 2004; #497.
Koo O, Rubinstein I, Önyüksel H. Development of camptothecin-pegylated phospholipid
micelles: solubility improvement and lyophilization studies. Controlled Release Society 31st
Annual Meeting Transactions, 2004; #551.
Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome: how many
ways do I look at thee? Chest 126: 1-2, 2004.
Hatipoglu U, Rubinstein I. Inflammation may play and important role in obstructive sleep
apnea syndrome. Advance for Managers of Respiratory Care 13: 40-41 and 79, 2004.
Sethi V, Önyüksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods in
Enzymology 391: 377-395, 2005.
Mutlu GM, Rubinstein I. The saga of obstructive sleep apnea syndrome and daytime
hypercapnia: work in progress. Chest 127: 698-699, 2005.
Rubinstein I. Human VIP-α: an emerging biologic response modifier to treat primary
pulmonary hypertension. Expert Reviews in Cardiovascular Therapeutics 3: 565-569, 2005.
Horvath I, Hunt J, Barnes PJ, Alvig K, Antczak A, Baraldi E, Becher G, van Beurden WJ,
Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C,
Israel Rubinstein, M.D.
104 of 115
Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P,
Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G,
Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath
condensate: methodological recommendations and unresolved questions. European Respiratory
Journal 26: 523-548, 2005.
Hatipoğlu U, Rubinstein I. Treatment of chronic rhinosinusitis with low-dose, long-term
macrolide antibiotics: an evolving paradigm. Current Allergy and Asthma Reports 5: 491-494,
2005.
Koo OM, Rubinstein I, Önyüksel H. Role of nanotechnology in targeted drug delivery and
imaging: a concise review. Nanomedicine 1: 193-212, 2005.
Mutlu GM, Mutlu E, Bellemeyer A, Rubinstein I. Pulmonary complications of anti-TNFα
antibody therapy. American Journal of Medicine 119: 639-646, 2006.
Hatipoğlu U. Rubinstein I. Anti-inflammatory treatment of chronic rhinosinusitis: a shifting
paradigm. Current Infectious Disease Reports 9: 193-200, 2007.
Mutlu GM, Bellmeyer A, Mutlu EA, Rubinstein I. The reply. American Journal of Medicine
120: e23, 2007.
Hatipoğlu U. Rubinstein I. Anti-inflammatory treatment of chronic rhinosinusitis: a shifting
paradigm. Current Allergy and Asthma Reports 8: 154-161, 2008.
Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine: addressing unmet
medical need in acute lung injury. Journal of Biomedical Nanotechnology 5: 614–619, 2009.
Rubinstein I. Research highlights. Nanomedicine (London) 6: 953-955, 2011.
Takekoshi D, Belvitch P, Rubinstein I. Long-term macrolide antibiotics in asthma therapy.
Reviews in Health Care 2011;2:243-258.
Rubinstein I, Zider B, Weinberg G. Lipid resuscitation reverses multidrug-induced cardiogenic
shock. Journal of Medical Toxicology 7:336, 2011.
Rubinstein I. Research highlights. Nanomedicine (London) 7: 631-633, 2012.
Rubinstein I, Weinberg G. Nanomedicine for chronic non-infectious arthritis: the clinician’s
perspective. Maturitas 73: 68-73, 2012.
Rubinstein I, Weinberg G. Nanomedicine for chronic non-infectious arthritis: the clinician’s
perspective. Nanomedicine: Nanotechnology, Biology and Medicine 8(Supplement): S77-S82,
2012.
Rubinstein I, Hatipoğlu U. Long-term, low-dose macrolide antibiotics therapy of patients with
chronic rhinosinusitis. Current Primary Care Reports (In press)
Israel Rubinstein, M.D.
105 of 115
Teaching experience:
2008-present PCOL 550 Biology and Pharmacology of the Lung, Department of
Pharmacology, University of Illinois at Chicago, Chicago, Illinois
2004-present Lectures to residents, Respiratory Care Lecture Curriculum, Department of
Medicine, University of Illinois at Chicago, Chicago, Illinois
1998-present Member, Tactics and Strategy graduate course, Department of Physiology
and Biophysics, University of Illinois at Chicago, Chicago, Illinois
1994-present Resident advisor, Department of Medicine, University of Illinois at
Chicago, Chicago, Illinois
1994-present Teaching medical residents, pulmonary fellows, post-doctoral fellows,
graduate students and summer students in the laboratory, University of
Illinois at Chicago, Chicago, Illinois
1993-present Weekly participation in section and departmental (Respiratory and Critical
Care, and Medicine) clinical and research conferences, University of Illinois
at Chicago, Chicago, Illinois
1993-present Lectures to medical students, residents and pulmonary fellows, University
of Illinois at Chicago, Chicago, Illinois
1994 Graduate Course in Physiology (Microcirculation), University of Nebraska
Medical Center, Omaha, Nebraska
1992-1993 Nursing Course in Physiology (Respiration), University of Nebraska
Medical Center, Omaha, Nebraska
1991-1993 Advanced Physiology, Department of Physiology and Biophysics,
University of Nebraska Medical Center, Omaha, Nebraska
1991-1993 Academic Advisor, College of Medicine, University of Nebraska Medical
Center, Omaha, Nebraska
1990-1993 Facilitator Orientation, Department of Internal Medicine, University of
Nebraska Medical Center, Omaha, Nebraska
1990-1993 Teaching pulmonary fellows, post-doctoral fellows and summer students in
the laboratory, University of Nebraska Medical Center, Omaha, Nebraska
1989-1993 Introduction to Clinical Medicine, Department of Internal Medicine,
University of Nebraska Medical Center, Omaha, Nebraska
Israel Rubinstein, M.D.
106 of 115
1989-1993 Medical Physiology, Department of Physiology and Biophysics, University
of Nebraska Medical Center, Omaha, Nebraska
1989-1993 Weekly participation in departmental (Internal Medicine, and Physiology
and Biophysics) clinical and research conferences, University of Nebraska
Medical Center, Omaha, Nebraska
1989-1993 Lectures for medical residents and pulmonary fellows, University of
Nebraska Medical Center, Omaha, Nebraska
1983-1985 Introduction to Clinical Medicine, Department of Medicine, Sackler School
of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Thesis Examination Committee:
Ashwini Pai, Ph.D. in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 2008; “A Novel Multitargeted Approach
for Therapeutic Intervention of Alzheimer’s Disease.”
Julia Cesur, M.Sc. in Bioengineering with Dr. Hayat Önyüksel, Department of
Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois; 2008; “Investigation of a Relationship Between Drug
Hydrophobicity and Solubilization in Lipid Nanocarriers.”
Prem Swaroop Mohanty, M.Sc. in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 2007; “Targeted
Nanomedicine of 17-Allylamino-17-demethoxygeldanamycin.”
Eunjung Jeon, M.Sc. in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois, 2007; “Peptide Interactions with Sterically
Stabilized Phospholipid Micelles.”
Vandana Keskar, Ph.D. in Biopharmaceutical Sciences with Dr. Richard A.
Gemeinhart, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois 2006; Preliminary
examination
Israel Rubinstein, M.D.
107 of 115
Otilia MY Koo, Ph.D. in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois, 2005; “A Novel Nanomedicine Against
Arthritis: Targeted camptothecin Phospholipid Micelles.”
Lalit R. Peddakota, M.Sc. in Bioengineering with Dr. Hayat Önyüksel, Department of
Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois, 2005; “Interactions of Pegylated Lipids with Model and
Cancer Cell Membranes.”
Beena Ashok, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois, 2005; “Development of Phospholipid Mixed
Micelles and Predictive Models for Solubilization of Drugs.”
Aparna Krishnadas, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois, 2004; “Targeted Delivery of Paclitaxel in
Phospholipid Micelles for Improved Chemotherapy of Breast Cancer.”
Carol F. Kirchhoff, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois, 2003; “Physical Pegylation of Therapeutic Proteins
for Improved Stability.”
Varun Sethi, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois, 2003; “Development and Delivery of VIP in
Phospholipid Carriers for the Treatment of Rheumatoid Arthritis.”
Salil Gandhi, M.Sc. in Bioengineering with Dr. Hayat Önyüksel, Department of
Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois, 2002; “Study of Secretin and PACAP1-38 Interactions with
Phospholipids.”
Sumeet Dagar, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois, 2002; “Targeted Carrier System for Breast
Cancer Imaging.”
Peng Li, M.Sc. in Pharmaceutics with Dr. Hayat Alkan-Önyüksel, Department of
Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois, 1999; “Phospholipid Micelles as Carriers
for Water Insoluble Drugs.”
Manisha Patel, M.Sc. in Bioengineering with Dr. Hayat Alkan-Önyüksel, Department of
Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of
Israel Rubinstein, M.D.
108 of 115
Illinois at Chicago, Chicago, Illinois, 1997; “Study of Interactions Between
Vasoactive Intestinal Peptide and Phospholipid Vesicles and Micelles.”
Florence Séjourné, M.Sc. in Bioengineering with Dr. Hayat Alkan-Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois, 1996; “Development of a
Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized
Liposomes.”
Tan Yong, Ph.D., in Physiology with Dr. William G. Mayhan, Department of
Physiology and Biophysics, University of Nebraska Medical Center, Omaha,
Nebraska, 1991; “An Intravital Study of the Factors Which Influence Vascular
Permeability of the Hamster Cheek Pouch: Implications for Inflammation.”
Personnel supervised:
Richard Ripper, Licensed Veterinary Technician 3, Jesse Brown VA Medical Center
and Department of Anesthesiology, College of Medicdine, University of Illinois
at Chicago, Chicago, Illinois
Michael Fettiplacae, MD/PhD student, Jesse Brown VA Medical Center
and Department of Anesthesiology, College of Medicdine, University of Illinois
at Chicago, Chicago, Illinois
Tonya Kuzmis, Ph.D. Post-doctoral Research Fellow, Department of Biopharmaceutical
Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago,
Illinois 2007-2009
Sok Bee Lim, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois 2005-2009
Amrita Banerjee, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois 2008-2009
Mentor Thaqi, B.Sc., Research Associate with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois 2008-2009
Stephanie Drake, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel,
Department of Bioengineering, College of Engineering, University of Illinois at
Chicago, Chicago, Illinois 2008-2009
Kenneth Brandenburg, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel,
Department of Bioengineering, College of Engineering, University of Illinois at
Chicago, Chicago, Illinois; 2007-2009
Israel Rubinstein, M.D.
109 of 115
Ashwini Pai, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 2004-2008
Umur S. Hatipoglu, M.D., Clinical Assistant Professor, Section of Respiratory and
Critical Care Medicine, Department of Medicine, University of Illinois at
Chicago College of Medicine, Michael Reese Hospital and Medical Center and
Christ Hospital, Chicago, Illinois; 2002-2008
Sondra Helina Turski, B.Sc., Research Associate, with Dr. Hayat Önyüksel, Department
of Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois; 2007-2008
Julia Cesur, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel, Department
of Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois; 2006-2008
Prem Swaroop Mohanty, M.Sc. Candidate in Biopharmaceutical Sciences with Dr.
Hayat Önyüksel, Department of Biopharmaceutical Sciences, College of
Pharmacy, University of Illinois at Chicago, Chicago, Illinois; 2005-2007
Eunjung Jeon, M.Sc. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 2003-2007
Esha Desai, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 2005-2007
Rupali Jain, Pharm.D., Post-Doctoral Research Fellow with Dr. Larry Danziger, Section
of Infectious Diseases, Department of Pharmacy Practice, University of Illinois
at Chicago College of Pharmacy, Chicago, Illinois; 2004-2006
Imre Soos, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel, Department of
Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois; 2004-2006
Otilia MY Koo, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 2000-2005
Beena Ashok, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 2000-2005
Israel Rubinstein, M.D.
110 of 115
Doan Nguyen, M.D., Resident, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 2004-2005
Lalit R. Peddakota, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel,
Department of Bioengineering, College of Engineering, University of Illinois at
Chicago, Chicago, Illinois; 2003-2005
Carol F. Kirchhoff, Ph.D. in Pharmaceutics with Dr. Hayat Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois; 1996-2003
Aparna Krishnadas, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Biopharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1999-2004
Christopher A. Schriever, Pharm.D., Research Assistant Professor, Section of Infectious
Diseases, Department of Pharmacy Practice, University of Illinois at Chicago
College of Pharmacy, Chicago, Illinois; 2003-2004
Enxian Lu, M.Sc. Candidate in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 2002-2004
Salah Lababidy, M.D., Resident, Department of Medicine, Christ Hospital, Oak Loan,
Illinois and College of Medicine, University of Illinois at Chicago, Chicago,
Illinois; 2002-2003
Imran Saleem, Ph.D., Post-Doctoral Research Fellow with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 2003-2004
Varun Sethi, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat Önyüksel,
Department of Biopharmaceutical Sciences, College of Pharmacy, University of
Illinois at Chicago, Chicago, Illinois; 1999-2003
Przemyslaw B. Radwanski, B.Sc., Undergraduate Research Fellowship in
Pharmaceutics with Dr. Hayat Alkan-Önyüksel, Department of
Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois; 2002
Brijesh Kumar, M.B.B.S., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 2000-2002
Takaya Tueshita, M.D., Visiting Scientist, Department of Anesthesia, Nippon Medical
School, Tokyo, Japan; 2000-2002; awarded Ph.D. by Nippon Medical School
based on work accomplished at UIC
Israel Rubinstein, M.D.
111 of 115
Allan M. Ramirez, M.D., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 2001
Salil Gandhi, M.Sc. Candidate in Bioengineering with Dr. Hayat Önyüksel, Department
of Bioengineering, College of Engineering, University of Illinois at Chicago,
Chicago, Illinois; 1999-2001
Sumeet Dagar, Ph.D. Candidate in Biopharmaceutical Sciences with Dr. Hayat
Önyüksel, Department of Pharmaceutics and Pharmacodynamics, College of
Pharmacy, University of Illinois at Chicago, Chicago, Illinois; 1997-2001
Kevin W. Garey, Pharm.D., Post-Doctoral Research Fellow with Dr. Larry Danziger,
Section of Infectious Diseases, Department of Pharmacy Practice, University of
Illinois at Chicago College of Pharmacy, Chicago, Illinois; 1998-2001
Ankur D. Mody, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory
and Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999-2001
Gokhan Mutlu, M.D., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999-2001
Rinku Chandiwala, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory
and Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999-2000
Ishrat J. Khan, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999-2000
Surendran Raja Raja Varma, M.B.Ch.B., Post-Doctoral Research Fellow, Section of
Respiratory and Critical Care Medicine, Department of Medicine, College of
Medicine, University of Illinois at Chicago, Chicago, Illinois; 1999-2000
Suchitra Varma, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999-2000
Mokarram Alafandy, Ph.D., Post-Doctoral Research Fellow with Dr. Hayat Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1999
Israel Rubinstein, M.D.
112 of 115
Hasina Dhanani, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory
and Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999
Yogesh Bhakta, B.Sc., Undergraduate Research Fellowship in Pharmaceutics with Dr.
Hayat Alkan-Önyüksel, Department of Pharmaceutics and Pharmacodynamics,
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois; 1998-
1999
Christopher Olopade, M.D., Associate Professor, , Section of Respiratory and Critical
Care Medicine, Department of Medicine, College of Medicine, University of
Illinois at Chicago, Chicago, Illinois; 1994-1999
Syed R. Akhter, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1997-1999
Amrit K. Makhija, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory
and Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1999
Shalini Sethi, M.B.Ch.B., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1998-1999
Jie Wei, M.D, Post-Doctoral Research Fellow, Section of Respiratory and Critical Care
Medicine, Department of Medicine, College of Medicine, University of Illinois
at Chicago, Chicago, Illinois; 1998
Pang Li, M.Sc. Candidate in Pharmaceutics with Dr. Hayat Alkan-Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1997-1999
Bavish Bodalia, B.Sc., Undergraduate Research Fellowship in Pharmaceutics with Dr.
Hayat Alkan-Önyüksel, Department of Pharmaceutics and Pharmacodynamics,
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois; 1998-
1999
Xiao-pei Gao, M.D., Research Assistant Professor, Section of Respiratory and Critical
Care Medicine, Department of Medicine, College of Medicine, University of
Illinois at Chicago; 1993-1998
Hiroyuki Ikezaki, M.D., Visiting Scientist, Department of Anesthesia, Nippon Medical
School, Tokyo, Japan; 1996-1998; awarded Ph.D. by Nippon Medical School
based on work accomplished at UIC
Israel Rubinstein, M.D.
113 of 115
Sergei Pakhlevaniants, M.S., Senior Research Specialist, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1994-1998
Manisha Patel, M.Sc. Candidate in Bioengineering with Dr. Hayat Alkan-Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1996-1997
Sarah Miller, M.Sc. Candidate in Bioengineering with Dr. Hayat Alkan-Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1997
Aimee Guerrieri, M.P.H. Candidate with Drs. Victoria Persky and Peter Scheff,
Environmental and Occupational Health Sciences, School of Public Health,
University of Illinois at Chicago, Chicago, Illinois; 1995-1996
Yuliya Kin, M.D., Post-Doctoral Research Fellow, Section of Respiratory and Critical
Care Medicine, Department of Medicine, College of Medicine, University of
Illinois at Chicago, Chicago, Illinois; 1996
Florence Séjourné, M.Sc. Candidate in Bioengineering with Dr. Hayat Alkan-Önyüksel,
Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois; 1994-1996
Hideyuki Suzuki, M.D., Ph.D., Visiting Scientist, First Department of Surgery, Nippon
Medical School, Tokyo, Japan; 1994-1996; awarded Ph.D. by Nippon Medical
School based on work accomplished at UIC
Mohammed Zakkar, M.D., Fellow, Section of Respiratory and Critical Care Medicine,
Department of Medicine, College of Medicine, University of Illinois at Chicago,
Chicago, Illinois; 1995-1996
Galina Pikovskaya, M.D., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1995-1996
Umur Hatipoglu, M.D., Resident, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1995-1996
Chih-Wei Hua, Ph.D. Candidate in Public Health with Dr. Peter Scheff, Environmental
and Occupational Health Sciences, School of Public Health, University of
Illinois at Chicago; 1995
Arkadi Demin, M.D., Post-Doctoral Research Fellow, Section of Respiratory and
Critical Care Medicine, Department of Medicine, College of Medicine,
University of Illinois at Chicago College of Medicine, Chicago, Illinois; 1995
Israel Rubinstein, M.D.
114 of 115
Jawed Abubaker, M.D., Resident, Department of Medicine, College of Medicine,
University of Illinois at Chicago, Chicago, Illinois; 1995
James A. Christon, M.D., Fellow, Section of Respiratory and Critical Care Medicine,
Department of Medicine, College of Medicine, University of Illinois at Chicago,
Chicago, Illinois; 1994-1995
Zoë Alikakos, Second Year Medical Student, College of Medicine, University of
Illinois at Chicago, Chicago, Illinois; 1994-1995
Kimberly Bloomingberg, Junior Student, University of Illinois at Chicago, Chicago,
Illinois; 1994
Xiao-pei Gao, M.D., Research Associate, Division of Respiratory and Critical Care
Medicine, Department of Internal Medicine, University of Nebraska Medical
Center, Omaha, Nebraska; 1990-1993
Phyllis Anding, Research Technician II, Division of Respiratory and Critical Care
Medicine, Department of Internal Medicine, University of Nebraska Medical
Center, Omaha, Nebraska; 1989-1993
Günther Müns, M.D.; Fellow, Division of Respiratory and Critical Care Medicine,
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha, Nebraska; 1992-1993
Khaled Magdy, M.D.; Fellow, Division of Respiratory and Critical Care Medicine,
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha, Nebraska; 1992-1993
Steven Zorn, M.D., F.C.C.P., Visiting Scholar, Center for Sleep Disorders, Division of
Respiratory and Critical Care Medicine Department of Internal Medicine,
University of Nebraska Medical Center; 1992-1993
Albert Curseen, M.D.; Fellow, Division of Respiratory and Critical Care Medicine,
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha, Nebraska; 1991-1993
Mahmoud Houmsse, M.D.; Post-Doctoral Research Fellow, Division of Respiratory and
Critical Care Medicine, Department of Internal Medicine, University of
Nebraska Medical Center, Omaha, Nebraska; 1991-1992
Jeffrey Engel, Senior Honors Student (Cornell University, Ithaca, New York),
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha, Nebraska; 1992
Jinshun Piao, M.D.; Post-Doctoral Research Fellow, Division of Respiratory and
Critical Care Medicine, Department of Internal Medicine, University of
Nebraska Medical Center, Omaha, Nebraska; 1992
Israel Rubinstein, M.D.
115 of 115
Sergei Belenky, M.D.; Post-Doctoral Research Fellow, Division of Respiratory and
Critical Care Medicine, Department of Internal Medicine, University of
Nebraska Medical Center, Omaha, Nebraska; 1991-1992
Tan Yong, M.D.; Ph.D. Candidate in Physiology with Dr. William G. Mayhan,
Department of Physiology and Biophysics, University of Nebraska Medical
Center, Omaha, Nebraska; 1991
Diane Schwery; Sophomore Honors Student (University of Nebraska, Lincoln),
Division of Respiratory and Critical Care Medicine, Department of Internal
Medicine, University of Nebraska Medical Center, Omaha, Nebraska; 1991
Shin Koizumi, M.D.; Visiting Scientist, Nippon Medical School, Tokyo, Japan; 1990